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Zusammenfassung 
Um auf externe Reize reagieren zu können und die Zellhomöostase aufrecht zu erhalten, 
ist die Regulation von Signalkaskaden für alle Organismen von großer Wichtigkeit. Bei 
Wirbeltieren stellt die Insulinsignalübertragung einen entscheidenden metabolischen 
Signalweg dar und eine Fehlregulation, wie sie zum Beispiel im Fall von Diabetes mellitus 
vorkommt, ist ein Gesundheitsrisiko in der alternden Gesellschaft. Die vorliegende Arbeit 
untersucht die Funktion von Cytohesinen und des Adapterproteins Connector enhancer of 
kinase suppressor of ras 1 (CNK1) im Insulinsignalweg. 
Bei Cytohesinen handelt es sich um Guaninnukleotid-Austauschfaktoren für ADP-
Ribosylierungsfaktoren (Arf)-GTPasen, die an der Insulinsignalübertragung beteiligt sind. 
Zelluläre Daten weisen darauf hin, dass CNK1 einen Komplex mit dem Cytohesin 
Arf nucleotide-binding site opener (ARNO) bildet. Dieser Komplex soll für die 
Translokation von ARNO zur Plasmamembran notwendig sein und wirkt an der 
Signalweiterleitung vom Insulinrezeptor zum zentralen Effektor Proteinkinase B (PKB) mit. 
Um die Rolle von ARNO innerhalb des Insulinrezeptor (IR)-Netzwerkes genauer zu 
verstehen, wurden in dieser Arbeit biochemische und biophysikalische Untersuchungen 
durchgeführt. Eine direkte Interaktion zwischen ARNO und dem IR wurde nicht 
nachgewiesen, jedoch konnte die Interaktion zwischen ARNO und CNK1 detailliert 
aufgeklärt werden. Pull-down Experimente, analytische Gelfiltration und isotherme 
Titrationskalorimetrie zeigten die direkte Interaktion der beiden Proteine über deren 
coiled-coil-Domänen. Proteinkristalle wurden generiert, die aufgrund schlechter Beugung 
von Röntgenstrahlen jedoch keine Strukturbestimmung ermöglichten. Um den Effekt der 
Komplexbildung auf die katalytische Aktivität von ARNO zu untersuchen, wurden 
Guaninnukleotid-Austauschreaktionen mit myristoylierten Arfs an Liposomen etabliert. In 
Einklang mit der Literatur lokalisiert wildtyp CNK1 nicht an Membranen und hatte keinen 
Einfluss auf den ARNO-vermittelten Nukleotidaustausch. Da sowohl aktiviertes CNK1 als 
auch ARNO an der Zellmembran lokalisiert sind, wurde CNK1 über einen Polyhistidin-Tag 
künstlich an funktionalisierte Liposomen gekoppelt. Trotz der erfolgreichen Liposomen-
Lokalisation, konnte unter diesen Bedingungen kein Austausch gemessen werden, 
weshalb die Auswirkung der Interaktion auf die ARNO-Aktivität mit einem anderen 
Verfahren untersucht werden muss. 
Mechanistisch ist es wahrscheinlich, dass CNK1 die Konzentration ARNO und hiermit 
aktiven Arfs an der Plasmamembran erhöht, was wiederum PIP2-vermittelt das 
Insulinsignal verstärkt. Lysin-Acetylierung innerhalb der PH-Domäne von CNK1 ist ein 
möglicher Rekrutierungsmechanismus, der durch weitere Studien bestätigt werden muss. 
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Abstract 
The tight regulation of signalling cascades is of crucial importance for organisms in order 
to react to external stimuli and maintain homeostasis. Insulin signalling is a key metabolic 
pathway in vertebrates and dysregulation as seen in the case of diabetes mellitus poses a 
major health risk to the ageing society. This work aims at a deeper understanding of the 
underlying intracellular signalling cascade, especially of the cytohesin-CNK1 complex. 
Cytohesins are guanine nucleotide exchange factors for GTPases of the ADP-ribosylation 
factor (Arf) family and were shown to be involved in insulin signalling. Cellular data further 
suggest that the adaptor protein Connector enhancer of kinase suppressor of ras 1 
(CNK1) forms a complex with the cytohesin Arf nucleotide-binding site opener (ARNO). 
This complex is required for the translocation to the plasma membrane and signal 
transduction from the insulin receptor to its downstream effector protein kinase B (PKB). 
To characterise interaction partners of ARNO and elucidate its mode of action within the 
insulin receptor (IR) signalling network, biochemical and biophysical approaches were 
undertaken. A direct interaction of ARNO with the IR could not be demonstrated, however 
this study characterises the interaction between ARNO and CNK1 in depth. Using 
pull-down, analytical size-exclusion chromatography and isothermal titration calorimetry 
approaches, a direct physical interaction between ARNO and CNK1 was shown. 
Furthermore, the interaction site was mapped to the respective coiled-coil domains of both 
proteins. Structural studies resulted in the generation of protein crystals, which however 
did not allow for structure determination due to poor X-ray diffraction. To elucidate the 
effect of complex formation on the catalytic activity of ARNO, an exchange assay using 
liposomes and myristoylated Arfs was established. The localisation as well as the effect of 
CNK1 on the exchange rate was tested in vitro. As expected, wildtype CNK1 did not 
localise to membranes and also did not affect ARNO-catalysed exchange. Since activated 
CNK1 as well as ARNO are membrane-bound, CNK1 was artificially tethered to 
functionalised liposomes via a hexahistidine-tag. Although the liposome tethering was 
successful, no exchange could be monitored under these conditions, and hence the 
consequences of the interaction on the exchange rate remain to be investigated using a 
modified approach. 
Possibly, CNK1 helps localise cytohesins to the plasma membrane which increases the 
concentration of activated Arf. Sustained Arf activity leads to higher levels in phosphatidyl-
inositol-4,5-bisphosphate (PIP2) and increased IR signalling. Lysine acetylation within the 
PH domain of CNK1 might be an important factor to direct CNK1 to the membrane and 
drive signalling but further studies need to confirm the specific mode of action. 
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1 Introduction 
1.1 Intracellular signalling 
For a multicellular organism, signal transmission, integration and processing are vital to 
react to external stimuli. Signals can be conveyed electrically via the nervous system or by 
soluble chemical messengers such as hormones and paracrine mediators. Once the 
messenger molecule has reached its target cell, it exerts its action by binding to a specific 
receptor. If the messenger molecule is membrane permeable like steroid hormones, the 
receptor can be located inside the cell (Germain et al. 2006). More often however, the 
mediating molecule cannot penetrate the cellular barrier and therefore binds to a receptor 
located within the cell membrane. Those transmembrane receptors consist of extra- and 
intracellular domains as well as a membrane-spanning domain to receive and transmit a 
signal. 
Most transmembrane receptors can be assigned to one of three categories: ion channels, 
G protein-coupled receptors and enzyme-linked receptors. The acetylcholine receptor is a 
typical example for an ion channel receptor which allows cations to pass when ligands 
such as acetyl choline (and many more) bind (Karlin 2002). G protein-coupled receptors 
are seven-pass transmembrane proteins and transfer the signal via the activation of an 
intracellular trimeric guanine nucleotide-binding protein (G protein). A light-sensitive 
G protein-coupled receptor is the rhodopsin photoreceptor located in the retina (Garriga 
and Manyosa 2002). Ligand binding to an enzyme-linked receptor activates enzymatic 
activity in the receptor itself or an associated protein via the induction of conformational 
changes. Typically, this leads to the activation of a kinase as in the case of the insulin 
receptor (Kasuga et al. 1982, Hubbard 2013). 
1.1.1 Intracellular signal transmission 
Once a receptor is activated, intracellular signalling molecules assist in relaying the signal 
to target proteins. Those signalling molecules can be so called “second messengers” like 
water-soluble 3’,5’-cyclic adenosine monophosphate (cAMP), Ca2+ or the lipid-soluble 
diacyl glycerol (DAG) (Newton et al. 2016). Phosphatidylinositol-3,4,5-trisphospate (PIP3) 
produced by phosphatidylinositol-3-kinase (PI3K) and cAMP constitute important second 
messengers in insulin signalling (Ruderman et al. 1990, Cohen 2006). 
Furthermore, proteins and protein complexes are major constituents of signalling 
cascades. The interplay of those components leads to signal transmission, amplification, 
integration and finally the desired effect. Proteins involved in signalling cascades can 
covalently modify other proteins (such as kinases), work as molar switches (GTPases) or 
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assist in the assembly of large signalling complexes (scaffold proteins). Finally, the 
signalling process results in alterations of gene expression, metabolism or cell shape to 
encounter the stimulus. Importantly, this is not a unidirectional process with clear 
beginning and end. The components are interconnected and several feedback 
mechanisms lead to signal attenuation and termination. In the case of the insulin receptor 
(IR), which is a receptor tyrosine kinase, protein tyrosine phosphatases (PTPases) stop 
the signalling once the ligand has dissociated (Sugimoto et al. 1994). 
1.1.2 Protein-protein interactions 
The molecular basis of signal transmission between proteins is their physical interaction 
and possibly covalent modification. Interaction with a binding partner can change the 
catalytic activity, alter the accessibility for other factors or simply shift the subcellular 
localisation and hence allow new functions. A modular set of specialised binding domains 
has evolved and was shown to be crucial for the majority of protein-protein interactions 
within signalling cascades. Important examples with relevance for this work are 
highlighted in the following paragraphs. 
Activation of signalling proteins often involves protein phosphorylation by kinases. The 
Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains both recognise 
phosphotyrosines in peptide sequences (Sadowski et al. 1986, Kavanaugh and Williams 
1994). SH2 domains consist of about 100 amino acids and were found in many signalling 
proteins such as the p85α subunit of PI3K (Russell et al. 1992, Booker et al. 1992). The 
PTB domains are structurally more diverse than SH2 domains and can be further 
classified. The insulin receptor substrate-1 (IRS1) binds via PTB to the activated, 
phosphorylated IR (Eck et al. 1996) and gave rise to the group of IRS-type PTB domains. 
Src homology 3 (SH3) domains are protein interaction modules of about 60 amino acids 
and bind to short proline-rich hydrophobic patches via their hydrophobic core (Yu et al. 
1992). The function is not comprehensively understood but SH3 domains seem to play a 
role in protein localisation and the assembly of signalling protein complexes (Schlessinger 
1994). The previously mentioned PI3K p85α subunit for example, also contains an SH3 
domain apart from its two SH2 domains (Koyama et al. 1993). 
Another domain similar to the SH2 and SH3 domains in respect to its sequence homology 
and overall functionality was discovered shortly afterwards, the pleckstrin homology (PH) 
domain (Musacchio et al. 1992, Haslam et al. 1993). In contrast to the aforementioned 
domains, PH domains primarily bind phosphorylated phosphoinositides but they also 
serve as protein-protein interaction modules (Harlan et al. 1994, Wang et al. 1994). Both 
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cytohesins and Connector enhancer of KSR 1 (CNK1), which this study focusses on, 
possess PH domains (Kolanus et al. 1996, Jaffe et al. 2004). 
Further, Domain present in PSD-95/DLG-1/ZO-1/2 (PDZ domains) comprise a 
heterogeneous group of modules which bind either C-terminal protein sequences or 
internal polypeptides with varying binding specificities (Ponting et al. 1997). CNK1 
possesses a PDZ domain consisting of 90 amino acids (Jaffe et al. 2004). 
Finally, the coiled-coil (cc) domain is introduced. First described by Francis Crick in the 
early 1950s, this motif usually consists of two to five α-helices wound around each other in 
a left-handed helix termed “supercoil” (Crick, F. H. C. 1953, Mason and Arndt 2004). The 
supercoil is formed by a seven-residue repeat which is commonly denoted [abcdefg]n. 
Here, a and d are typically nonpolar residues located at the inside of the helix while e and 
g are solvent exposed residues which account for the specificity between the helices 
(Mason and Arndt 2004). 3-5 % of all amino acids in proteins form a coiled-coil motif and 
so do cytohesins and CNK1 (Mason and Arndt 2004, Wolf et al. 1997, Chardin et al. 1996, 
Fritz and Radziwill 2011). Fig. 1-1 shows the parallel dimeric coiled-coil of yeast 
transcription factor GCN4. 
 
Fig. 1-1: The coiled-coil domain in the yeast leucine zipper GCN4. If the lysine at position 16 
(arrow, asparagine in the wildtype protein, an “a” position according to cc nomenclature) is mutated 
to glutamine, also trimers can form apart from the shown dimer. The structure is depicted in 
cartoon representation with the hydrophobic a and d positions shown as sticks (PDB-ID 1ZIK, 
Gonzalez et al. 1996). 
1.1.3 The function of scaffold proteins 
Scaffold proteins are usually rich in the protein interaction motifs described above since 
one of their main tasks is to mediate binding of at least two other proteins involved in a 
signalling cascade. Protein scaffolds can localise a complex to a certain cellular 
compartment but are usually devoid of catalytic activity themselves. At least four distinct 
functions for scaffold proteins were identified: The assembly of a signalling complex, the 
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determination of the subcellular localisation, the coordination of positive and negative 
feedback and the protection of activated signalling molecules from inactivation (Shaw and 
Filbert 2009). 
The most fundamental function of scaffold proteins is the assembly of different 
components of a signalling cascade, which can lead to improved efficiency as well as 
specificity. Targeting a complex to a certain localisation was shown for the A-kinase 
anchor proteins (AKAPs), which tether cAMP-dependent protein kinase A (PKA) to 
different sites in the cell (Wong and Scott 2004, Hirsch et al. 1992). An example for 
feedback coordination is the mitogen-activated protein kinase (MAPK) cascade. The 
cascade involves the initial activation of a small G protein followed by three subsequent 
kinases. It was suggested, that the scaffold protein Ste5 could enhance kinase specificity 
and also limit the amplification of the signal (Burack and Shaw 2000). Finally, proteins can 
be protected from inactivation by scaffolds. Especially the shielding effect on 
phosphorylated proteins was studied and mathematically modelled. In these cases, 
phosphatases cannot access the phosphorylation site and the signal is maintained 
(Locasale et al. 2007). 
CNK1, 14-3-3 proteins and IQGAP1 are important scaffolds involved in insulin signalling 
and will be discussed later in chapter 1.4 (Lim et al. 2010, Craparo et al. 1997, Chawla et 
al. 2017). 
1.2 Insulin signalling 
Energy metabolism is an essential task which has to be tackled by every organism from 
bacteria and paramecium to blue whale. Glucose can be generated from higher molecular 
weight nutrients and is a key energy source for many organisms. In vertebrates, a system 
based on the two hormones insulin and glucagon has evolved to regulate the blood 
glucose level and was intensively studied in mammals (Navarro et al. 1999). A tightly-
regulated blood glucose level is vital for organismal survival and growth and its regulation 
is outlined in the subsequent chapters. 
1.2.1 Blood glucose homeostasis 
The normal fasting plasma glucose concentration is < 110 mg/dL (6.1 mM) in human; 
fasting plasma glucose of ≥ 126 mg/dL (7.0 mM) defines diabetes mellitus (WHO and IDF 
2006). Low blood glucose levels are critical since the brain uses glucose almost as its sole 
energy source (Mergenthaler et al. 2013). Hypoglycaemia hence causes functional brain 
failure and profound and prolonged hypoglycaemia (usually of iatrogenic origin) results in 
brain death (Cryer 2007). 
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Diabetes mellitus is a major health risk and 415 million adults were estimated to suffer 
from diabetes mellitus worldwide including 193 million undiagnosed cases (International 
Diabetes Federation 2015). Insufficient treatment results in complications ranging from 
pregnancy complications, diabetic foot syndrome and chronic kidney disease to 
retinopathy (International Diabetes Federation 2015). Obviously, the function of the 
human body is highly dependent on a tightly controlled blood glucose level and therefore 
a sophisticated regulatory system has evolved. 
The most important components in blood glucose regulation are the two peptide 
hormones insulin and glucagon (fig. 1-2). When the blood glucose level rises, for example 
after food intake, β cells of the pancreas produce the anabolic insulin. This leads to 
glucose uptake by muscle and liver cells and storage in the form of glycogen. Additionally, 
adipocytes store energy in form of triglycerides. When the blood glucose level decreases, 
α cells of the pancreas produce catabolic glucagon. This causes glycogenolysis and 
gluconeogenesis in order to maintain blood sugar levels. 
 
Fig. 1-2: The blood glucose level is tightly controlled by insulin and glucagon. If the blood 
glucose level rises, for example after food intake, β cells of the pancreas produce insulin. In turn, 
glucose is taken up by liver and muscle cells and can be stored as polymeric glycogen. When the 
blood glucose level falls, α cells of the pancreas produce glucagon which leads to glycogenolysis 
and a following increase in blood glucose levels. Graphics taken from colourbox.de. 
It could later be shown that additional hormones finetune the actions of insulin and 
glucagon. Amylin is also produced in pancreatic β cells and suppresses postprandial 
glucagon secretion (Moore and Cooper 1991). Glucagon-like peptide-1 (GLP-1) is 
produced in L-cells of the intestine and enhances insulin effects (Nauck et al. 1993). 
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1.2.2 Insulin 
During this work, the intracellular insulin signalling network was further investigated which 
is the reason why I will focus on this part of the blood glucose homeostasis in the 
following. 
Insulin was discovered in 1922 and pancreatic extracts were used for patient treatment 
just one year afterwards (Macleod 1922, Ward and Lawrence 2011). The amino acid 
sequence of insulin was solved in the early 1950s and insulin became the first protein to 
be sequenced (Sanger and Tuppy 1951a, Sanger and Tuppy 1951b, Sanger and 
Thompson 1953a, Sanger and Thompson 1953b). Insulin consists of a 21 amino acid 
A-chain and a 30 amino acid B-chain. Both chains are connected via two disulphide 
bridges between CysA7 and CysB7 as well as CysA20 and CysB19. Additionally, there is 
an intramolecular disulphide bridge between CysA6 and CysA11. 
The three-dimensional structure of hexameric porcine insulin was determined in 1969 and 
the authors found that “in each molecule the A chain is a compact unit around which the 
B chain is wrapped” (Adams et al. 1969). A more recent structure of porcine insulin is 
shown in fig. 1-3. Note, that the structure of insulin changes upon receptor binding and 
this flexibility is required for receptor interaction (Derewenda et al. 1991). 
 
Fig. 1-3: The three-dimensional structure of porcine insulin. The A-chain (ochre) is linked to 
the B-chain (light blue) via two disulphide bridges. The structure is depicted in cartoon 
representation with the intramolecular disulphide bridges shown as yellow sticks (PDB-ID 4INS, 
Baker et al. 1988). 
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1.2.3 The insulin receptor 
It took over thirty years from the first postulation that insulin interacted with the cell 
membrane in order to facilitate sugar uptake into cells in 1949 until the general 
composition of the receptor was elucidated (Levine and Goldstein 1949, Massague et al. 
1980). The receptor is a heterotetramer which is formed of two extracellular α subunits 
and two β subunits, which consist of an extracellular and an intracellular part. The 
α subunits are connected via several disulphide bonds and each α subunit is linked to a 
β subunit by another disulphide bond (Sparrow et al. 1997). Fig. 1-4 shows the three-
dimensional structure of the receptor. 
 
Fig. 1-4: The three-dimensional structure of the insulin receptor. A | Reconstruction of the 
complete insulin receptor from solved partial structures. One heterodimer consisting of an α and 
a β subunit is shown in light blue, the other in dark blue. Insulin PDB-ID 1TRZ (Ciszak and Smith 
1994), extracellular domain (ectodomain) PDB-ID 3LOH (Croll et al. 2016), transmembrane domain 
PDB-ID 2MFR (Li et al. 2014), intracellular kinase domain PDB-ID 1IRK (Hubbard et al. 1994). 
B | The inactive and activated intracellular (kinase) domain (ICD) of the insulin receptor. Tyrosines 
1158, 1162 and 1163 (green) situated in the activation loop (blue) are phosphorylated (red and 
yellow). Hence, the kinase can bind ATP (magenta) to phosphorylate substrates (red). Inactive IR-
ICD PDB-ID 1IRK (Hubbard et al. 1994), active, triple phosphorylated IR-ICD PDB-ID 1IR3 
(Hubbard 1997). The activation mechanism is further described in the text. Adapted from 
PDB 2016. 
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The IR is a receptor tyrosine kinase with the catalytic sites located in either of the two 
intracellular β chains. Upon insulin binding, the kinase domains trans-phosphorylate each 
other within a region called activation loop which in turn enables effector binding and 
phosphorylation (Kasuga et al. 1982, Hubbard 1997). 
In the following, I will briefly go through some structural features of the different receptor 
domains and comment on the activation mechanism. The three-dimensional structure of 
the receptor ectodomain was solved in 2006 (McKern et al. 2006). The receptor is heavily 
glycosylated (Cosgrove et al. 1995) and consists of (starting from the extracellular 
N-terminus) a leucine-rich repeat domain (L1), a cysteine-rich region (CR), a second 
leucine-rich repeat domain (L2) and three fibronectin type III (FnIII-1, FnIII-2, FnIII-3) 
domains as well as an insert domain (ID) within the FnIII-2 domain (Ebina et al. 1985, 
Ward and Lawrence 2011). The ID domain also encompasses a critical α-chain (αCT) 
segment. The dimer “adopts a folded-over conformation that places the ligand-binding 
regions in juxtaposition”, which turned out to be different from previous models (McKern et 
al. 2006). A revised structure revealed further details and improved some model 
weaknesses but confirmed the overall “inverted V” structure (Croll et al. 2016). Recently, a 
structure of insulin bound to its primary receptor binding site could be solved using 
truncated IR constructs (Menting et al. 2013). Insulin interacts with the αCT segment and 
induces a conformational change but there is also minor contact to L1. “The αCT segment 
displaces the B-chain C-terminal β-strand [of insulin] away from the hormone core, 
revealing the mechanism of a long-proposed conformational switch in insulin upon 
receptor engagement” (Menting et al. 2013). Two insulin molecules can bind to a 
heterotetramer IR with high affinity, further binding sites require higher concentrations 
leading to negative cooperativity (Ward et al. 2013, Meyts 2015). 
The structure of the transmembrane region embedded in micelles was solved by nuclear 
magnetic resonance (NMR) studies and showed a well-defined helical structure, which is 
crucial for relaying the signal to the cell interior (Li et al. 2014). 
The first crystal structure of the intracellular kinase domain of the IR was obtained in the 
mid-1990s (Hubbard et al. 1994). Typical for kinases, the ICD consists of an N-terminal 
and a C-terminal lobe. In the inactive state, Tyr1162 interacts with the catalytic site as a 
pseudo-substrate. It cannot be phosphorylated because the activation loop prevents 
proper Mg2+-ATP binding by the catalytic Asp1150 (fig. 1-4). Three years later, the 
structure of the activated kinase was determined in the same group and revealed the 
activation mechanism (Hubbard 1997). In the active state, the activation loop undergoes a 
large conformational change allowing autophosphorylation of Tyr1158, Tyr1162 and 
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Tyr1163 by the second dimer (in trans) as well as access for Mg2+-ATP and substrate 
proteins like IRS1. How insulin binding exactly elucidates theses conformational changes 
is still under investigation and no structure of the complete receptor exists yet. Negative 
regulators like adaptor protein with PH and SH2 domains (APS) were found to bind 
directly to the phosphotyrosines in the activation loop via their SH2 domains (Hu et al. 
2003). Another important mechanism in downstream signalling is the phosphorylation of 
Tyr972, which is localised in the juxtamembrane (JM) region. IRS proteins bind to the IR 
via their PTB domains to this phosphotyrosine after receptor activation (Gustafson et al. 
1995). In contrast to other RTKs, The JM of IR has an inhibitory function. It is exerted via 
Tyr984, which is no phosphorylation site (Li et al. 2003b, Hubbard 2004). 
1.2.4 Intracellular insulin signalling pathway 
A pubmed search for “insulin signal[l]ing” yields more than 34000 research articles which 
demonstrates the large scope of this topic. It is furthermore clear that many interesting 
aspects of insulin signalling cannot be covered in depth in this work since the field is very 
wide. I would like to refer the reader to four comprehensive review articles, which also 
served as the basis for this chapter (Cohen 2006, Saltiel 2016, Wilcox 2005, Ward and 
Lawrence 2011). 
It took many years from the identification of insulin in 1922 (Macleod 1922) to the 
elucidation of the main involved intracellular factors. The main function of insulin is 
lowering the blood glucose levels by enhancing the conversion of glucose to its storage 
forms. In muscle and adipose tissue, glucose is converted to glucose 6-phosphate by 
hexokinase and in the liver by glucokinase. Glucose is finally stored as glycogen in 
muscle and the liver or as triglycerides in fat tissue. The key enzyme for glycogen storage 
is the glycogen synthase (GS), which catalyses the last step of glycogen formation, the 
coupling of uridine diphosphate glucose (UDP-glucose) to a pre-existing glycogen 
molecule. An excess of glucose 6-phosphate activates GS. Further it was found in 
muscle, that insulin stimulates GS by converting a less active, phosphorylated GS into its 
dephosphorylated form and hence implied that kinases/phosphatases are part of the 
insulin signalling cascade (Villar-Palasi and Larner 1960). How does insulin cause the 
conversion of glucose to its storage form glycogen by GS activation on a molecular level? 
The signal to store glucose in form of glycogen starts with insulin binding to its receptor 
(fig. 1-5). As described in detail in chapter 1.2.3, the IR is a receptor tyrosine kinase (RTK) 
which is autophosphorylated upon conformational changes within the activation loop 
(Hubbard 1997). The phosphorylated IR now serves as a docking site for adaptor proteins 
like IRS1, which is in turn phosphorylated (White et al. 1985, Sun et al. 1993). 
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SH2 domain-containing proteins can now bind the phosphorylated IRS1. This is the case 
for the regulatory p85 subunit of PI3K, which recruits the functional kinase to the plasma 
membrane (Ruderman et al. 1990). PI3K converts the membrane lipid 
phosphatidylinositol-4,5-bisphosphate (PIP2) into the second messenger 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), whose concentration increases as a 
result. Hence, 3-phosphoinositide-dependent protein kinase-1 (PDK1) as well as 
protein kinase B (PKB) bind to PIP3 via their PH domains (Komander et al. 2004, James et 
al. 1996). PDK1 phosphorylates PKB at Thr308 which greatly enhances kinase activity of 
PKB (Alessi et al. 1997). Additionally, PKB is activated by a phosphorylation at Ser473 by 
mammalian target of rapamycin (mTOR), which is still subject of current investigation 
(Sarbassov et al. 2005). 
 
Fig. 1-5: The intracellular insulin signalling network. The signalling cascade is described in the 
text. IR, insulin receptor; IRS1, insulin receptor substrate-1; PI3K, phosphatidylinsositol-3-kinase; 
PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PDK1, 
3-phosphoinositide-dependent protein kinase-1; PKB, protein kinase B; GSK3, glycogen synthase 
kinase-3; GS, glycogen synthase; GSP, glycogen synthase phosphatase; PDE, 
phosphodiesterase; cAMP, cyclic AMP; PKA, protein kinase A; HSL, hormone-sensitive lipase. 
Adapted from Cohen 2006. 
As one of the last steps, active PKB inhibits glycogen synthase kinase-3 (GSK3) by 
phosphorylating GSK3α at Ser21 and GSK3β at Ser9 (Cross et al. 1995). With GSK3 
inactivated, the glycogen synthase (GS) gets dephosphorylated by glycogen synthase 
phosphatase (GSP) which activates GS and finally leads to the accumulation of glycogen. 
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In contrast to muscle cells, energy is stored in form of lipids in adipocytes. Insulin 
enhances lipid synthesis and inhibits lipolysis (Saltiel 2016). PKB phosphorylates a 
phosphodiesterase (PDE), which is activated and causes a drop in cAMP concentration 
(fig. 1-5, Kitamura et al. 1999, Ahmad et al. 2009). Thus, protein kinase A (PKA) is less 
active and the hormone-sensitive lipase (HSL) remains in its non-phosphorylated, inactive 
state. This results in blocked lipolysis (Anthonsen et al. 1998, Strålfors et al. 1984). PKB 
also phosphorylates the transcription factor FoxO1 which excludes it from the nucleus and 
stops expression of gluconeogenetic and lipolytic genes (Gross et al. 2009). 
Another extremely important effect of insulin is the translocation of glucose transporters, 
namely GLUT-4 to the cell membrane in muscle cells and adipocytes. This leads to 
enhanced glucose uptake into the tissue and hence a decrease in blood glucose level. 
While it is clear that insulin and muscle activity trigger the translocation, the exact 
mechanism is still under investigation. Apparently, PKB phosphorylates the GTPase 
activating protein AS160 which leads to the inactivation of several Rab GTPases (Sano et 
al. 2003). AS160 was shown to enhance the insulin-stimulated GLUT-4 exocytosis but 
does not affect down-regulation by endocytosis (Zeigerer et al. 2004). 
Insulin stimulation also modulates gene expression, cell proliferation and differentiation. 
For those effects, a further signalling pathway is essential, the mitogen-activated protein 
kinase (MAPK) signalling cascade (Avruch 1998). Binding of IRS or SHC to the activated 
IR also recruits the adaptor protein growth factor receptor-bound protein-2 (GRB2). GRB2 
in turn recruits son of sevenless (SOS), which is an exchange factor for the small GTPase 
RAS, the start of the MAPK cascade (Pronk et al. 1993). RAS activates the Raf kinase by 
membrane recruitment, which then phosphorylates MAPK/ERK kinase (MEK) and finally 
activates the effector kinase extracellular-signal regulated kinase (ERK). 
Taken together, hallmarks of insulin signalling are complex kinase cascades involving lipid 
and nucleotide-based second messengers. The kinase PKB is central in the mediation of 
metabolic insulin effects. 
1.3 Small GTPases and their guanine nucleotide exchange factors 
As already pointed out in chapter 1.1, guanine nucleotide-binding proteins (G proteins or 
GTPases) constitute an important class of signalling molecules. They can be grouped into 
two classes: Heterotrimeric G protein-coupled receptors and monomeric small G proteins. 
As the name suggests, the first class consists of three subunits (α, β and γ), which 
associate with a seven-transmembrane-span receptor. Upon receptor activation, Gα 
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separates from the Gβγ complex and both are responsible for further signal transduction 
(activation mechanism reviewed in Oldham and Hamm 2008). 
Most of the small monomeric G proteins belong to the Rat sarcoma (Ras) superfamily with 
more than 150 members in human, which can further be subdivided into the five classes: 
Ras, Ras homologous (Rho), Ras related in brain (Rab), Ras related nuclear protein 
(Ran) and ADP ribosylation factor (Arf) (Wennerberg et al. 2005). As mentioned before, 
small GTPases are involved in several occasions in the insulin signalling pathway such as 
GLUT-4 exocytosis and MAPK signalling (Sano et al. 2003, Pronk et al. 1993). 
Ras proteins are further implicated in many diseases such as cancer and also psychiatric 
disorders and are therefore a subject of intensive research (Simanshu et al. 2017). Rho 
GTPases are particularly well known for their involvement in actin organisation and cell 
migration; RhoB was shown to regulate membrane trafficking, cell proliferation, DNA 
repair and apoptosis (Vega and Ridley 2016). Rab GTPases are key regulators of 
vesicular transport mechanisms and vesicle budding. Different isoforms were found to 
localise to specific compartments (Goody et al. 2017). Ran proteins on the other hand are 
primarily engaged in nuclear-cytoplasmic transport (Nagai and Yoneda 2012). Finally, 
ARF GTPases are involved in vesicular trafficking and are discussed in detail in 
chapter 1.3.1. 
GTPases can be regarded as a molecular switch: In their basal state, they are in their 
inactive, GDP-bound conformation (fig. 1-6). 
 
Fig. 1-6: GTPases act as molecular switches. The GDP-bound GTPase is considered its inactive 
state since it is usually not involved in signal transmission. Guanine nucleotide exchange factors 
(GEFs) expel the bound GDP which enables GTP binding. The active, GTP-bound form has a 
largely different three-dimensional structure and can now interact with effector proteins. The signal 
is terminated with the help of GTPase-activating proteins (GAPs), which stimulate the GTPase 
activity. The GTP γ-phosphate is hydrolysed and released and the GTPase returns to its GDP-
bound, inactive state. 
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Guanine nucleotide exchange factors (GEFs) displace the nucleotide and GTP, which is 
at a ten times higher concentration in cells than GDP, binds to the GTPase (Traut 1994, 
Vetter and Wittinghofer 2001). The evoked conformational change enables binding of 
effector proteins and downstream signalling. GTPase-activating proteins (GAPs) 
accelerate the intrinsically low GTPase activity which leads to the hydrolysis of GTP to 
GDP and the GTPase returns to its inactive state. 
All small GTPases possess a nucleotide binding and hydrolysis function which is located 
in the around 20 kDa large “G domain” with a universal structure and switch mechanism. 
The domain consists of a “mixed six-stranded β sheet and five helices located on both 
sides” (Vetter and Wittinghofer 2001). The Asn/Thr-Lys-Xaa-Asp motif (Xaa: any amino 
acid) in conjunction with the phosphate-binding loop (P loop) are most important for 
nucleotide binding (Vetter and Wittinghofer 2001, Saraste et al. 1990) alongside with Mg2+ 
(Lenzen et al. 1998). Small GTPases are characterised by two “switch regions” first 
discovered in Ras, which show increased flexibility and enable effector binding (Milburn et 
al. 1990, Farrar et al. 1997). While the different GDP-bound G proteins show a large 
structural variety, GTP-bound G proteins are stunningly similar to enable effector binding 
(Sprang 1997). Vetter compares the changes after nucleotide hydrolysis to “a loaded-
spring mechanism where release of the γ-phosphate after GTP hydrolysis allows the two 
switch regions to relax into the GDP-specific confirmation” (Vetter and Wittinghofer 2001). 
The switching mechanism is exemplified for ARF1 in fig. 1-7 B. 
While this is the classical view on GTPase biology, the distinction of inactive GDP-bound 
GTPase and active GTP-bound GTPase became blurry during the last years. Novel 
binding partners of GDP-bound Rab27a in pancreatic β cells were identified and Rab27a-
GDP controls endocytosis of the secretory membrane (Yamaoka et al. 2015). 
1.3.1 ADP ribosylation factor (ARF) GTPases 
In the following, I will focus on the group of ARF-GTPases since they were an important 
subject of investigation in this study. ARF-GTPases were discovered in the mid-1980s as 
a cofactor required for cholera toxin to ADP-ribosylate the stimulatory regulatory element 
of adenylate cyclase and cause its toxic effect (Kahn and Gilman 1986). Further, its ability 
to bind GDP and GTP was described (Kahn and Gilman 1986, O'Neal et al. 2005) and it is 
this characteristic which confers the function as a molecular switch to the protein. 
In mammals, there are six ARFs which are grouped into three classes according to their 
sequence homology: Class I comprises ARF1, ARF2 (missing in human) and ARF3, 
class II comprises ARF4 and ARF5, while the sole member of class III is ARF6 (Kahn et 
al. 2006). Class I ARFs enable the assembly of coat protein complexes on budding 
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vesicles within the secretory pathway. ARF1 was shown to be involved in COPI as well as 
clathrin coat formation (Serafini et al. 1991, Austin et al. 2000, Ren et al. 2013). Class II 
ARFs were less intensely studied but evidence accumulates that ARF4 regulates 
retrograde endosome-to-Golgi transport and intraorganellar traffic in the ER-Golgi 
intermediate compartment (ERGIC) in conjunction with class I ARFs (Nakai et al. 2013, 
Ben-Tekaya et al. 2010). ARF6, alongside ARF1, is the best characterised ARF. It 
regulates endosomal traffic and membrane remodelling (reviewed in D'Souza-Schorey 
and Chavrier 2006). 
In order to fulfil this multitude of crucial functions, ARFs show several structural features, 
which also distinguish them from other small GTPases (fig. 1-7). 
 
Fig. 1-7: Activation of ARF GTPases. A | Schematic representation of ARF activation. GTP 
binding liberates the N-terminally myristoylated amphipathic helix, which enables membrane 
association. SW1/2, switch 1/2. Adapted from Donaldson and Jackson 2011. B | Comparison of 
ARF1-GDP and ARF1-GTP shows the large structural change. The interswitch region pushes the 
N-terminal helix out. ARF1-GDP PDB-ID 1HUR (Amor et al. 1994), ARF1-GTP PDB-ID 1O3Y 
(Shiba et al. 2003). Adapted from Gillingham and Munro 2007. 
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At their N-terminus, ARFs possess an amphipathic helix. After methionine processing, the 
N-terminal glycine is modified with a lipid, a C14 myristoyl group (Kahn et al. 1988). Both 
elements facilitate membrane tethering of ARFs (Amor et al. 1994). The N-terminal helix 
further locks the GTPase in its GDP-bound inactive conformation (Amor et al. 1994, 
Liu et al. 2009). 
Upon GDP to GTP exchange, the region between switch 1 and switch 2, called 
“interswitch”, changes conformation. These two newly oriented β sheets in turn displace 
the N-terminal helix form a hydrophobic pocket, leading to facilitated membrane 
attachment (Antonny et al. 1997). ARF6 however is associated with membranes also in its 
GDP bound form (Macia et al. 2004). 
1.3.2 Sec7 domain exchange factors and GAPs control ARF GTPases 
The aforementioned activation process, the exchange of GDP for GTP, is triggered by 
guanine nucleotide exchange factors (GEFs) of the Sec7 family. They are named after 
their catalytic Sec7 domain, which is homologous to the yeast ARF GEF sec7p (Achstetter 
et al. 1988). Based on domain organisation, the 15 human ARF GEFs can be grouped 
into five classes (tab. 1-1). The fact that 15 activating proteins exist for only five human 
ARF GTPases suggests that ARF activity needs to be tightly controlled in time and space. 
Tab. 1-1: Human ARF GEF families. All GEF proteins possess the catalytic Sec7 domain. 
GBF/BIG, Golgi BFA-resistance factor 1/BFA-inhibited GEF; EFA6, exchange factor for Arf6; PSD, 
pleckstrin and Sec7 domain containing; BRAG, Brefeldin-resistant Arf GEF; Fbox8, F-box only 
protein 8. Taken from Casanova 2007. 
Family Human proteins 
GBF/BIG GBF1, BIG1, BIG2 
Cytohesins Cytohesin-1, Cytohesin-2 (ARNO), Cytohesin-3 (GRP1), Cytohesin-4 
EFA6/PSD EFA6A (PSD), EFA6B (PSD4), EFA6C (PSD2), EFA6D (PSD3) 
BRAGs BRAG1, BRAG2 (GEP100), BRAG3 
Fbox Fbox8 
 
The Sec7 domain consists of approximately 200 amino acids and its catalytic activity 
depends on a “glutamic finger” within a hydrophilic loop, which was shown by mutational 
studies and confirmed by X-ray crystallography (Cherfils et al. 1998, Béraud-Dufour et al. 
1998, Renault et al. 2003). In cytohesins, the catalytic Sec7 domain is flanked by an 
N-terminal coiled-coil domain which serves as an interaction module and the C-terminal 
PH domain, which binds phosphoinositides (Klarlund et al. 2000) (fig. 1-8). 
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Fig. 1-8: Modular structure of cytohesins. Cytohesins have a molecular weight of approximately 
45 kDa and possess an N-terminal coiled-coil (cc) domain, a central Sec7 domain and a C-terminal 
pleckstrin homology (PH) domain. There is also a polybasic region (pbr) at the very C-terminus. 
In the cytohesin ARNO, Glu156 destabilises GDP and Mg2+ bound to ARF1 and thus 
allows GTP to bind, which is approximately at a ten times higher intracellular 
concentration than GDP (Béraud-Dufour et al. 1998, Renault et al. 2003, Traut 1994) 
(fig. 1-9). 
 
Fig. 1-9: Complex of NΔ17ARF1-GDP and the catalytically inactive ARNOE156K charge 
reversal mutant. GDP (green carbon atoms, stick representation) is bound to the truncated ARF1 
(turquoise, cartoon representation). The ARNO Sec7 domain (ochre, cartoon representation) is 
associated with the N-terminally truncated GTPase but since the catalytic Glu156 is mutated to Lys 
(red sticks), the complex is stabilised and the nucleotide cannot be displaced. PDB-ID 1R8S 
(Renault et al. 2003). 
Since the intrinsic GTPase activity of ARFs is comparatively low, GAPs are needed to end 
ARF signalling. This GAP activity was first discovered in bovine brain extracts (Randazzo 
and Kahn 1994). A specific ARF GAP domain was described just one year later and 
subsequently discovered in a heterogeneous group of 24 mammalian proteins with a large 
variety in structure and size (Cukierman et al. 1995, Gillingham and Munro 2007). The 
domain comprises approximately 140 amino acids and is characterised by four cysteine 
residues which form a zinc finger. A conserved arginine inserts into the active site and 
Lys156 
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might directly participate in GTP hydrolysis, although opposing models have been 
suggested (Mandiyan et al. 1999, Goldberg 1999). 
1.3.3 Membranes and feedback loops influence ARF activity 
Since ARF GTPases as well as their exchange factors interact with membranes in their 
active states, it comes as no surprise that there is a well-orchestrated interplay between 
the proteins and the membrane which is crucial for the regulation of activity. 
ARF GTPases are controlled by a double layer of autoinhibition. First, the myristoylated 
N-terminal helix has to be displaced from its hydrophobic pocked by membrane binding 
since the helix occludes the binding site for the GTP γ-phosphate (Amor et al. 1994, Liu et 
al. 2009). Second, the reorientation of the interswitch region remodels the GTP-binding 
site and also helps in displacing the N-terminal helix and hence secures membrane 
attachment (Antonny et al. 1997). The necessity of membranes to relieve autoinhibition 
was demonstrated by the fact that the isolated Sec7 domain cannot promote nucleotide 
exchange on full-length myristoylated ARF in absence of membranes (Chardin et al. 
1996). Hence, membranes prime the GTPase by spontaneous and transient attachment. 
Additionally, membranes are also required for an effective orientation and close proximity 
of ARF and GEF. Cytosolic GEFs of the cytohesin family are autoinhibited by a C-terminal 
polybasic region (pbr) (DiNitto et al. 2007). However, two mechanisms target cytohesins 
to the membrane. The PH domain binds to phosphoinositides, namely 
phosphatidylinositol-4,5-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) (Chardin et al. 1996, Klarlund et al. 2000). Furthermore, the positively charged pbr 
interacts with negatively charged lipid headgroups like phosphatidylserine (Macia et al. 
2000). The extent of membrane influence becomes apparent when comparing catalytic 
efficiencies. Kcat/KM for an ARNO construct composed of Sec7 and PH domain increases 
by four orders of magnitude for myr-ARF1 compared to the soluble NΔ17ARF1 (Nawrotek 
et al. 2016). 
The notion that ARF does not only represent a substrate of ARNO but can also recruit 
ARNO as an effector to the plasma membrane and hence change its activity was 
introduced about 10 years ago (Cohen et al. 2007). The interaction was found to depend 
on the ARNO PH domain, phosphoinositides and ARF6 being in its GTP-bound state. 
Compared to this cellular study, the mechanism was further dissected biochemically using 
liposomes and purified myristoylated ARFs (Stalder and Antonny 2013). ARF6-GTP 
stimulated ARNO at nanomolar concentrations and also ARF1-GTP contributed to a 
positive feedback loop.  
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1.4 Cytohesins and scaffold proteins in insulin signalling 
There are about 20000 human protein-coding genes and the resulting gene products are 
situated inside of a cell which is crowded with other proteins and macromolecules such as 
nucleic acids (Ezkurdia et al. 2014). Scaffold proteins, which were introduced in 
chapter 1.1.3, have evolved to orchestrate and finetune protein-protein interactions in this 
setting. Before focussing on CNK1, which is the central scaffold protein in this study, I 
would like to mention some other examples of scaffold proteins in insulin signalling. 
The probably best-known scaffold in insulin signalling is IRS1 (White et al. 1985). The 
PTB domain of IRS1 binds the JM region of the activated phosphorylated insulin receptor 
(Eck et al. 1996). IRS1 is then phosphorylated and serves as a docking platform for 
further proteins and hence fulfils the classical role of an adaptor protein (Sun et al. 1993). 
One of those interacting proteins belongs to a further group of scaffold protein itself, the 
14-3-3 proteins (Craparo et al. 1997). 14-3-3 proteins were later shown to be involved in 
GLUT-4 recycling by interacting with the phosphorylated Rab GAP AS160 (Ramm et al. 
2006). 
IQ motif containing GTPase activating protein 1 (IQGAP1) binds to the IR as well as to 
IRS1 and is required for PKB and MAPK downstream signalling (Chawla et al. 2017). As 
pointed out in chapter 1.2.4, the GRB2 scaffold is another factor involved in the MAPK 
signalling branch of insulin action (Pronk et al. 1993). GRB scaffolds are also implicated in 
insulin signal termination. GRB14 acts as a pseudosubstrate for the IR and inhibits its 
activity (Depetris et al. 2005). Further, GRB10 and GRB14 bind with their different 
domains to an IR-Ras-phosphoinositide complex thus limiting signal propagation (Depetris 
et al. 2009). 
The CNK family of scaffold proteins and their involvement in cytohesin-dependent insulin 
signalling will be discussed in depth in the following chapters. 
1.4.1 The CNK family of scaffold proteins 
Five mammalian Connector enhancer of kinase suppressor of Ras (CNK) proteins have 
been described, which are all characterised by a plethora of interaction domains (Fritz and 
Radziwill 2011). Fig. 1-10 illustrates the modular structure of CNK1 including the classical 
interaction modules sterile alpha motif (SAM), PDZ and cc. CNK2A (MAGUIN-1), CNK2B 
(MAGUIN-2) and CNK3A furthermore possess a central domain of unknown function 1170 
(DUF1170). CNK3A lacks the C-terminal PH and cc domain, while the last member, 
CNK3B (IPCEF1) lacks the N-terminus and consists of a PH domain, a serine-rich region 
and a conserved region among chordate (CRAC). 
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Relatively little research has been conducted on this protein family but a substantial body 
of knowledge arises from research performed in the Radziwill group. They found CNK1 to 
be involved in MAPK signalling by showing that it regulates Src-mediated Raf1 kinase 
activation (Ziogas et al. 2005). Further, CNK1 was established as a new PKB interaction 
partner which promotes cell proliferation through FoxO signalling (Fritz et al. 2010). 
 
Fig. 1-10: Modular structure of CNK1. SAM, sterile alpha motif; CRIC, conserved region in CNK; 
PDZ, Domain present in PSD-95/DLG-1/ZO-1/2; PH, pleckstrin homology; cc, coiled-coil. 
Also the group of Alan Hall expanded the knowledge of CNK1, especially its involvement 
in signalling downstream of Rho GTPase. CNK1 is an effector of Rho-GTP and the CNK1 
PH domain is required for Rho interaction. CNK1 bridges the interaction with Rho and Ras 
effectors and might therefore mediate the crosstalk between both pathways (Jaffe et al. 
2004). The involvement in the MAPK signalling was further substantiated by the 
identification of the Rho-specific GEFs Net1 and p115RhoGEF as well as two kinases of 
the JNK MAP kinase pathway (MLK2 and MKK7), which all interact with CNK1 (Jaffe et al. 
2005). 
1.4.2 Cytohesins in insulin signalling 
The link between insulin signalling and cytohesins was first discovered in the late 1990s 
when it was shown that ARNO, Cytohesin-3 and ARF6 are recruited to the cell membrane 
upon insulin stimulation (Venkateswarlu et al. 1998, Shome et al. 1997, Langille et al. 
1999). Analyses of downstream signalling afterwards revealed that ARNO mediates the 
activation of ARF and phospholipase D (Li et al. 2003a). 
More information on cytohesin-dependent insulin signalling could be obtained by using a 
chemical GEF activity inhibitor termed SecinH3 specific for cytohesins (Hafner et al. 2006, 
Fuss et al. 2006). In Drosophila melanogaster, mutations in the cytohesin homologue 
steppke as well as chemical inhibition by SecinH3 led to slowed growth in all key fly 
development stages. Impaired insulin signalling was identified to cause the effects as 
shown by reduced PKB activation and expression profile analysis of insulin-dependent 
transcription (Fuss et al. 2006). 
Also when SecinH3 was fed to mice, a diabetic-like phenotype including insulin resistance 
and reduced expression in of glycolytic, fatty acid and ketone body metabolism genes in 
the liver was evoked (Hafner et al. 2006). This further confirmed the involvement of 
cytohesins also in mammalian insulin signalling. Since SecinH3 inhibited IRS1 but not IR 
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phosphorylation, Hafner and colleagues concluded that cytohesins are involved in the 
early steps of the signalling cascade after IR activation. 
Cytohesins were also implicated in GLUT-4 regulation. PKB phosphorylates Cytohesin-3 
and promotes GLUT-4 recycling via its effector ARF6 (Li et al. 2012). 
It was also found that the involvement of cytohesins is not limited to the downstream 
effects of IR but cytohesins also mediate insulin-like growth factor receptor (IGFR) 
signalling in a prostate cancer cell line (Weizhong et al. 2011). 
1.4.3 The involvement of CNK1 in insulin signalling 
Cytohesins were discovered as a major interaction partner of the previously introduced 
scaffold protein CNK1 (chapter 1.4.1) by using a pull-down/mass spectrometry approach. 
The C-terminal domain of CNK1 and the coiled-coil domain of cytohesins were required to 
facilitate the membrane recruitment of ARNO upon insulin stimulation (Lim et al. 2010). 
The authors postulated a direct protein-protein interaction, which was however not strictly 
proven since the results were obtained by co-immunoprecipitations from cell lysates. The 
authors report that the CNK1-cyothesin interaction is critical for the activation of the 
PI3K/PKB downstream cascade from IR and IGFR and that microenvironments with 
elevated PIP2 levels are essential for signal transmission. The question of how CNK1 is 
localised to the membrane is not addressed; their developed model is depicted in 
fig. 1-11. 
 
Fig. 1-11: Model of CNK1-cytohesin involvement in insulin signalling. CNK1 recruits 
cytohesins to the plasma membrane in an insulin-dependent manner. Activated ARF leads to 
increased PIP2 production via allosteric activation of phosphatidylinositol-4-phosphate-5-kinase 
(PIP5K). Increased PIP2 levels subsequently facilitate IRS1 binding and enhance the signalling 
cascade. IR, insulin receptor; IRS1, insulin receptor substrate-1; PI3K, phosphatidylinsositol-3-
kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; 
PDK1, 3-phosphoinositide-dependent protein kinase-1; PKB, protein kinase B. Adapted from 
Lim et al. 2010 and Cohen 2006. 
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2 Aim of the Project 
A detailed understanding of complex signalling networks is the fundamental prerequisite 
for the development of therapeutics in many areas. Insulin signalling is a key metabolic 
pathway with high significance and dysregulation is associated with diabetes mellitus, a 
disease affecting hundreds of millions of people worldwide (WHO and IDF 2006). 
This works aims at understanding the molecular basis of certain insulin signalling 
components. In particular, cytohesins, which are guanine nucleotide exchange factors for 
Arf GTPases, and the scaffold protein CNK1 were investigated. The involvement of 
cytohesins in insulin signalling is subject to research since the late 1990s (Venkateswarlu 
et al. 1998, Shome et al. 1997) and pharmacological blockage of cytohesins induces a 
diabetic-like phenotype in mice (Hafner et al. 2006). CNK1 forms a complex with 
cytohesins and positively regulates insulin signalling (Lim et al. 2010). 
In order to understand the mode of action, respective components were heterologously 
expressed and analysed by biochemical means. It was assessed whether the cytohesin 
ARNO directly interacts with the insulin receptor and changes its activity. The interaction 
between ARNO and CNK1 was characterised via pull-down assays, analytical size-
exclusion chromatography and isothermal titration calorimetry. Crystallisation approaches 
were undertaken to determine the three-dimensional structure of the complex. 
It was hypothesised that CNK1 directly affects the catalytic activity of ARNO. To test this 
hypothesis, the localisation to membranes was evaluated in liposome flotation assays and 
a liposome-dependent nucleotide exchange assay was established using myristoylated 
ARFs. Since it is activated, membrane-bound CNK1 which most likely exerts its action 
within the cell, different strategies were employed to tether CNK1 to liposomes and 
evaluate the effect on the localisation and catalytic activity of ARNO. 
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3 Results 
3.1 Influence of cytohesins on the insulin receptor activity 
The involvement of cytohesins in the insulin signalling pathway was first discovered in 
1998 (Venkateswarlu et al. 1998). Specifically, the translocation of the cytohesin ARNO to 
the cell membrane upon insulin stimulation was described. Li and colleagues 
subsequently postulated a direct interaction between ARNO and the insulin receptor (IR) 
(Li et al. 2003a). However, their approach, performing immunoprecipitation experiments of 
the insulin receptor α subunit from HIRcB cell lysates and analysing bound ARNO 
constructs, does not allow conclusions about direct interactions. The question of 
mediating co-factors or proteins remains to be addressed. 
Two ground-breaking publications from 2006 shed further light on the involvement of 
cytohesins in insulin signalling by making use of the chemical GEF activity inhibitor 
SecinH3 (Hafner et al. 2006, Fuss et al. 2006). Hafner and co-workers proposed a 
physical association between a cytohesin-ARF complex with the insulin receptor-IRS 
complex since activation of insulin receptor substrate-1 (IRS1) was hampered by SecinH3 
and both complexes were co-immunoprecipitated. 
To test whether the involvement of cytohesins is rooted in an enhanced IR activity, in vitro 
autophosphorylation assays were performed in this work. Further, diverse biochemical 
interaction studies were carried out in order to investigate the possibility of a direct 
interaction between the insulin receptor intracellular domain (IR-ICD) and ARNO. 
3.1.1 Quality control of purified proteins 
In order to ascertain the proper folding and structural integrity of the heterologously 
expressed and purified components for the succeeding studies, their catalytic activities 
were tested using appropriate in vitro assays. The IR-ICD was obtained via Sf9 cell 
expression followed by immobilised metal ion affinity chromatography (IMAC) and size-
exclusion chromatography (SEC) purification. ARNO was heterologously expressed in 
E. coli and also purified via IMAC. After enzymatic affinity tag removal, the protein was 
subjected to SEC as a last purification step. 
Upon binding of insulin to the IR, the adjacent kinase domains of the IR-ICD trans-
phosphorylate each other at three tyrosine residues within the activation loop at positions 
Tyr1158, Tyr1162 and Tyr1163 (Hubbard 1997). Addition of high concentrations of 
magnesium (30 mM MgCl2) typically leads to receptor aggregation followed by 
autophosphorylation (Herrera and Rosen 1986). Using this approach, the activity of the 
IR-ICD was tested (fig. 3-1 A). Antibodies specific to the phosphotyrosines (pY) in the 
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activation loop as well as a general pY antibody could detect activation of the IR within 
one minute after ATP/MgCl2 addition. 
 
Fig. 3-1: IR-ICD and ARNO are catalytically active. A | 525 nM IR-ICD was mixed with 
30 mM MgCl2 and 1 mM ATP and samples were taken at the indicated time points. The samples 
were applied to 10 % SDS-PAGE, transferred via western blot and detected with α-pY and α-
pY1162/1163 antibodies. B | 20 nM and 200 nM ARNO catalyse the GDP to Mant-GTP exchange 
on 400 nM NΔ17ARF1. The exchange reaction was monitored by Mant-FRET at 297/455 nm. 
ARNO catalyses the exchange of GDP to GTP on small GTPases of the ADP ribosylation 
factor (ARF) family leading to their activation (Kolanus 2007). The activity of 
heterologously expressed ARNO was tested using a Mant-GTP binding assay. The 
exchange of GDP to Mant-GTP on the soluble, N-terminally truncated NΔ17ARF1 was 
measured by monitoring the Mant-FRET fluorescence increase. Clearly, ARNO 
possesses exchange activity and can thus be used for the following analyses (fig. 3-1 B). 
3.1.2 Autophosphorylation of IR-ICD remains constant upon ARNO presence 
To investigate if ARNO or its non-auto inhibited truncation ARNOΔpbr (DiNitto et al. 2007) 
directly influence the autophosphorylation and hence activation of IR-ICD, an in vitro setup 
was chosen. Previously, the catalytic activity of ARNOΔpbr was also confirmed using the 
Mant-GTP binding assay (data not shown). As described in chapter 5.2.11, MgCl2 induces 
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receptor autophosphorylation and the extent of tyrosine phosphorylation was evaluated 
via western blot analysis. Fig. 3-2 shows that the activation takes place fast and the 
amount of pY remains constant after 15 sec. 
 
Fig. 3-2: IR-ICD autophosphorylation remains constant upon ARNO addition. 525 nM IR-ICD 
was mixed with a tenfold ARNO excess, 30 mM MgCl2 and the reaction was started with 1 mM 
ATP. Samples were taken at the indicated time points and applied to 10 % SDS-PAGE, transferred 
via western blot and detected with α-pY antibody. 
Autophosphorylation remained constant in presence or absence of ARNO constructs. This 
finding indicates that the receptor activation is independent from ARNO in this setting. 
That is in line with studies performed in HepG2 cells showing that neither 
autophosphorylation of the IR nor its density on the cell surface was affected by blocking 
cytohesins (Hafner et al. 2006). 
3.2 Physical interaction of ARNO and the insulin receptor 
As previously described, experimental data show that ARNO is involved in the early steps 
of insulin signalling and therefore a direct physical interaction has been proposed (Li et al. 
2003a, Hafner et al. 2006). In this thesis, diverse biochemical and biophysical methods 
were applied to investigate the possibility of a direct protein-protein interaction. 
3.2.1 Label transfer and microscale thermophoresis suggest interaction of ARNO 
          and the insulin receptor 
Chemical crosslinking constitutes a means of covalently linking interaction partners which 
are in close proximity. Apart from stable interactions, this enables the detection of 
transient protein-protein interactions, which are otherwise hard to identify (Das and Fox 
1979, Arora et al. 2017). 
For the current investigation, the trifunctional crosslinking reagent Sulfo-SBED was used. 
It consists of a biotin moiety, a sulfonated N-hydroxysuccinimide (Sulfo-NHS) active ester 
and a photoactivatable aryl azide (see chapter 5.2.13). In a first step, the compound is 
coupled via its NHS group to primary amines of one of the interaction partners. The 
modified protein is then incubated with its putative interaction partner and the aryl azide is 
activated by UV light, interacting with diverse functional groups in vicinity. Cleaving the 
disulphide bridge within the crosslinker finally separates the crosslinked proteins and 
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transfers the biotin group, which can be detected via western blot using streptavidin (Alley 
et al. 2000). 
 
Fig. 3-3: Label transfer suggests interaction between ARNO and IR-ICD. A | 250 nM Sulfo-
SBED modified ARNO (indicated with the asterisk) was incubated with 1 µM IR-ICD, IR-KC and 
MBP. After 3 min UV irradiation, the disulphide bonds were reduced with 100 mM DTT and the 
samples were applied to 10 % SDS-PAGE. The proteins were transferred via western blot and 
detected with fluorescently labelled streptavidin. B | The label transfer is bidirectional. 
250 nM Sulfo-SBED modified IR-ICD (indicated with the asterisk) was incubated with 1 µM ARNO 
constructs or negative controls GST and MBP. After 3 min UV irradiation, the disulphide bonds 
were reduced with 100 mM DTT and the samples were applied to 12.5 % SDS-PAGE. The proteins 
were transferred via western blot and detected with fluorescently labelled streptavidin. 
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In a first step, the label transfer from labelled ARNO to IR-ICD, the kinase core of IR 
lacking the C-terminal tail (IR-KC) and the negative control maltose-binding protein (MBP) 
was investigated (fig. 3-3 A). 
The strongest label transfer was observed from ARNO to IR-ICD. Of note, the label was 
also transferred to IR-KC and to a lesser extent to MBP. Fig. 3-3 B shows the reverse 
setup, where IR-ICD was initially labelled. Although the transfer seems most intense to 
ARNO and ARNOΔpbr, there is clearly also a label transfer to the control proteins 
including GST. This indicates that the conditions, although optimised with reduced 
irradiation/incubation times and presence of detergent, were not selective enough to 
clearly prove a specific interaction. 
Another means of interaction analysis is microscale thermophoresis (MST). Here, the 
changes in migration behaviour of fluorescently labelled particles upon ligand binding are 
exploited to quantify binding affinities. This technology utilises the fact that molecules 
migrate in a temperature gradient depending on their size, charge and hydration shell and 
at least one of those parameters changes upon ligand binding (Jerabek-Willemsen et al. 
2011, Seidel et al. 2013). 
The binding behaviour of the complete intracellular domain (IR-ICD) and the kinase core 
(IR-KC) to ARNO were compared. While no saturable interaction of ARNO with IR-KC can 
be seen, an interaction with IR-ICD seems possible and a dissociation constant (KD) of 
around 7 µM was inferred (fig. 3-4). In order to further test this finding, pull-down, 
analytical size-exclusion chromatography and ITC experiments were performed. 
 
Fig. 3-4: MST differentiates interaction of ARNO with IR-ICD and IR-KC. Both IR constructs 
were serially diluted (from 100 µM to 5 nM) and mixed with a constant concentration of 100 nM 
fluorescein labelled ARNO. The measurement was performed in duplicate with 40 % LED power 
and 10 % MST power. The normalised changes in fluorescence (thermophoresis including t-jump) 
are plotted against the logarithmic concentration of IR-ICD/IR-KC and the data is fitted using a 
model derived from the law of mass action. Error bars represent the standard deviation, n = 2. 
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3.2.2 Further analytical methods fail to confirm the interaction between IR-ICD 
          and ARNO 
Pull-down experiments are a well-established procedure to detect new or confirm putative 
protein-protein interactions. Similar to immunoprecipitations, a “bait” protein is immobilised 
on a solid support like functionalised polymeric beads and bound partners are analysed 
after incubation and washing steps (Einarson et al. 2007). 
In this case, glutathione sepharose beads were loaded with either GST or GST-tagged 
IR-ICD. ARNO was added in a fivefold molar excess and the bead-bound proteins were 
analysed via SDS-PAGE (fig. 3-5). While GST and GST-IR-ICD can be recovered in the 
eluate fraction, ARNO remains unbound in the supernatant fraction. Hence, this pull-down 
does not indicate an interaction of ARNO and GST-IR-ICD. 
 
Fig. 3-5: Pull-down shows no interaction between ARNO and GST-IR-ICD. 5 µM GST or 5 µM 
GST-IR-ICD were incubated with 25 µM ARNO and 10 µL glutathione sepharose 4B beads for 
30 min at room temperature (RT) while shaking. After washing, the bound proteins were eluted with 
50 mM reduced glutathione (GSH). The input, supernatant after beads incubation and the eluate 
fractions were analysed via 10 % SDS-PAGE and stained with Coomassie blue. Neither at 0.05 % 
nor at 0.15 % Triton X-100 ARNO bound to GST-IR-ICD. 
Another method of detecting molecular complex formation is the analytical size-exclusion 
chromatography (SEC). SEC, also termed gel filtration, separates molecules due to their 
hydrodynamic radius, which corresponds well with the molecular weight of globular 
proteins (Hong et al. 2012). While small molecules pass through all pores of the beads 
and have an accordingly long retention time, larger molecules do not enter the matrix and 
elute early. 
Initially, ARNO and IR-ICD were analysed separately. ARNO eluted at 12.1 mL, IR-ICD at 
14.2 mL (fig. 3-6). Compared with the molecular weight standard, this hints at monomeric 
3 Results 
28 
IR-ICD and probably dimeric ARNO. Note that ARNO elutes at a higher molecular weight 
as expected for a 93 kDa dimer (calculated MW according to standard 134 kDa). 
However, the coiled-coil dimerisation motif most likely conveys a non-globular but rather 
extended quaternary structure to the protein resulting in a higher hydrodynamic radius. 
When an equimolar mixture of ARNO and IR-ICD were applied to the column, the elution 
profile resembled exactly the profile of the single proteins. This argues against complex 
formation. In this case, a higher molecular weight complex would have been expected to 
elute earlier. 
 
Fig. 3-6: Analytical size-exclusion chromatography suggests no interaction between ARNO 
and IR-ICD. 100 µL of 50 µM ARNO, 50 µM IR-ICD and a mixture of 50 µM ARNO/50µM IR-ICD 
were applied to a Superdex 200 10/300 GL gel filtration column. The elution profile of the mixture 
exactly matches the profile of the individual proteins, arguing against complex formation. The 
dotted lines indicate the elution maxima of a molecular weight standard. 
To broaden the analytical spectrum further, isothermal titration calorimetry (ITC) was also 
tested to investigate the interaction between ARNO and IR-ICD. The basic principle is to 
measure the required energy to keep the temperature of a reference and a reaction 
chamber constant after repeated addition of a defined amount of a ligand to the molecule 
in the reaction chamber (Pierce et al. 1999, Ladbury 2004). This in turn allows to obtain 
the complete thermodynamic description of a given interaction including the KD value, 
enthalpy and entropy. 
After overnight dialysis, the experiment was carried out at 15 °C. Seven times higher 
concentrated IR-ICD was injected into the chamber containing ARNO (fig. 3-7). As a 
control, also a buffer to buffer injection was performed. The heat development of both 
experiments was in a similar range and therefore binding cannot be shown. 
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Taken together, the interaction analyses could not confirm a stable interaction between 
IR-ICD and ARNO. However, transient interactions cannot be ruled out, which constitute a 
large proportion of protein-protein interactions in cellular signalling complexes (Perkins 
et al. 2010). 
 
Fig. 3-7: ITC shows no interaction between IR-ICD and ARNO. 211 µM IR-ICD was added into 
32 µM ARNO in 18 injections of 2 µL. The measurement was performed at 15 °C after protein 
dialysis overnight. The heat development for the IR-ICD to ARNO injection is in a similar range as 
for the buffer to buffer control and no binding can be inferred. 
3.3 Biochemical characterisation of the ARNO-CNK1 complex 
Identifying and characterising the individual components of complex signalling cascades is 
a challenging but inevitable task on the road to a comprehensive understanding of cellular 
processes and the development of targeted therapies. So far, several studies have been 
undertaken on cellular and organismal level to decipher the involvement of cytohesins in 
insulin signalling (Venkateswarlu et al. 1998, Li et al. 2003a, Hafner et al. 2006, Fuss et al. 
2006, Lim et al. 2010). While binding of ARNO to the IR remains uncertain (chapter 3.2), 
using a pull-down approach coupled to mass spectrometry analysis, Lim and colleagues 
identified cytohesins as a major interaction partner of the scaffold protein connector 
enhancer of kinase suppressor of Ras 1 (CNK1). Moreover, they showed that the C-
terminal domain of CNK1 and the coiled-coil domain of cytohesins are required to facilitate 
the membrane recruitment of ARNO upon insulin stimulation (Lim et al. 2010). Therefore, 
they conclude that both proteins interact with each other directly. However, taken into 
account that the experiments were based on co-immunoprecipitations from cell lysates, 
this conclusion can be described as daring although definitively standing to reason. 
I therefore set out to study the putative ARNO-CNK1 interaction in more depth, including 
the mapping of involved domains and KD determination. The chosen in vitro approach is 
suitable to rule out the necessity of cellular cofactors and enables the analysis of the 
interaction in a defined environment. 
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3.3.1 The cc domains of CNK1 and ARNO are required for the interaction 
Since Lim and colleagues had reported the importance of the ARNO cc domain and the 
CNK1 C-terminal domain comprising a cc domain (Lim et al. 2010), I speculated that the 
interaction is dependent on both cc domains and therefore created cc deletion mutants of 
either proteins (termed Δcc). 
In a pull-down setup, GST-ARNO and GST-ARNOΔcc were incubated with CNK1 and 
CNK1Δcc in presence of glutathione sepharose beads and the bound proteins were 
analysed via SDS-PAGE after washing steps (fig. 3-8). The GST pull-down using 
purified proteins reveals that ARNO and CNK1 interact directly without the 
requirement of additional proteins. Further, it shows that the cc domains of both 
GST-ARNO and CNK1 are required for the interaction. When either of the cc 
domains is lacking, no binding could be detected. 
 
Fig. 3-8: The coiled-coil domains of ARNO and CNK1 are needed for the protein-protein 
interaction. 1 µM GST-ARNO constructs and 1 µM CNK1 constructs were mixed with 10 µL 
glutathione sepharose 4B beads in buffer containing 0.15 % Triton X-100 and incubated for 3 h at 
4 °C. Bound proteins were eluted with 50 mM GSH, resolved by 10 % SDS-PAGE and stained with 
Coomassie blue. 
3.3.2 The ARNO cc domain is necessary and sufficient for the CNK1 interaction 
Next, it was tested whether the ARNO cc domain is sufficient for CNK1 interaction. 
Therefore, the interaction of GST-ARNO, the ARNO cc domain fused to GST (GST-
ARNO-cc) and ARNO lacking the cc domain fused to GST (GST-ARNOΔcc) with CNK1 
was evaluated using the pull-down approach described above. Expectedly, GST-ARNO 
interacts with CNK1 while GST-ARNOΔcc does not (fig. 3-9). It is also obvious, that the 
ARNO cc domain alone is able to interact with CNK1. However, the amount of CNK1 
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pulled is slightly less arguing for a somewhat weaker affinity compared to full-length 
ARNO. 
 
Fig. 3-9: The ARNO cc domain is necessary and sufficient for CNK1 interaction. 1 µM GST-
ARNO constructs and 1 µM CNK1 were mixed with 10 µL glutathione sepharose 4B beads in buffer 
containing 0.15 % Triton X-100 and incubated for 3 h at 4 °C. Bound proteins were eluted with 
50 mM GSH, resolved by 10 % SDS-PAGE and stained with Coomassie blue. GST-ARNO and 
GST-ARNO-cc interact with CNK1 while GST-ARNOΔcc does not bind CNK1. 
3.3.3 The CNK1 cc domain is sufficient for ARNO interaction 
Using the pull-down method, it was further investigated, whether the cc domain of CNK1 
is sufficient for the interaction with ARNO. To ensure that the interaction is independent 
from the tag fused to the protein, a second tag apart from GST was also used. The so 
called HaloTag® is a 34 kDa mutated hydrolase (haloalkane dehalogenase), which 
covalently binds to a chloroalkane ligand (Zhang et al. 2006). The His272 to Phe mutation 
within the catalytic triad renders the formed ester bond between the HaloTag® and its 
ligand unhydrolysable. Since the HaloTag® fusion protein is covalently attached to the 
beads, elution, i.e. boiling the beads in sample buffer containing a high concentration of 
SDS, only yields the interacting protein but not the HaloTag® fusion protein itself. 
For protein purification purposes, the CNK1 cc domain was fused to MBP connected via a 
linker including a TEV cleavage site. Since the fusion protein is larger and hence easier to 
detect than the 7.4 kDa cc domain only, pull-down experiments with the MBP fusion 
protein and also the isolated CNK1 cc domain were performed. 
GST-ARNO interacts with MBP-CNK1-cc as well as CNK1-cc but not with the negative 
controls MBP and the insulin receptor C-terminus (fig. 3-10). If GST was bound to the 
beads as a control, no unspecific binding with any proteins could be observed. Using the 
same setup, the experiment was repeated with the HaloTag® ARNO fusion (fig. 3-11). 
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Here, the results resembled exactly the GST pull-down findings: Halo-ARNO interacts with 
CNK1-cc whether it is fused to MBP or not and does not interact with the control proteins. 
Beads just covered with the Halo protein do not interact with MBP-CNK1-cc nor CNK1-cc. 
It has to be noted that Halo-ARNO and Halo are absent in the analysed eluate fractions 
since the HaloTag® attaches covalently to the HaloLinkTM resin. The CNK1-cc band is 
visualised weakly due to its small size and lack of high resolution in the SDS-PAGE. 
 
Fig. 3-10: GST-pull-down shows that CNK1-cc is sufficient for ARNO interaction. A | 1 µM 
GST-ARNO or 1 µM GST was mixed with 5 µM MBP-CNK1-cc or 5 µM MBP and 10 µL glutathione 
sepharose 4B beads. The samples were prepared in buffer containing 0.15 % Triton X-100 and 
incubated for 3 h at 4 °C. Bound proteins were eluted with 50 mM GSH, resolved by 12.5 % SDS-
PAGE and stained with Coomassie blue. B | 5 µM GST-ARNO or 5 µM GST was mixed with 
5 µM CNK1-cc or 5 µM insulin receptor C-terminus (IR-CT) as negative control and 10 µL 
glutathione sepharose 4B beads. The samples were prepared in buffer containing 0.15 % 
Triton X-100 and incubated for 3 h at 4 °C. Bound proteins were eluted with 50 mM GSH, resolved 
by 15 % SDS-PAGE and stained with Coomassie blue. 
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Fig. 3-11: HaloTag® pull-down supports that CNK1-cc is sufficient for ARNO interaction. 
A | 5 µM Halo-ARNO or 5 µM Halo was mixed with 5 µM MBP-CNK1-cc or 5 µM MBP and 10 µL 
HaloLinkTM resin. The samples were prepared in buffer containing 0.15 % Triton X-100 and 
incubated for 4 h at 4 °C. Bound proteins were eluted by boiling the sample in SDS-PAGE loading 
buffer, resolved by 12.5 % SDS-PAGE and stained with Coomassie blue. B | 5 µM Halo-ARNO or 
5 µM Halo was mixed with 5 µM CNK1-cc or 5 µM insulin receptor C-terminus (IR-CT) and 10 µL 
HaloLinkTM resin. The samples were prepared in buffer containing 0.15 % Triton X-100 and 
incubated for 4 h at 4 °C. Bound proteins were eluted by boiling the sample in SDS-PAGE loading 
buffer, resolved by 15 % SDS-PAGE and stained with Coomassie blue. 
Taken together, the pull-down analyses showed that the CNK1 cc domain is sufficient to 
interact with ARNO independent of the tags used for the pull-down.  
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3.3.4 Analytical SEC and ITC confirm the ARNO-CNK1 interaction 
Having mapped the binding site of both proteins to their respective cc domains, the 
question of affinity and stoichiometry remained. Additionally, the interaction should be 
confirmed by independent techniques. 
Analytical SEC was applied to validate the ARNO-CNK1 interaction (fig. 3-12). When 
applied separately to the column, CNK1 and ARNO eluted at 12.3 mL and 11.6 mL, 
respectively. According to a molecular weight standard, this corresponds to dimeric CNK1 
and ARNO, which is also at least dimeric (see chapter 5.2.14). The fact that CNK1 
possesses a cc domain as well as a sterile alpha motif (SAM), both of which are able to 
drive dimerisation, supports this notion (Mason and Arndt 2004, Stapleton et al. 1999). 
When CNK1 and ARNO were applied in a 1:1 molar ratio, a new peak at an elution 
volume of 10.6 mL emerged, indicating the formation of a higher molecular weight 
complex. SDS-PAGE analysis of the peak fractions confirmed that it contained CNK1 as 
well as ARNO (fig. 3-12 A). Notably, a fraction of ARNO remained unbound, which can be 
deduced by the small peak remaining at the retention volume of ARNO and by the 
corresponding SDS-PAGE fraction. This peak got even more pronounced, when a 2:1 
molar mixture of ARNO to CNK1 was analysed (data not shown). On the other hand, it 
vanished at the expense of an even higher complex peak when a 1:2 molar ratio of ARNO 
to CNK1 was subjected to the column. This result led to the hypothesis, that ARNO and 
CNK1 form a 1:2 complex. Expectedly, no complex formation was observed when 
ARNOΔcc was incubated with CNK1 (fig. 3-12 B). 
A similar experiment was also performed to confirm that the CNK1 cc domain is sufficient 
for the interaction with ARNO (fig. 3-13). The cc domain in MBP-CNK1-cc does not lead to 
dimerisation, as the protein elutes close to the expected molecular weight of the monomer 
at 14.3 mL. The MBP-CNK1-cc fusion protein eluted together with ARNO. Clearly, the 
CNK1-cc domain is responsible for complex formation, as MBP alone does not co-elute 
with ARNO (fig. 3-13 B). However, using the MBP-CNK1-cc fusion protein, no hint for the 
formation of a 2:1 complex could be obtained. 
In summary, the analytical SEC experiments confirmed the interaction between ARNO 
and CNK1 and raise the possibility of the formation of a 1:2 complex. SEC also validated 
the finding that the CNK1 cc domain is sufficient for the ARNO interaction. As a next step, 
ITC experiments were performed. They offer two advantages: First, ITC enables the 
deduction of the KD value and hence the quantification of the affinity. Second, apart from 
binding enthalpy and entropy, also the stoichiometry of the interaction can be obtained to 
test the analytical SEC findings. 
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Fig. 3-12: Analytical SEC confirms the interaction of ARNO and CNK1. 100 µL of the indicated 
concentrations of ARNO, ARNOΔcc and CNK1 and respective mixtures were analysed via 
analytical SEC using a Superdex 200 10/300 GL at a flow rate of 0.4 mL/min. A | The ARNO-CNK1 
complex elutes at a lower retention time and the presence of both proteins could be verified by 
10 % SDS-PAGE/Coomassie blue staining. B | The ARNO construct lacking the cc domain does 
not interact with CNK1. 
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Fig. 3-13: Analytical SEC confirms that the CNK1 cc domain is sufficient for ARNO 
interaction. 100 µL of 30 µM ARNO, 30 µM MBP-CNK1-cc and 30 µM MBP as well as respective 
mixes were analysed via analytical SEC using a Superdex 200 10/300 GL at a flow rate of 
0.4 mL/min. A | The presence of both MBP-CNK1-cc and ARNO could be verified by 10 % SDS-
PAGE/Coomassie blue staining. The MBP-CNK1-cc peak at 14.3 mL completely vanished. 
B | ARNO does not interact with the negative control MBP. 
As a final tool for interaction analysis, ITC measurements were performed. When ARNO 
was injected into CNK1, the interaction could be confirmed (fig. 3-14 A). Furthermore, the 
stoichiometry of 2 CNK1 molecules binding 1 ARNO molecule, as suggested by analytical 
SEC, was verified. The KD value was determined as 2.6 nM ± 0.9 nM indicating a highly 
affine interaction. Note however, that the signal-to-noise ratio is rather weak and the 
steepness of the curve with only one point in the transition zone limits the accuracy of the 
measurement. This limitation can in principle be circumvented by lowering the 
3 Results 
37 
concentrations of the reactants in the syringe and the chamber. However, this also 
reduces the signal intensity and thereby further deteriorates the signal-to-noise ratio. 
Thus, it was decided to also test the interaction between MBP-CNK1-cc and ARNO, which 
might have a slightly lower affinity. In this case, higher concentrations can be used leading 
to a better signal intensity (fig. 3-14 B). 
 
Fig. 3-14: ITC experiments confirm the interaction of ARNO with CNK1 and MBP-CNK1-cc. 
A | 101 µM ARNO were injected into 12 µM CNK1 at 25 °C using proteins previously dialysed 
against the same buffer overnight. The KD value could be determined as 2.6 ± 0.9 nM. B | 244 µM 
MBP-CNK1-cc were injected into 23 µM ARNO at 25 °C using proteins previously dialysed against 
the same buffer overnight. Injections of MBP-CNK1-cc into buffer were subtracted. The KD value 
could be determined as 43 ± 164 nM. C | 95 µM ARNOΔcc was injected into 11 µM CNK1 at 25 °C 
using proteins previously dialysed against the same buffer overnight. No interaction was observed. 
D | 70 µM ARNO was injected into 11 µM CNK1 at 25 °C using proteins previously dialysed against 
the same buffer overnight. No interaction was observed. 
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Indeed, compared to full-length CNK1, the affinity of MBP-CNK1-cc was lower with a KD of 
43 nM ± 164 nM. As in the analytical SEC experiments, a 1:1 complex is suggested for 
the MBP-CNK1-cc interaction with ARNO. Both interactions are enthalpically driven as 
can be deduced from the negative change in enthalpy (ΔH). As negative controls, the 
titration of ARNOΔcc into CNK1 and ARNO into CNK1Δcc were performed (fig. 3-14 C 
and D). In line with the previous experiments, no interactions were found. 
3.4 Crystallisation of ARNO-CNK1 complexes 
One way of understanding the foundation of biomolecular interactions is the elucidation of 
the three-dimensional structure. X-ray crystallography has long been the only means of 
structure determination at atomic resolution but is now complemented by nuclear 
magnetic resonance techniques (Rupp 2009). Additionally, single particle cryo-electron 
microscopy has become yet another powerful tool for 3D structure reconstruction (Wang 
and Wang 2017). Due to better availability and compatibility with the molecular weight of 
ARNO-CNK1 complexes, crystallisation trials were undertaken to decipher the molecular 
interaction of ARNO and CNK1. 
3.4.1 Generation of complexes for crystallisation 
Obtaining diffracting protein crystals is the prerequisite for structure determination via 
X-ray crystallography. At the same time, it constitutes one of the most challenging steps in 
the process. Two general concepts were employed to increase the likelihood of crystal 
formation: First, different truncation constructs of ARNO and CNK1 were used. Protein 
crystals can only form if intermolecular interactions of neighbouring proteins in the crystal 
lattice enable an ordered alignment. To allow for different crystal arrangements, the 
shortened ARNOΔpbr and ARNO-cc-Sec7 constructs were used alongside full-length 
ARNO. Additionally, either the isolated cc domain of CNK1 or full-length CNK1 were co-
crystallised with the different ARNO constructs. Second, a high degree of homogeneity 
helps avoiding crystal defects and therefore raises the chances of crystal formation. 
Sample uniformity was enhanced by applying the complex to a size-exclusion 
chromatography step prior to crystallisation. This removes high molecular weight 
aggregates and also reduces the amount of protein not forming a complex. Although I had 
the possibility of setting up and evaluating several crystal screens, most of this work was 
performed by Dr Kanchan Anand, Karlsruhe Institute of Technology/University of Bonn. I 
am very grateful for her advice and help. 
Fig. 3-15 shows the purity of the complexes obtained by size-exclusion chromatography 
and respective crystals which could be produced using the sitting and hanging drop 
methods. Especially the complex formed of ARNO-cc-Sec7 and CNK1-cc reached high 
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purity. Although crystals showed blue colour when treated with IZIT dye, strengthening the 
probability of being protein crystals, they did not diffract X-rays when tested at a 
synchrotron beamline. To improve the quality of crystals, several techniques were used, 
e.g. dehydration, various types of seeding, the use of different precipitant ratios and also 
hanging drop crystallisation. Further improvement at different levels is possible, such as 
the exploration of different constructs and more crystallisation conditions, which help in 
obtaining better quality single crystals. 
 
Fig. 3-15: Crystallisation of diverse ARNO-CNK1 complexes. A | The crystallisation complexes 
were obtained by mixing the respective proteins and applying them to the HiLoad 16/600 Superdex 
200 pg or HiLoad 16/600 Superdex 75 pg (for ARNO-cc-Sec7/CNK1-cc). The final samples were 
applied to 15 % SDS-PAGE (10 % for ARNO/CNK1) and stained with Coomassie blue. B | The 
shown crystals were grown in the hanging drop vapour diffusion method at 10 °C under the 
following conditions: ARNO:CNK1, 1 M ammonium phosphate dibasic, 0.1 M imidazole/HCl, pH 8, 
0.2 M sodium chloride; ARNO:CNK1-cc, 12.5 % PEG 1000, 12.5 % PEG 3350, 12.5 % 2-methyl-
2,4-pentanediol, 0.03 M sodium nitrate, 0.03 M sodium phosphate, dibasic, 0.03 M ammonium 
sulphate, 0.1 M HEPES/MOPS, pH 7,5; ARNOΔpbr:CNK1-cc, 0.1 M sodium citrate, pH 6.5, 0.2 M 
ammonium acetate, 5 % ethylene glycol, 15 % low and medium MW PEG mix; ARNO-cc-
Sec7:CNK1-cc, 0.1 M sodium citrate, pH 6.5, 20 % PEG 6000, 0.2 M zinc chloride. The typical 
crystal size was 50-150 µm x 40-50 µm x 20-30 µm.  
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3.5 The influence of CNK1 on the ARNO exchange activity 
Having established the binding mode of CNK1 and ARNO, the next question was to 
decipher the underlying mechanism of the ARNO-CNK1 complex in insulin signalling. 
Endogenous CNK1 is found exclusively in the cytoplasm of serum-starved cells and 
insulin stimulation redistributes a fraction to the cell membrane (Lim et al. 2010). Earlier 
studies showed that the presence of another CNK protein, CNK3B, also termed IPCEF1, 
enhances ARNO exchange activity towards ARF6 in a radioactive GTPγS in vitro binding 
assay (Venkateswarlu 2003). Since active ARFs are localised via their N-terminal 
amphipathic helix and myristoyl moiety to membranes, myristoylated ARF1 and ARF6 
were purified and the effect of CNK1 on ARNO-mediated exchange was studied in a lipid 
environment. 
3.5.1 Purification of myristoylated ARF1 and ARF6 
ARF proteins are myristoylated in vivo to facilitate membrane localisation (D'Souza-
Schorey and Chavrier 2006, Kahn et al. 1988). N-Myristoylation refers to the addition of a 
14 carbon atom saturated fatty acid to the N-terminal glycine of proteins (Wright et al. 
2010). While ARF6 is permanently tethered to membranes independent of the bound 
nucleotide (Macia et al. 2004), ARF1 is cytoplasmic in its GDP-bound inactive state and 
localises to the plasma membrane upon GTP binding (Donaldson and Jackson 2011, 
Antonny et al. 1997, Duijsings et al. 2009, Chun et al. 2008). 
Two different methods have been described to produce myristoylated ARFs (myr-ARF) in 
a heterologous expression system. Traditionally, ARFs are co-expressed with an 
N-myristoyltransferase (NMT) in E. coli in presence of sodium myristate. The 
myristoylated protein is subsequently isolated via ammonium sulphate precipitation, 
followed by anion exchange chromatography or gel filtration (Franco et al. 1995, Ha et al. 
2005). Due to low yields, a different approach was developed for ARF6. Here, the non-
myristoylated ARF6 and NMT are expressed separately. The proteins are then mixed in 
presence of myristoyl-Coenzyme A (myristoyl-CoA) and the myristoylated ARF is 
recovered by ammonium sulphate precipitation (Padovani et al. 2013). 
To purify myristoylated ARF1, a modified protocol of Franco and colleagues was used 
(Franco et al. 1995). In short, non-tagged ARF1 was co-expressed with the pHV738 
plasmid, which I obtained as a generous gift from Prof Richard A. Kahn, Emory University 
Atlanta (Van Valkenburgh and Kahn 2002). The plasmid bears the sequence of the 
human NMT1 under control of the IPTG inducible tac promotor as well as the E. coli 
methionine aminopeptidase (MetAP) under control of its endogenous promotor. 60 min 
after addition of sodium myristate and NMT induction, ARF1 expression from the 
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pMON5840-ARF1wt vector was induced. The pMON5840-ARF1wt plasmid was a 
generous gift from Prof Felix Wieland, Heidelberg University and Dr Frank Adolf. The cell 
lysate was precipitated at 35 % ammonium sulphate to enrich myristoylated ARF1, 
desalted, applied to anion exchange chromatography and, as a last step, purified by SEC. 
The result is depicted in fig. 3-16. 
 
Fig. 3-16: Purification of myr-ARF1. A | The lysate was precipitated at 35 % ammonium sulphate 
and then resolubilised (resolubilised precipitate) and rebuffered (rebuffered lysate). The first peak 
of the Diethylaminoethyl (DEAE) sepharose anion chromatography contained the target protein 
which could be further purified by SEC. Respective fractions were analysed via 12.5 % SDS-PAGE 
and Coomassie stain. B | Mass spectrometric analysis of the final sample confirmed the successful 
myristoylation. The mass spectrum obtained at 16 min was deconvoluted leading to a mass of 
20774.2 Da, which is in good accordance with the theoretical MW of 20775.9 Da for myr-ARF1. 
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While the resolubilised ammonium sulphate precipitate still contained many contaminants, 
the first peak of the anion exchange chromatography eluate yielded a relatively pure 
sample, which was further purified and rebuffered using SEC. Following analysis of the 
final sample by liquid chromatography-mass spectrometry (LC-MS) confirmed the protein 
identity to be myr-ARF1. No considerable amounts of non-myristoylated ARF1 were 
detected. 
For the purification of myr-ARF6, the in vitro myristoylation approach was pursued 
(Padovani et al. 2013). First, hexahistidine-tagged ARF6 and NMT were expressed in 
E. coli and purified separately via IMAC and SEC (fig. 3-17 A and B). The yield for NMT 
was comparatively low but since only small amounts are needed for myristoylation, this 
constitutes a negligible issue. 
As described in more detail in chapter 5.2.7, ARF6 was then myristoylated in vitro. 100 µM 
ARF6 was mixed with 1 µM NMT and 160 µM myristoyl-CoA. The mixture was incubated 
at room temperature for 4.5 h. To separate myr-ARF6 from non-myristoylated ARF6, 
myr-ARF6 was recovered by 30 % ammonium sulphate precipitation and was then 
rebuffered by overnight dialysis. To confirm the myristoylation, the final sample was 
analysed via LC-MS (fig. 3-17 C). The myristoylated protein could be detected, while no 
traces of non-myristoylated ARF6 were found. 
Since the purification of non-myristoylated ARFs is easier and leads to a higher yield, it 
was also tested whether ARF1 could be myristoylated in vitro using the published 
approach (Padovani et al. 2013). However, no myristoylated protein could be obtained. 
The reason is unclear but could be a non-accessible N-terminal glycine. Also, pre-loading 
ARF1 with GTP could not change this (data not shown). Of note, other groups have tried 
to avoid the need for the sophisticated and time-consuming purification of myr-ARFs. 
They have replaced the lipid modification by a simple histidine-tag which allows them to 
tether GTPases to nickel-lipid containing membrane systems (Peurois et al. 2017). 
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Fig. 3-17: Purification and in vitro myristoylation of ARF6. A and B | The cleared lysate was 
applied to Protino® nickel nitrilotriacetic acid (Ni-NTA) resin. After wash steps with 20 mM 
imidazole, the proteins were eluted with 250 mM imidazole. Finally, ARF6 was applied to a 
HiLoadTM 16/600 Superdex 75 pg and NMT to a HiLoadTM 16/600 Superdex 200 pg column. 
Respective fractions were analysed via 12.5 % SDS-PAGE and Coomassie stain. C | After in vitro 
myristoylation and ammonium sulphate precipitation, mass spectrometric analysis of the final 
sample confirmed the successful myristoylation of ARF6. The mass spectrum obtained at 14 min 
was deconvoluted leading to a mass of 20897.7 Da, which is in good accordance with the 
theoretical MW of 20897.0 Da for myr-ARF6. The peak at 20 min did not match a protein spectrum. 
The characteristic steps of 44 Da rather point to the presence of polyethylene glycol. 
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3.5.2 Creating a lipid system for nucleotide exchange assays 
ARFs are localised to biological membranes in their active state via their N-terminal 
amphipathic helix and myristoylation (Donaldson and Jackson 2011, Franco et al. 1995, 
Antonny et al. 1997). In order to study ARFs in solution, N-terminal truncations have been 
generated. These GTPases do not localise to membranes, however studies showed that 
the catalytic activity of exchange factors towards soluble ARFs and membrane-bound 
myr-ARFs differ significantly by more than two orders of magnitude (Padovani et al. 2014). 
Since the membrane environment changes kinetics to a large extent, I chose to work with 
myristoylated ARFs and a suitable lipid system. Several lipid systems, like detergent 
micelles (Tanford and Reynolds 1976), bicelles (Sanders and Landis 1995) and nanodiscs 
(Bayburt and Sligar 2003) are available to study membrane or membrane-associated 
proteins. For ARFs, the vast majority of published in vitro data so far has been generated 
using liposomes (Robbe and Antonny 2003). Since this system has proven to work 
particularly well for ARF GTPases, it was chosen for subsequent activity and localisation 
studies. 
Liposomes are spherical-shaped vesicles formed of at least one lipid bilayer (Laouini et al. 
2012, Akbarzadeh et al. 2013). They were prepared following the general protocol as 
described for ARF activity studies (Robbe and Antonny 2003, Stalder et al. 2011) with a 
defined composition of 20 % L-α-phosphatidylethanolamine (PE), 30 % 
L-α-phosphatidylserine (PS), 48 % (or 50 %) L-α-phosphatidylcholine (PC) and 2 % 
(or no) L-α-phosphatidylinositol-4,5-bisphosphate (PIP2). Briefly, a total of 2 mM lipids was 
mixed in 2 mL chloroform/methanol and the solvent was evaporated in a pointed hand 
vice. The lipids were rehydrated in 1 mL buffer, subjected to five freeze-thaw cycles and 
extruded through a polycarbonate membrane with a pore size of 100 nm. The liposomes 
were stored at room temperature until use. 
The dynamic light scattering (DLS) method was used to assess the size distribution of the 
liposomes. It enables the deduction of the particle size by measuring the diffusion speed 
due to Brownian motion (Stetefeld et al. 2016). 
Fig. 3-18 shows that the liposomes possessed a uniform size of around 130 nm and that 
the size remained constant over a period of 11 days. In order to avoid ageing and 
oxidation of the lipids, the liposomes were used for a maximal period of four days after 
production. 
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Fig. 3-18: DLS analysis of liposomes confirms their expected size. The prepared liposomes 
were diluted 1:100 and measured in the DLS Zetasizer nano Series S. The averages of 3 
measurements, each consisting of 15 runs of the same sample are shown in the intensity 
representation. 
A 0 % PIP2, Day 0 
B 0 % PIP2, Day 11 
C 2 % PIP2, Day 0 
D 2 % PIP2, Day 11 
Size [nm] 
Size [nm] 
Size [nm] 
Size [nm] 
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3.5.3 Establishing a nucleotide exchange assay for myr-ARF1 and myr-ARF6 
Assessing the catalytic activity of exchange factors on ARF GTPases can be performed 
by several means. Initially, the GDP to GTP exchange was monitored through binding or 
release of radioactively labelled nucleotides such as [35S]GTPγS and [3H]GDP (Kahn and 
Gilman 1986, Franco et al. 1995). At the same time, it was discovered that the intrinsic 
tryptophan fluorescence of ARFs increases upon GTP binding, which can be exploited to 
monitor catalytic activity (Kahn and Gilman 1986, Antonny et al. 1997). Additionally, the 
binding or release of fluorescently labelled nucleotide analogues can be measured (as 
performed in Stalder et al. 2011). 
Testing several different exchange assay formats, the Mant-GDP release assay proved to 
work most stably with the experimental setup using a Tecan plate reader. Thus, it was 
chosen for the following analyses. When Mant-GDP is bound to the GTPase, excited 
tryptophan residues transfer energy to the Mant moiety via FRET. The radiationless 
energy transfer results in a high emission fluorescence signal at around 450 nm when the 
tryptophans are exited at approximately 280 nm. 
For establishing the assay, the general scheme was adopted from Stalder et al. 2011. 
However, several adjustments had to be made because the original experiments were 
conducted using a fluorescence spectrophotometer and a cuvette setup. In this work on 
the other hand, a Tecan plate reader equipped with a fluorescence module was used. 
Notably, microtiter plates with a modified non-binding surface need to be used. This 
avoids sticking of the proteins as well as the Mant-nucleotide to the plastic, which would 
otherwise result in a drop of signal intensity. 
Fig. 3-19 shows that 1 nM of ARNO is sufficient to elucidate a Mant-GDP to GTP 
exchange in presence of liposomes (200 µM total lipid concentration) and 100 µM GTP. 
While myr-ARF1 could be pre-incubated with GTP for temperature adaptation to 37 °C, 
this could not be done with myr-ARF6. For myr-ARF6, the spontaneous exchange of 
Mant-GDP to GTP in absence of exchange factor was too high, which can be deduced by 
the red curve in fig. 3-19 B. Therefore, the exchange was initiated by ARNO addition 
without prior temperature equilibration. 
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Fig. 3-19: Development of a Mant-GDP release ARNO activity assay for myr-ARF1 and 
myr-ARF6. 400 nM myr-ARF1 or myr-ARF6 were pre-loaded with 1 µM Mant-GDP. The exchange 
reaction in presence of liposomes (2 % PIP2, 200 µM total lipid concentration) and 100 µM GTP 
was initiated by the addition of the indicated concentrations of ARNO. The reaction was performed 
at 37 °C and monitored by the decreasing Mant-FRET. A | For myr-ARF1, the sample was 
incubated at 37 °C for 20 min prior to the addition of ARNO to allow for complete temperature 
equilibration. 1 nM ARNO elicits the desired exchange and was chosen for the next experiments. 
B | Since the intrinsic exchange without exchange factor for myr-ARF6 is higher than for 
myr-ARF1, the measurement was started immediately. 1 nM ARNO elicits the desired exchange 
and was chosen for the next experiments. 
  
3 Results 
48 
3.5.4 The impact of CNK1 on the ARNO exchange activity 
CNK1 depletion inhibits insulin signalling as shown by a reduced phosphorylation of IRS1 
and PKB (Lim et al. 2010). One possible explanation for the involvement of CNK1 is the 
direct alteration of the ARNO exchange activity as shown for CNK3B (Venkateswarlu 
2003). To test this hypothesis, exchange assays as described above using 1 nM ARNO 
were performed and CNK1 was titrated from 1 nM to 20 nM. Additionally, the experiment 
was repeated in triplicate for a fixed concentration of 2 nM CNK1. The experiments were 
performed on myr-ARF1 (fig. 3-20) as well as myr-ARF6 (fig. 3-21). 
 
Fig. 3-20: CNK1 does not enhance ARNO exchange activity on myr-ARF1. 400 nM myr-ARF1 
was pre-loaded with 1 µM Mant-GDP. The exchange reaction in presence of liposomes (2 % PIP2, 
200 µM total lipid concentration) and 100 µM GTP was initiated by the addition of 1 nM ARNO or 
mixtures of 1 nM ARNO and the indicated CNK1 concentrations. The reaction was performed at 
37 °C and monitored by the decreasing Mant-FRET signal. The black lines show the 
mono-exponential fits of the data assuming pseudo-first order kinetics. 
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Fig. 3-21: CNK1 does not influence ARNO exchange activity on myr-ARF6. 400 nM myr-ARF6 
was pre-loaded with 1 µM Mant-GDP. The exchange reaction in presence of liposomes (2 % PIP2, 
200 µM total lipid concentration) and 100 µM GTP was initiated by the addition of 1 nM ARNO or 
mixtures of 1 nM ARNO and the indicated CNK1 concentrations. The reaction was performed at 
37 °C and monitored by the decreasing Mant-FRET signal. The black lines show the 
mono-exponential fits of the data assuming pseudo-first order kinetics. 
The nucleotide exchange kinetics were analysed assuming pseudo-first order rate 
constants which were obtained by fitting the fluorescence traces using a 
mono-exponential fit (black curves in fig. 3-20 and fig. 3-21). Since the signal remains 
constant if no ARNO is added to myr-ARF1, no apparent initial rate constant can be 
deduced. In presence of 1 nM ARNO, the rate constant was 0.009 s-1. When CNK1 was 
added, this dropped to around 0.005 s-1, for concentrations higher than 2 nM CNK1, as 
confirmed via the triplicate measurement (fig. 3-20 B). 
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In contrast, CNK1 does not seem to influence the ARNO exchange on myr-ARF6 at all 
(fig. 3-21). While the initial rate constant was 0.002 s-1 in absence of ARNO due to the 
higher spontaneous exchange, this increased to around 0.013 s-1 when ARNO was added 
independent of the presence and concentration of CNK1. 
Taken together, CNK1 did not enhance of the exchange activity of ARNO towards 
myr-ARF1 nor myr-ARF6. 
3.6 The CNK1 membrane localisation 
3.6.1 Membrane localisation of CNK1 wildtype 
Using the Mant-GDP release assay, no enhancement of nucleotide exchange by CNK1 on 
the ARNO/ARF system was observed (chapter 3.5.4). One possible explanation is the 
localisation of the ARNO-CNK1-complex since the exchange activity of ARNO towards 
GTPases is dependent on its membrane targeting. In the cytosol, cytohesins reside in 
their autoinhibited form where the C-terminal polybasic region occludes the ARF binding 
site (DiNitto et al. 2007). Membrane binding contributes to the release of autoinhibition 
and was shown to be crucial for the activity of the Sec7-containing ARF-GEF Brag2 
(Karandur et al. 2017). 
Since GEF activity is linked to membrane localisation, it was investigated whether CNK1 
wildtype localises to liposomes used in the exchange assays. It was hypothesised that 
CNK1 remained unbound to liposomes and therefore failed to enhance the amount of 
ARNO at the membrane via its tight interaction, leaving the exchange activity unaffected. 
To address this question, liposome flotation assays were performed (Bigay and Antonny 
2005). The assay is based on ultracentrifugation of a protein/liposome mixture in sucrose, 
which is overlaid with a sucrose cushion of lower concentration and a buffer layer. If the 
protein binds to the liposomes, it migrates to the top fraction alongside the lipids. If it does 
not interact with the liposomes, the protein stays in the bottom fraction. The result is 
shown in fig. 3-22. 
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Fig. 3-22: CNK1 does not recruit ARNO to the liposome fraction. 30 nM ARNO and 
30 nM CNK1 were prepared in a 30 % sucrose containing buffer and overlaid with two layers of 
25 % sucrose and 0 % sucrose, respectively. After centrifugation at 240000 xg, top fraction 
(containing liposomes and bound proteins), middle fraction and bottom fraction (containing 
unbound protein) were analysed via 10 % SDS-PAGE and western blot. T = top fraction, 
M = middle fraction, B = bottom fraction. Note, that protein amounts of top, middle and bottom 
fraction cannot directly be compared due to the procedure of sample taking (chapter 5.2.21). 
A | ARNO bound to liposomes containing 2 % PIP2 but not to liposomes without PIP2. In presence 
of CNK1, the total ARNO amount was larger and the free ARNO proportion increased, probably 
due to reduced sticking. B | CNK1 was predominantly found in the bottom fraction, not bound to 
liposomes. When ARNO was present, a certain proportion of CNK1 was also recovered in the 
liposome containing layer. 
While part of ARNO bound to the PIP2 containing liposomes, it did not bind to liposomes 
without PIP2, which was expected since the ARNO PH domain specifically binds PIP2 and 
PIP3 (Chardin et al. 1996, Klarlund et al. 2000). CNK1 in general remained in the bottom 
fraction indicating no interaction with the liposomes. When mixed with ARNO, some CNK1 
shifts to the liposome-bound top fraction, but another phenomenon interferes with straight-
forward data interpretation: The total protein amount of either protein increases, when 
they are mixed. This is probably due to reduced sticking of the complex to the 
polycarbonate centrifugation tubes. Taken together, CNK1 does not bind to liposomes and 
does not affect ARNO localisation to a large extent. 
Recent data suggests that CNK1 is only localised to the plasma membrane if it is 
acetylated by CREB (cyclic adenosine 3’,5’-monophosphate response element-binding 
protein)-binding protein (CBP) within its PH domain (Fischer et al. 2017). In the next step, 
it was therefore tested whether an acetylation-mimic mutant, CNK1K414Q, localises to 
liposomes and can be used to investigate the activated form of CNK1. 
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3.6.2 Membrane localisation of the CNK1K414Q mutant 
CNK1K414Q was shown to localise constitutively at the plasma membrane of HeLa cells 
and was used as an acetylation-mimic mutant in a recent study (Fischer et al. 2017). 
However, the authors did not identify the mechanism why acetylation of Lys414 and the 
abovementioned CNK1K414Q mutant led to plasma membrane localisation. It was therefore 
tested whether the binding can be reconstituted in vitro using the liposome flotation assay 
employed earlier. Fig. 3-23 shows that neither CNK1 nor CNK1K414Q bind to liposomes. 
Apparently, the reductionist liposome model is incapable of reconstructing the membrane 
recruitment of CNK1K414Q as observed in living cells. Similar to CNK1 wildtype, CNK1K414Q 
does not accelerate the exchange of ARNO on myr-ARF1 (supporting fig. A-2). 
 
Fig. 3-23: CNK1K414Q does not bind to liposomes. 30 nM CNK1 and 30 nM CNK1K414Q were 
prepared in a 30 % sucrose containing buffer and overlaid with two layers of 25 % sucrose and 
0 % sucrose, respectively. After centrifugation at 240000 xg, top fraction (containing liposomes and 
bound proteins), middle fraction and bottom fraction (containing unbound protein) were analysed 
via 10 % SDS-PAGE and western blot. T = top fraction, M = middle fraction, B = bottom fraction. 
Note, that protein amounts of top, middle and bottom fraction cannot directly be compared due to 
the procedure of sample taking (chapter 5.2.21). Both proteins can be found in the bottom fraction 
which indicates that they do not interact with the liposomes (2 % PIP2). 
  
3 Results 
53 
3.6.3 Tethering His-tagged CNK1 to liposomes containing Ni-complexing lipids 
Since the CNK1K414Q mutant did not bind to liposomes, I aimed to artificially tether the 
His-tagged CNK1 wildtype to liposomes containing the DGS-NTA(Ni) lipid. The headgroup 
of this lipid coordinates a nickel ion similar to Ni-NTA agarose beads and binds the 
hexahistidine-tag of recombinant proteins. Liposomes supplemented with 5 % DGS-
NTA(Ni) have already been successfully used to tether His-tagged ARFs and exchange 
activity could be monitored (Peurois et al. 2017). Production of liposomes led to particles 
in the expected size range (supporting fig. A-3). In order to test if His-tagged CNK1 binds 
to liposomes containing DGS-NTA(Ni), concentrations of 5-25 % were tested (fig. 3-24). 
Unlike to the previously mentioned publication, where a concentration of 5 % DGS-
NTA(Ni) was sufficient (Peurois et al. 2017), a concentration of 25 % needed to be used to 
tether the majority of CNK1 to the liposomes. When concentrations of 5 % and 10 % were 
used, almost the complete protein amount remained free in solution. 
 
Fig. 3-24: Binding of His-tagged CNK1 to liposomes with increasing concentration of DGS-
NTA(Ni). 60 nM His-tagged CNK1 was prepared in a 30 % sucrose containing buffer without 
reducing agent and overlaid with two layers of 25 % sucrose and 0 % sucrose, respectively. After 
centrifugation at 240000 xg, top fraction (containing liposomes and bound proteins), middle fraction 
and bottom fraction (containing unbound protein) were analysed via 10 % SDS-PAGE and western 
blot. T = top fraction, M = middle fraction, B = bottom fraction. Note, that protein amounts of top, 
middle and bottom fraction cannot directly be compared due to the procedure of sample taking 
(chapter 5.2.21). Increasing DGS-NTA(Ni) concentrations led to localisation of CNK1 to the 
liposome fraction (2 % PIP2). 
Subsequently, the effect of CNK1 on ARNO-mediated exchange on myr-ARF1 was tested 
using liposomes containing 5 % and 25 % DGS-NTA(Ni). The exchange with liposomes 
containing 5 % DGS-NTA(Ni) worked but expectedly CNK1 showed no effect (fig. 3-25 A). 
When the liposomes were supplemented with 25 % DGS-NTA(Ni), no exchange could be 
observed at all, even if the ARNO concentration was raised to 20 nM (fig. 3-25 B). 
Unfortunately, the effect of CNK1 on the ARNO exchange activity could thus not be further 
investigated by artificially tethering His-tagged CNK1 to the membrane. Liposomes with 
10 % and 15 % DGS-NTA(Ni) also did not allow any exchange reaction to be monitored 
(data not shown). 
Taken together, the exchange reaction of ARNO on myr-ARFs could be successfully 
reconstructed in vitro using PIP2-containing liposomes, however the effect of membrane-
localised CNK1 is still not completely understood. 
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Fig. 3-25: Exchange assays using DGS-NTA(Ni) containing lipids failed to elucidate the 
effect of CNK1. 400 nM myr-ARF1 was pre-loaded with 1 µM Mant-GDP using a buffer without 
reducing agent. The exchange reaction in presence of liposomes (200 µM total lipid concentration, 
5 % or 25 % DGS-NTA(Ni), 2 % PIP2) and 100 µM GTP was initiated by the addition of 1 nM 
ARNO or mixtures of 1 nM ARNO and the indicated CNK1 concentrations (A). For 25 % DGS-
NTA(Ni), ARNO concentrations of up to 20 nM were tested (B). The reaction was performed at 
37 °C and monitored by the decreasing Mant-FRET signal. The black lines show the mono-
exponential fits of the data assuming pseudo-first order kinetics. 
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4 Discussion 
Insulin signalling is a key metabolic pathway in vertebrates and dysregulation in form of 
diabetes mellitus poses a major health risk to the ageing society (Navarro et al. 1999, 
WHO and IDF 2006). Thus, understanding the molecular mechanisms of how the insulin 
signal is processed within the cell is decisive for developing new strategies for pathway 
modification and hence treatment of diabetes. The signalling process is described in 
chapter 1.2.4 and consists of the activation of the IR, a receptor tyrosine kinase, and a 
downstream signalling cascade involving phosphoinositides and several other kinases. It 
has long been known that cytohesins, exchange factors for ARF GTPases, are also 
involved in this process (Venkateswarlu et al. 1998) and their role was further investigated 
during this work. 
4.1 The influence of ARNO on IR activity 
In the late 1990s it became apparent that cytohesins are involved in insulin signalling and 
that the cytohesin ARNO is translocated to the cell membrane upon insulin stimulation 
(Venkateswarlu et al. 1998). Two more recent studies then shed further light on the 
cytohesin involvement in insulin signalling and showed that chemical inhibition of 
cytohesins leads to insulin resistance phenotype (Hafner et al. 2006, Fuss et al. 2006). 
Insulin-dependent localisation of cytohesins at the cell membrane raised the question of 
whether the influence of cytohesins on IR signalling could be rooted in enhanced receptor 
activity, which could be deduced from an increase in autophosphorylation. Therefore, 
in vitro autophosphorylation experiments were performed (fig. 3-2). Typically, in vitro 
autophosphorylation is induced by MgCl2, which leads to augmented intermolecular 
interactions between the IR molecules and hence autophosphorylation (Herrera and 
Rosen 1986). Addition of a tenfold molar excess of ARNO and ARNOΔpbr did not alter IR 
autophosphorylation, arguing against a direct influence of ARNO on the receptor activity. 
This approach however comes with certain limitations: Autophosphorylation was 
monitored devoid of a membrane environment and was induced by an artificial stimulus, 
which relies on mild receptor aggregation (Herrera and Rosen 1986). Additionally, 
autophosphorylation proceeds very fast under these conditions and the experimental 
setup was unable to detect differences occurring during the first 15 sec after initiation of 
autophosphorylation. In order to monitor these early kinetics, a stopped-flow approach 
would have to be chosen. 
However, the experiment supports earlier cellular approaches (Hafner et al. 2006). The 
study found that neither autophosphorylation nor the density of the IR was affected by 
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blocking cytohesins in HepG2 cells. Instead, the first hint at reduced pathway activity due 
to chemical cytohesin blockage was a decreased phosphorylation of IRS1 (Hafner et al. 
2006). 
4.2 Putative physical interaction between ARNO and IR 
Due to the involvement in the early steps of IR signalling, a direct interaction between 
ARNO and the IR was proposed, even if the receptor autophosphorylation remains 
unaffected by cytohesins (Li et al. 2003a, Hafner et al. 2006). 
In order to test the hypothesis of a direct protein-protein contact, several biochemical 
approaches using the purified proteins were employed (chapter 3.2). While the label 
transfer and microscale thermophoresis techniques suggested a physical interaction 
(fig. 3-3 and fig. 3-4), this finding could not be confirmed by pull-down, analytical SEC nor 
ITC experiments (fig. 3-5, fig. 3-6 and fig. 3-7). 
The performed experiments deliver contradictory results. One explanation might be a 
difference in sensitivity. Especially transient interactions, which are a common feature of 
protein interaction networks, are challenging to detect (Perkins et al. 2010). Crosslinking 
experiments like the label transfer facilitate the detection of weak and transient 
interactions, however they increase the risk of detecting false positive interactions; the 
detectable label transfer from ARNO to MBP and IR-ICD to GST shows that unspecific 
interactions were also found. This underlines that the cross-linking approach is very 
sensitive to the concentrations of crosslinker and interaction partners used as well as the 
crosslinking duration. 
The ITC method represents a well-established biochemical approach to investigate 
biomolecular interactions based on the detection of small temperature changes during the 
controlled mixing of interaction partners (Ladbury 2004). The range of detection is limited 
by the signal intensity in case for high affinity measurements, where low sample 
concentrations need to be used. For affinities in the millimolar to micromolar range on the 
other hand, the required high sample concentrations can be limiting. To obtain a complete 
measurement set, the concentration of the injected partner needs to be approximately one 
order of magnitude higher concentrated than the expected KD. In the case of proteins, 
concentrations exceeding 500 µM to 1 mM are often very hard to achieve and lead to 
aggregation. Therefore, weak affinities cannot be elucidated under those circumstances. 
Due to solubility limitations and the consumed total protein amount, IR-ICD was injected at 
approximately 200 µM (fig. 3-7). Hence, weak binding (KD ≥ 20 µM) cannot be ruled out by 
the ITC approach. 
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Similarly, also for analytical SEC and pull-down approaches, the complex needs to be 
rather stable to be detected. 
The phosphorylation status of the IR-ICD adds another level of complexity since the 
interaction with cytohesins could be phosphorylation-dependent. However, the MST and 
pull-down experiments were repeated with phosphorylated receptors and no change in 
interaction behaviour could be seen (data not shown). 
Although co-immunoprecipitation studies indicated an insulin-dependent interaction of 
cytohesins with the IR-IRS1 complex in cells (Hafner et al. 2006), a direct interaction 
between ARNO and the IR could not be shown unambiguously using purified proteins. 
However, transient binding with low affinity is a possible mode of action. 
4.3 Properties of the ARNO-CNK1 complex 
Since the interaction between ARNO and the IR-ICD remains uncertain and a high-affinity 
interaction appears unlikely, another postulated interaction was investigated. Here, the 
interaction between ARNO and the scaffold protein CNK1 was followed up. Scaffold 
proteins mediate binding in signalling cascades and can lead to complex assembly, a 
specific subcellular localisation, coordination of feedback loops and protection of activated 
signalling molecules from inactivation (Shaw and Filbert 2009). The most prominent 
scaffold protein within the IR signalling pathway is certainly IRS1, which directly binds the 
phosphorylated IR, gets phosphorylated and relays the insulin signal further within the cell 
(White et al. 1985, Eck et al. 1996, Sun et al. 1993). 
CNK1 is a multidomain scaffold protein and cytohesins were discovered to be a major 
interaction partner (Lim et al. 2010). In the same study, the authors showed that the 
CKN1-cytohesin complex is critical for the activation of the PI3K/PKB cascade 
downstream of the IR. CNK1 depletion in HeLa cells reduced the insulin-induced 
localisation of endogenous cytohesins to the cell membrane and ARF activity. The 
ARNO cc domain as well as the C-terminal domain of CNK1 were identified to be critical 
for the interaction and the involvement of CNK1 in insulin signalling. However, all 
experiments were performed in cell culture and hence a direct physical interaction without 
the need of cofactors remained to be proven (Lim et al. 2010). 
4.3.1 ARNO and CNK1 interact via their coiled-coil domains 
Pull-down experiments with GST-ARNO and CNK1 constructs lacking their respective 
coiled-coil domains showed that an interaction could only be detected when both 
cc domains were present (fig. 3-8). Subsequent pull-down experiments further confirmed 
the important role of the ARNO cc domain (fig. 3-9). Not only GST-ARNO was able to 
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pull-down CNK1, also the isolated ARNO cc domain fused to GST interacted with CNK1 
and only slightly less CNK1, as compared to full-length ARNO, could be eluted indicating 
a somewhat reduced affinity. When the ARNO cc domain was deleted, no interaction with 
CNK1 was observed. Hence the ARNO cc domain is necessary and sufficient for the 
interaction with CNK1. 
GST-ARNO and Halo-ARNO were used to confirm that also the CNK1 cc domain is 
sufficient for the ARNO interaction (fig. 3-10 and fig. 3-11). The CNK1 cc domain and the 
CNK1 cc domain fused to MBP both interacted with the ARNO fusions while control 
proteins remained in the supernatant fraction. The CNK1-cc band is visualised rather 
weakly due to its small size and lack of high resolution in the SDS-PAGE. This could be 
circumvented by using TRIS-Glycine PAGE or gradient PAGE. Taken together, the 
pull-down experiments successfully mapped the interaction sites of ARNO and CNK1 to 
their respective cc domains and were in line with the published cellular data (Lim et al. 
2010). 
4.3.2 The ARNO-CNK1 complex is stable and highly affine 
Stoichiometry and affinity are two further questions which were addressed in this work. 
Analytical SEC confirmed the requirement of the ARNO cc domain (fig. 3-12) and the 
interaction between ARNO and CNK1. Furthermore, different protein ratios were tested. 
While a 1:1 molar ratio of ARNO and CNK1 led to one major peak consisting of both 
proteins and a second peak which predominantly consisted of ARNO, a 1:2 ratio led to 
one peak containing both proteins (fig. 3-12 A). It is noteworthy that the molecular weights 
of the single proteins as well as the complex only roughly match the theoretical elution 
volumes according to the calibration curve created using standard proteins. Critically, SEC 
separates proteins according to their hydrodynamic radius and not according to the actual 
molecular weight. For globular proteins such as thyroglobulin, γ-globulin, ovalbumin and 
myoglobin of the SEC standard, the hydrodynamic radius correlates very well with the 
molecular weight and the approximation of molecular weights of globular proteins is thus 
sufficiently exact. Since ARNO dimerises via its cc domain, it likely rather adopts an 
extended rod-like structure resulting in an elution volume corresponding to a higher 
molecular weight. 
In order to investigate stoichiometry and especially affinity independently, ITC 
experiments were performed using ARNO and CNK1 or MBP-CNK1-cc (fig. 3-14). The 
ITC experiment using full-length proteins confirmed the 1:2 stoichiometry, which can be 
deduced clearly from the data since a steep increase from the unbound to bound state 
does not interfere with stoichiometry calculations. The affinity was determined as 
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2.6 nM ± 0.9 nM, however the low signal intensity and the steep transition zone limit the 
accuracy of the measurement. Since the signal intensity was already low, lowering the 
reactant’s concentrations was no option. Also altering the temperature did not affect the 
affinity significantly. In order to circumvent this problem, the MBP-CNK1-cc construct was 
used, which interacted with ARNO with a KD value in the double-digit nanomolar range. 
This supports the first finding of pull-down experiments, that the cc domain of either 
protein is sufficient for the interaction but has a slightly lower affinity compared to the full-
length protein. Taken together, the data showed that ARNO and CNK1 interact in a 1:2 
ratio with a very high affinity. 
Apparently, CNK1 is able to disrupt the cc interaction of the ARNO dimer to form a 
heterotrimer consisting of two CNK1 molecules and one ARNO molecule. Theoretically 
also a complex of four CNK1 and two ARNO molecules is thinkable, although the elution 
volume in the SEC experiments clearly argues against this option. The biological 
consequences of this particular interaction mode are uncertain since the activity of 
cytohesins is independent from its oligomeric form (DiNitto et al. 2007). It can be 
speculated that this oligomeric form enables the proper integration within a larger 
signalling complex or influences membrane localisation. Dimers as well as trimers are 
frequent occurrences of cc interactions and single amino acids can determine the 
oligomeric state; also, a mixture of different states is possible (Mason and Arndt 2004). 
Hence, a regulatory mechanism dependent on the oligomeric state is conceivable, 
although the mechanism is uncertain at this point. 
4.3.3 Crystallisation failed to provide deeper insight into the ARNO-CNK1 complex 
In order to understand the molecular basis of the ARNO-CNK1 interaction, the three-
dimensional structure should be solved by X-ray crystallography. One of the most difficult 
steps in structure determination is the generation of robust and diffracting protein crystals. 
Since flexible regions such as N- and C-termini can hamper proper crystal packaging, 
several truncated constructs of ARNO were used for co-crystallisation with CNK1 or the 
CNK1 cc domain. The proteins could be generated in sufficient amounts and a SEC step 
before crystallisation was performed to increase sample homogeneity. This approach led 
to several crystals which could be stained with IZIT dye, indicating that the crystals were 
most likely composed of protein. Even though crystal shape and size were optimised in 
the hanging-drop method, none of the crystals diffracted when tested at the synchrotron 
beamline. Unfortunately, crystallisation conditions are practically impossible to predict and 
a rational approach to increase the likelihood of a successful crystallisation is limited. 
Testing more initial conditions as well as further constructs enhances the chances of 
finding appropriate crystallisation conditions but can be a very time-consuming process. 
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However, shortening the constructs too much bears the risk of deviating from the cellular 
situation resulting in a misleading conclusion. Interestingly, the 1 ARNO:2 CNK1 ratio 
found for the full-length proteins was not resembled when the MBP-CNK1-cc construct 
was used (fig. 3-14 B). Therefore, constructs resembling the 1 ARNO:2 CNK1 ratio should 
primarily be considered for future crystallisation studies. 
4.4 Monitoring ARNO activity on myr-ARFs in vitro: Approach and 
challenges 
The catalytic activity of exchange factors on GTPases can be monitored using different 
approaches. Since assays based on intrinsic tryptophan fluorescence (Kahn and Gilman 
1986, Antonny et al. 1997) and fluorescently labelled fluorophores (as in Stalder et al. 
2011) exist, no radioactive assays were performed (Kahn and Gilman 1986, Franco et al. 
1995). 
Exchange reactions have been monitored using full-length myristoylated ARFs in 
presence of liposomes or by employing a more simplistic model in solution using ARFs 
devoid of the N-terminal myristoylated amphipathic helix (NΔ17ARF1 and NΔ13ARF6, 
Antonny et al. 1997). Notably, kinetics are significantly faster when myristoylated ARFs 
are used (Nawrotek et al. 2016). Since the membrane environment changes kinetics 
drastically and the reaction takes place at the membrane within the cell (Stalder et al. 
2011, Padovani et al. 2014), a liposome model was chosen for the analyses in this work 
(Stalder et al. 2011). 
4.4.1 Purification of myristoylated ARFs 
Heterologously expressed ARFs can either be myristoylated during expression by 
co-expressing an NMT (Franco et al. 1995) or by expressing ARF and NMT separately 
and then performing the myristoylation in vitro (Padovani et al. 2013). Since myristoylated 
ARFs have a higher tendency to bind membranes, the purification is quite tedious and 
yields are comparatively low. Therefore, I pursued the in vitro myristoylation approach for 
ARF6 which led to a pure final protein with a very high degree of myristoylation (fig. 3-17). 
The process worked well, and hence this approach was also tested for ARF1, which has 
not been published. However, neither GDP nor GTP loaded ARF1 could be myristoylated, 
possibly since the N-terminus was inaccessible. A new attempt to circumvent the complex 
purification of myristoylated ARFs is the use of hexahistidine-tagged ARFs in combination 
with liposomes containing DGS-NTA(Ni) (Peurois et al. 2017). Although the exchange 
kinetics are slightly slowed down, this approach might replace the use of myristoylated 
ARFs for certain applications in the future. 
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4.4.2 Different ways to monitor exchange activity on ARFs 
Intrinsic tryptophan fluorescence and fluorescently labelled GTP or GDP analogues are 
both used to monitor exchange activity on ARFs. Indeed, both techniques are frequently 
used complementary within one study (Stalder et al. 2011). Working with GDP and GTP 
can be beneficial since the kinetics with the natural nucleotides is studied, while 
fluorescent modifications such as a Mant moiety attached to the ribose can influence 
nucleotide binding. However, characteristics of fluorescently labelled nucleotides were 
found to generally resemble the non-modified versions and fluorescent nucleotide 
analogues have successfully been used in the past to study cytohesin/ARF nucleotide 
exchange kinetics (Hiratsuka 1983, Stalder et al. 2011, Malaby et al. 2013). 
Also, the choice of whether Mant-GTP binding to ARF-GDP or Mant-GDP dissociation 
from ARF-Mant-GDP is monitored can be varied and both approaches were performed in 
the abovementioned publications. No specific experimental setup is particularly preferred 
in a certain situation. For the exchange reactions in presence of liposomes however, I 
found the use of a Mant-GDP release assay most reliable (fig. 3-19). Notably, a Tecan 
plate reader was used in the experiments, while most published data were generated in a 
fluorescence spectrophotometer equipped with a stirring device, probably accounting for a 
better signal-to-noise ratio. The assay worked best when myr-ARFs were pre-loaded with 
a rather small excess of Mant-GDP (1 µM) over the myr-ARF (400 nM). Additionally, 
myr-ARF1 was pre-incubated with GTP for temperature equilibration before ARNO 
addition which was impossible for myr-ARF6. The spontaneous exchange of Mant-GDP to 
GTP in absence of exchange factor was too high, probably due to the permanent 
localisation of myr-ARF6 to the membrane (Macia et al. 2004). Why this setup proved to 
be superior to intrinsic tryptophan fluorescence or a Mant-GTP binding assay remains 
elusive. 
4.5 The mechanism of CNK1 involvement in insulin signalling 
CNK1 depletion results in the same effect on insulin signalling (Lim et al. 2010) as 
inhibition of cytohesins (Hafner et al. 2006), namely the reduction of IRS and PKB 
phosphorylation. Since another member of the CNK family, CNK3B directly affects ARNO 
exchange activity (Venkateswarlu 2003), it was tested whether also CNK1 might enhance 
the exchange activity of cytohesins. Unlike for CNK3B, CNK1 did not accelerate the 
ARNO mediated exchange in solution (data not shown) nor in a lipid environment 
(fig. 3-20 and fig. 3-21). There are three possible explanations for this result: 1. ARNO and 
CNK1 do not interact under the tested exchange conditions, 2. the ARNO-CNK1 complex 
does not localise to the liposomes and 3. CNK1 exerts its action in the insulin signalling 
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pathway independent of the ARNO exchange rate. The possibility that ARNO and CNK1 
do not interact at 1 nM to 20 nM cannot be ruled out, however that fact that already the 
CNK1 cc domain interacts with ARNO in the double-digit nanomolar range and that the 
full-length proteins show an even higher affinity argues against this option. Additionally, 
similar buffer conditions were used in the exchange assay as well as the interaction 
studies. All data have hinted at a very stable interaction and it is overall highly unlikely that 
ARNO and CNK1 do not interact in the tested exchange assay. The localisation of CNK1 
is discussed in the next chapter. 
4.5.1 The CNK1 localisation 
Exchange factors exert their catalytic activity towards ARF GTPases at the cell membrane 
and are in their auto-inhibited state in the cytosol (DiNitto et al. 2007, Karandur et al. 
2017). The co-localisation of exchange factor and GTPase at the membrane is therefore 
an important prerequisite for exchange activity and a higher concentration of membrane-
bound cytohesins correlates with an increased level of activated GTPase. It was therefore 
investigated whether CNK1 localises to the liposomes used for exchange assays and in 
how far it influences ARNO localisation (fig. 3-22). The performed liposome flotation assay 
showed that CNK1 did not interact with liposomes and hence did not increase the amount 
of membrane-bound ARNO. Possibly, a certain amount of ARNO is even sequestered in 
solution via CNK1 (fig. 3-22), which might explain the reduced exchange kinetics on 
myr-ARF1 (fig. 3-20). 
This result is in line with recent literature, where cellular experiments showed that CNK1 
only localises to the plasma membrane after it has been acetylated within its PH domain 
(Fischer et al. 2017). It was therefore tested whether the acetylation-mimic mutant 
CNK1K414Q localised to the liposomes. However, also the acetylation-mimic mutant 
remained unbound to liposomes (fig. 3-23). Since Fischer and colleagues were unable to 
elucidate the exact mechanism of membrane targeting, it is unclear why the acetylation-
mimic mutant localises to the plasma membrane but not to the prepared liposomes. 
Apparently, another factor is required for lipid binding, which is only present in the cell. A 
simplistic phosphoinositide binding mode can be excluded, since CNK1 only binds weakly 
and non-specifically to phosphoinositides (Jaffe et al. 2004) and masking the positive 
charge of lysine would rather decrease than increase phosphoinositide binding as shown 
for the lysine acetylation within the PH domain of PKB (Sundaresan et al. 2011). 
Because CNK1 remained unbound to liposomes, it was next artificially tethered to 
liposomes. The method was adapted from Peurois, who was able to bind hexahistidine-
tagged ARFs to liposomes complemented with DGS-NTA(Ni), a lipid with a nickel-
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containing headgroup, which can chelate the affinity tag (Peurois et al. 2017). A titration 
experiment clearly showed that unlike to the publication, where 5 % DGS-NTA(Ni) was 
sufficient to bind histidine-tagged ARFs, a higher DGS-NTA(Ni) concentration needed to 
be used. Only when the concentration was raised to 15 % and 25 %, a substantial amount 
of histidine-tagged CNK1 bound to the liposomes (fig. 3-24). While the exact reason for 
this difference remains unclear, it can be speculated that the affinity tag of CNK1 is less 
well accessible and might be covered by parts of CNK1, a protein which is significantly 
larger than ARF GTPases. As the next step, the exchange reaction of ARNO on 
myr-ARF1 using liposomes with DGS-NTA(Ni) was tested (fig. 3-25). The exchange using 
5 % DGS-NTA(Ni) works, but CNK1 does not affect the exchange rate. This was expected 
since CNK1 behaves the same way as in a setup using liposomes without DGS-NTA(Ni), 
remaining free in solution. 
Unfortunately, the exchange could not be monitored on liposomes with higher DGS-
NTA(Ni) concentration (fig. 3-25 B). Even when the ARNO concentration was increased, 
no exchange reaction, recognisable by a drop in fluorescence intensity, could be 
observed. The reason for this remains elusive but apparently the high DGS-NTA(Ni) 
concentration hampers the proper arrangement of ARNO and myr-ARF1 at the surface of 
the liposomes. Hence, the question of whether CNK1 can increase the local ARNO 
concentration at membranes and therefore contributes to an increased ARF signalling 
remains unclear. 
4.5.2 A possible mode of action for the ARNO-CNK1 complex 
This work could clearly demonstrate that ARNO and CNK1 directly interact with one 
another and form a stable complex (chapter 3.3). Previous research showed that CNK1 
directs cytohesins to the cell membrane and established CNK1 “as a new positive 
regulator of insulin signalling” (Lim et al. 2010). All findings to this point indicate that the 
CNK1-ARNO interaction is highly stable and of permanent nature. So why is CNK1 
required in IR signalling and how is it regulated? According to the model shown in 
fig. 1-11, it is likely that CNK1 helps localise cytohesins to the plasma membrane, 
resulting in a higher ARF activation with increased PIP2 levels, which facilitates the 
recruitment of IRS1 and hence reinforces the insulin signal. It remains elusive, how CNK1 
is directed to the cell membrane upon insulin stimulation. One possible mechanism is 
lysine acetylation within its PH domain as recently shown (Fischer et al. 2017). Stimulation 
with EGF as well as IGF enhanced CNK1 acetylation by CBP via RAS/RAF/MEK/ERK 
signalling which reinforces ERK signalling and in turn again increases the amount of 
acetylated CNK1 (Fischer et al. 2017). 
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5 Materials and Methods 
5.1 Material 
5.1.1 Equipment 
Analytical balance CPA324S Sartorius 
Anion exchange column HiTrap DEAE FF GE Healthcare 
Autoclave VX-150 Systec 
Balance BL1500S Sartorius 
Block heater Stuart Scientific 
Centrifuge 5427 R Eppendorf 
Centrifuge 5804 R Eppendorf 
Cooling cabinet Unichromat 1500 “Pro” Uniequip 
Desalting column HiPrepTM 26/10 GE Healthcare 
DLS cuvette ZEN2112 ultra low volume Malvern Instruments 
DLS equipment Zetasizer Nano S Malvern Instruments 
FPLC, ÄKTA GE Healthcare 
French press and pressure cell FA-032 Thermo Scientific 
Gastight syringes, 50 µL, 500 µL, 1000 µL Hamilton 
High-performance centrifuge J-26S XP with 
rotors JLA-8.1000 and JA-25.50 
Beckman coulter 
HPLC, Agilent 1100 Agilent Technologies 
HPLC column MultoHigh®-Bio-200-C18 5 µ CS-Chromatographie Service GmbH 
Imaging System Odyssey LI-COR Biotechnology 
Incubator Heratherm  Thermo Scientific 
Incubator Innova 40R New Brunswick 
Incubator Multitron Pro Infors HT 
ITC iTC200 MicroCalorimeter Microcal 
Liposome mini extruder Avanti Polar Lipids 
Magnetic stirrer IKAMAG® RCT IKA 
Mass spectrometer esquire HCT Bruker 
Microwave Bosch 
MST instrument Monolith NT.115 NanoTemper Technologies 
Overhead tumbler DTR-30 Grant-bio 
pH meter Mettler Toledo  
Pipette controller accu-jet® pro Brand GmbH & Co KG 
Pipettes Research (plus) Eppendorf 
Plate reader Infinite M1000 Pro Tecan 
Power supply for electrophoresis E802 Consort 
Rotary evaporator Laborota 4000-efficient Heidolph instruments 
SDS‐PAGE equipment and chambers BioRad 
SEC column HiLoad 16/600 Superdex 200 pg GE Healthcare 
SEC column HiLoad 16/600 Superdex 75 pg GE Healthcare 
SEC column Superdex 200 10/300 GL GE Healthcare 
Semi dry blotting chamber Pegasus Phase GmbH 
Spectrophotometer NanoDrop 2000c Thermo Scientific 
Thermomixer comfort Eppendorf 
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Ultracentrifuge OptimaTM MAX-XP with rotor 
TLA-100 
Beckman coulter 
Ultrasound bath Sonorex Super 10P Bandelin 
UV light source, MiniBIS DNR Bio Imaging Systems 
Vertical shaker KS 501 digital IKA 
Vortex 4 basic IKA 
Water bath GFL 
Water system MicroPure UV/UF Thermo Scientific 
 
5.1.2 Chemicals and reagents 
4-(2-aminoethyl)benzenesulfonyl fluoride 
(AEBSF) 
Serva 
Acetic acid, p. a. Roth 
Acetone, p. a. Roth 
Acetonitrile, LC-MS grade Roth 
Acrylamide-Bisacrylamide solution (37.5:1) Roth 
Adenosine 5′-triphosphate (ATP) AppliChem 
Agar Agar Roth 
Ammonium persulphate (APS), p. a. Roth 
Ammoniumsulphate, p. a. Roth 
Ampicillin, ≥ 99 % Roth 
β-mercaptoethanol, p. a. Roth 
Bestatin Serva 
Bromophenol blue  Merck 
BSA fraction V PAN Biotech 
BSA, fatty acid free Roth 
Chloramphenicol Sigma 
Chloroform, HPLC grade Roth 
Coomassie Blue G  Serva 
Dimethylformamide (DMF), ≥ 99.5 % Roth 
Dimethylsulphoxide (DMSO), ACS Acros organics 
Dithiothreitol (DTT), p. a. Roth 
E-64 Serva 
Ethanol, HPLC grade Roth 
Ethylendiaminetetraacetic acid (EDTA), p. a. AppliChem 
Ethylene glycol bis(β-aminoethyl)-ether) 
N,N,N',N' tetraacetic acid (EGTA), p. a. 
Roth 
Formic acid, LC-MS grade Roth 
Gel filtration standard BioRad 
Glycerol, Ph. Eur. Roth 
Glycine, p. a. Roth 
Guanosine 5′-diphosphate (GDP), ≥ 96 % Sigma 
Guanosine 5′-triphosphate (GTP), ≥ 95 % Sigma 
HEPES, p. a. Roth 
Hydrochloric acid, Ph. Eur. VWR Chemicals 
Imidazole, ≥ 99 % Merck 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Carbolution 
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Isopropanol, p. a. Roth 
IZIT dye Hampton Research 
Kanamycin, > 750 I. U./mg Roth 
L-Glutathione, reduced (GSH) AppliChem 
LB medium Lennox Roth 
Magnesium chloride, p. a. Fluka 
Maltose, ≥ 99 % Sigma 
Mant-GDP, ≥ 95 % Jena Bioscience 
Mant-GTP, ≥ 95 % Jena Bioscience 
Methanol, LC-MS grade Roth 
Myristoyl-Coenzyme A (Myristoyl-CoA), ≥ 95 % Sigma 
Nalidixic acid, ≥ 99 % Roth 
N,N,N’,N’-Tetramethylendiamine (TEMED)  Roth 
NHS-Fluorescein Thermo Scientific 
PAGE Ruler Prestained Plus Thermo Scientific 
Phosphoramidon Serva 
Potassium acetate, p. a. Roth 
Potassium hydroxide, p. a. Roth 
Sodium acetate, p. a. Roth 
Sodium chloride, p. a. Roth 
Sodium dodecyl sulphate (SDS), p. a. AppliChem 
Sodium hydroxide, p. a. Roth 
Sodium myristate, ≥ 99 % Sigma 
Sucrose, ≥ 99.5 % Sigma 
Sulfo-SBED label transfer reagent Thermo Scientific 
Thimerosal AppliChem 
Tris(2-carboxyethyl)phosphine (TCEP), ≥ 98 % Roth 
Tris(hydroxymethyl)aminomethane (TRIS), 
≥ 99.9 % 
Roth 
Triton X-100  AppliChem 
Tween 20, Ph. Eur. AppliChem 
 
5.1.3 Consumables 
Amylose resin #E8021L New England Biolabs 
Blotting paper Macherey-Nagel 
Capillaries for MST, standard treated NanoTemper Technologies 
Centrifugation tubes (15 mL and 50 mL) Sarstedt 
Columns for affinity purification, Protino®, 
35 mL, Ø 21.7 mm 
Macherey-Nagel 
Concentrator Vivaspin Turbo 15 Sartorius 
Concentrator Vivaspin 15 R 2000 MWCO HY Sartorius 
Desalting columns NAP-5 GE Healthcare 
Dialysis units, Slide-A-Lyzer® MINI, 10K  Thermo Scientific 
Dialysis membrane, 6-8 kDa Spectra/Por 
Disposable cuvettes Roth 
Gastight syringes Hamilton 
Glutathione agarose 4B, Protino ® Macherey-Nagel 
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Glutathione sepharose 4B resin GE Healthcare 
HaloLinkTM resin Promega 
Liposome membrane Nucleopore Track-Etch-
Membrane 0.1 µm 
Whatman 
Liposome membrane filter support Whatman 
Membrane filters ME24 GE Healthcare 
Multiwell assay plate 96 well half area non-
binding surface 3993 
Corning 
Multiwell assy plate 96 well transparent round 
bottom REF 82.1582 
Sarstedt 
Ni-NTA agarose, Protino® Macherey-Nagel 
Nitrocellulose membranes GE Healthcare 
Petri dishes #391-0455 VWR 
Pipette tips Sarstedt 
Reaction tubes (1.5 mL, 2 mL, 15 mL, 50 mL) Sarstedt 
Reaction tubes, protein LoBind Eppendorf 
Serological pipettes (5-50 mL) Sarstedt 
Sf-900 III SFM medium ThermoFisher Scientific 
Syringes DiscarditTM BD 
Syringe filters Rotilabo® 0.22 µm Roth 
Ultracentrifuge centifuge tubes 7 x 21 mm 
thickwall polycarbonate, 230 µL 
Beckman coulter 
 
5.1.4 Antibodies 
Antibody Species Dilution Manufacturer, number 
Phospho-Tyr Mouse 1:5000 Santa Cruz sc7020 
Insulin receptor pY1162/1163 Rabbit 1:1000 CellSignaling #3024 
ARNO Mouse 1:1000 Abnova #H00009266-MO2 
CNK1 Mouse 1:500 BD 611734 
IR-Dye Streptavidin 800 CW (no antibody) – 1:10000 LI-COR 926-32230 
Goat-anti-mouse DyLight 800 Goat 1:15000 CellSignaling #5257 
Donkey-anti-rabbit 800 CW Donkey 1:20000 LI-COR 926-32213 
 
5.1.5 Phospholipids 
Phospholipid Origin Manufacturer, number 
L-α-Phosphatidylethanolamine (PE) Liver, bovine Avanti 840026P 
L-α-Phosphatidylserine (PS) Brain, porcine Avanti 840032P 
L-α-Phosphatidylinositol-4,5-bisphosphate (PIP2) Brain, porcine Avanti 840046P 
L-α-Phosphatidylcholine (PC) Egg, chicken Sigma P2772-1G 
1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-
carboxypentyl)iminodiacetic acid)succinyl] nickel 
salt (DGS-NTA(Ni)) 
Synthetic Avanti 790404C 
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5.1.6 E. coli strains and Sf9 cells 
Strain Genotype Supplier 
Escherichia coli BL21 (DE3) E. coli B F– dcm ompT hsdS(rB–mB–) gal 
λ(DE3) 
Thermo Fisher 
Escherichia coli BL21 (DE3) RIL E. coli B F– dcm ompT hsdS(rB–mB–) gal 
λ(DE3) Hte [argU ileY leuW Camr] 
Agilent 
Spodoptera frugiperda Sf9 IPLB-Sf-21-AE derivative Thermo Fisher 
 
5.1.7 Plasmids and constructs 
Construct N-terminal Affinity tag Vector manufacturer 
pFastBac1-HT-IR-ICD 6 x His Thermo Fisher 
pFastBac1-HT-IR-KC 6 x His Thermo Fisher 
pASK-IBA101-HT-ARNO 6 x His IBA GmbH 
pASK-IBA101-HT-ARNOdpbr 6 x His IBA GmbH 
pET28-HT-ARNO-GS2-PH 6 x His Novagen 
pET28-HT-ARNO-Sec7 6 x His Novagen 
pASK-IBA101-HT-ARNO-cc-Sec7 6 x His IBA GmbH 
pACEBac1-HT-CNK1 6 x His ATG biosynthetics 
pACEBac1-HT-CNK1K414Q 6 x His ATG biosynthetics 
pACEBac1-HT-CNK1dcc 6 x His ATG biosynthetics 
pET15-Nd17ARF1 6 x His Novagen 
pET52-ARF6 6 x His (C-terminal) Novagen 
pET28-HT-hNMT 6 x His Novagen 
pMON5840-ARF1wt – Prof Felix Wieland 
pHV738 (hNMT, MetAP) – Prof Richard A. Kahn 
pGEX6P-GST GST GE Healthcare 
pACEBac1-GST-IR-ICD GST ATG biosynthetics/ 
GE Healthcare 
pGEX6P-ARNO GST GE Healthcare 
pGEX6P-ARNOdcc GST GE Healthcare 
pGEX6P-ARNOcc GST GE Healthcare 
pET28-HT-HaTh Halo Novagen/Promega 
pET28-HT-HaTh-ARNO Halo Novagen/Promega 
pET28-MBPT-IR-CT MBP Novagen 
pET28-MBPT-CNK1-cc MBP Novagen 
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5.2 Methods 
5.2.1 Protein concentration determination 
Protein concentrations were determined by applying the Beer-Lambert law, which makes 
use of the absorbance of ultraviolet radiation (280 nm) by certain amino acids. The 
equation 
𝐴ଶ଼଴ = log
𝐼଴
𝐼
= 𝜀ଶ଼଴ × 𝑙 × 𝑐 
links the absorbance at 280 nm (A280, dimensionless) with the molar extinction coefficient 
(ε280, M-1 × cm-1), the path length (l, cm) and the concentration (c, M). This corresponds to 
the log of the initial light intensity (I0) divided by the light intensity after sample penetration 
(I). The theoretical molar extinction coefficients were determined via the web tool 
ProtParam by ExPASy (http://web.expasy.org/protparam/) based on the number of 
tryptophans and tyrosines in the amino acid sequence, which absorb ultraviolet light by 
their delocalised π electron system (Walker 2005). The absorbance measurements were 
performed in triplicates on the NanoDrop spectrophotometer using 2 µL samples. 
5.2.2 SDS-PAGE analysis 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used to evaluate the 
approximate protein molecular weight and purity due to the migration behaviour of the 
denatured protein in an electrical field (Laemmli 1970). The SDS molecules convey a 
uniform charge to the proteins leading to a separation according to the molecular weight. 
The denaturation is achieved by the detergent SDS, the reducing agent DTT and 
exposing the sample to 95 °C for 5 min prior to electrophoresis. In order to estimate the 
molecular weight, the PAGE Ruler Prestained Plus standard was used. Electrophoresis 
was performed in running buffer for 50 min at 200 V using a polyacrylamide gel containing 
10 %, 12.5 % or 15 % acrylamide. The gels were stained for at least 30 min in Coomassie 
blue staining solution and subsequently destained with 10 % acetic acid, which was 
heated in the microwave (adapted from Merril 1990). The gels were imaged using the 
LI-COR Odyssey scanner, 700 nm channel. In case only specific proteins ought to be 
visualised, western blotting and immunodetection (chapter 5.2.3) were performed instead 
of the Coomassie staining procedure. The required buffers for gel preparation, sample 
preparation and staining/destaining are listed below. 
4 x Stacking gel buffer 
 0.5 M TRIS 
 14 mM SDS 
 pH 6.8 
4 x Separating gel buffer 
 1.5 M TRIS 
 14 mM SDS 
 pH 8.8 
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5 x Running buffer 
 125 mM TRIS 
 960 mM glycine 
 17 mM SDS 
 pH 8.2 (do not titrate) 
6 x SDS loading buffer 
 1 M TRIS, pH 6.8 
 30 % (v/v) glycerol 
 15 % (w/v) SDS 
 600 mM DTT 
 0.01 % (w/v) bromophenol blue 
Staining solution 
 30 % (v/v) methanol 
 10 % (v/v) acetic acid 
 0.1 % (w/v) Coomassie blue G 
Destaining solution 
 10 % (v/v) acetic acid 
 
Tab. 5-1: Preparation of one polyacrylamide gel. 
 Separating Gel Stacking Gel 
Percentage 10 % 12.5 % 15 % 4 % 
30 % Acrylamide 1667 µL 2083 µL 2500 µL 213 µL 
Water 2045 µL 1629 µL 1212 µL 975 µL 
4 x Separating buffer 1250 µL - 
4 x Stacking buffer - 400 µL 
TEMED 8 µL 2 µL 
APS 30 µL 10.4 µL 
 
5.2.3 Western blotting and immunodetection 
Visualisation of specific proteins was achieved by first resolving proteins via SDS-PAGE 
(chapter 5.2.2), transferring them onto a nitrocellulose membrane and subsequent 
detection with specific antibodies. For the transfer, the semi dry approach adapted from 
Kyhse-Andersen was performed (Kyhse-Andersen 1984). The gel and the nitrocellulose 
membrane were shortly equilibrated in cathode buffer and anode buffer II respectively. 
Gel and membrane were then assembled between three pieces of Whatman paper 
soaked in cathode buffer facing the cathode side and two pieces of Whatman paper 
soaked in anode buffer II plus one piece of Whatman paper soaked in anode buffer I 
facing the anode side. In order to transfer the proteins to the membrane, a current of 
2 mA/cm2 of gel was applied for 45 min. 
After the transfer, unspecific binding sites on the membrane were blocked for 1 h using 
TBST + 5 % (w/v) BSA while shaking. The primary antibody was incubated in the required 
dilution (chapter 5.1.4) for 2 h at room temperature (RT) or overnight at 4 °C. The blot was 
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rinsed three times with TBST for 5 min and then incubated with the fluorescently labelled 
secondary antibody for 1 h at RT. All antibodies were diluted in TBST + 5 % (w/v) BSA. 
The blot was rinsed again three times for 5 min with TBST and imaged using the LI-COR 
Odyssey scanner. Since the streptavidin was directly labelled with a fluorescence tag, the 
blot was incubated for 1 h with the streptavidin dilution after blocking, washed three times 
with TBST and subsequently imaged. 
Anode buffer I 
 300 mM TRIS 
 pH 10.4 
Anode buffer II 
 25 mM TRIS 
 pH 10.4 
Cathode buffer 
 25 mM TRIS 
 40 mM glycine 
 pH 9.4 
TBST 
 20 mM TRIS 
 136 mM NaCl 
 0.1 % (v/v) Tween 20 
 pH 7.6 
5.2.4 Protein production 
E. coli BL21 (DE3) cells or E. coli BL21 (DE3) RIL cells conveying additional tRNAs for 
arginine, isoleucine and leucine (chapter 5.1.6) were transformed with the respective 
expression vector providing kanamycin or ampicillin resistance by heat shock 
transformation (adapted from Hanahan 1983). Therefore, 25 µL of the competent cells 
were mixed with 10-100 ng of the construct and incubated on ice for 15 min. A 45 sec 
heat shock at 42 °C was applied and the cells were chilled on ice for another 2 min. 
500 µL of LB medium was added and the cells were allowed to grow for 60 min at 37 °C 
with 350 rpm shaking. The cells were pelleted by centrifugation at 2700 xg for 2 min, 
resuspended in 100 µL LB and then spread on a selective plate containing 50 µg/mL 
kanamycin or 100 µg/mL ampicillin and incubated overnight at 37 °C. In case BL21 (DE3) 
RIL cells were used (see tab. 5-2), the selective plate as well as the starter culture were 
additionally supplemented with 50 µg/mL chloramphenicol. To set up a starter culture, one 
colony from the selective plate was transferred into a 250 mL baffled flask filled with 
50 mL LB medium containing the required antibiotics in the same concentration as 
previously stated and incubated overnight in an incubation shaker at 37 °C and 160 rpm. 
For protein production, 2 L LB cultures containing the abovementioned antibiotics but no 
chloramphenicol were inoculated in 5 L baffled flasks with 50 mL of the overnight culture. 
The overnight cultures were also used to prepare glycerol stocks for easier re-expression. 
Therefore, 500 µL of the bacterial culture was mixed with 500 µL 50 % glycerol and stored 
at -80 °C. The cells were grown at 37 °C with 110 rpm shaking until OD600 reached ~0.5 
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and gene expression was induced by addition of 0.5 mM isopropyl β-D-1-thiogalacto-
pyranoside (IPTG). Cells were either allowed to grow at 37 °C for 5 h or at 20 °C overnight 
(tab 5-2), in which case the cells were cooled down for 30 min at 4 °C prior to induction. 
After expression, the cells were centrifuged at 4000 xg (rotor JLA-8.100) for 20 min, the 
supernatant was discarded and the cell pellet was stored at -80 °C until further 
processing. 
Proteins unsuited for production in E. coli were produced in Sf9 cells using the Bac-to-Bac 
vector system by Thermo Scientific (tab. 5-3). Expression was performed by Yvonne 
Aschenbach. Approximately 2.5 L Sf-900 III SFM culture medium with 2 million cells/mL 
were infected 1:1000 with the V1 virus stock and incubated for 3 days at 27 °C with 
80 rpm shaking. The cells were harvested at 1200 xg (rotor JLA-8.100) for 12 min, the 
supernatant was discarded and the cell pellet was stored at -80 °C until further 
processing. 
Tab. 5-2: Bacterial strains and expression conditions used for different constructs. ARNO-
Sec7 and NΔ17ARF1 were expressed and purified by Max Yin and Volkmar Fieberg, respectively. 
Construct E. coli strain Temperature, Duration Antibiotic  
pASK-IBA101-HT-ARNO BL21 (DE3) RIL 20 °C, o/n Ampicillin 
pASK-IBA101-HT-ARNOdpbr BL21 (DE3) RIL 20 °C, o/n Ampicillin 
pET28-HT-ARNO-GS2-PH BL21 (DE3) 20 °C, o/n Kanamycin 
pET28-HT-ARNO-Sec7 BL21 (DE3) 37 °C, 5 h Kanamycin 
pASK-IBA101-HT-ARNO-cc-Sec7 BL21 (DE3) 20 °C, o/n Ampicillin 
pET15-Nd17ARF1 BL21 (DE3) 37 °C, 5 h Ampicillin 
pET52-ARF6 BL21 (DE3) 37 °C, 5 h Ampicillin 
pET28-HT-hNMT BL21 (DE3) 20 °C, o/n Kanamycin 
pGEX6P-GST BL21 (DE3) 20 °C, o/n Ampicillin 
pGEX6P-ARNO BL21 (DE3) 20 °C, o/n Ampicillin 
pGEX6P-ARNOdcc BL21 (DE3) 20 °C, o/n Ampicillin 
pGEX6P-ARNOcc BL21 (DE3) 20 °C, o/n Ampicillin 
pET28-HT-HaTh BL21 (DE3) 20 °C, o/n Kanamycin 
pET28-HT-HaTh-ARNO BL21 (DE3) 20 °C, o/n Kanamycin 
pET28-MBPT-IR-CT BL21 (DE3) RIL 20 °C, o/n Kanamycin 
pET28-MBPT-CNK1-cc BL21 (DE3) RIL 20 °C, o/n Kanamycin 
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Tab. 5-3: Constructs expressed in Sf9 cells. Expression performed by Yvonne Aschenbach. 
Construct Expression host Expression conditions 
pFastBac1-HT-IR-ICD Sf9 cells 3 days, 27 °C 
pFastBac1-HT-IR-KC Sf9 cells 3 days, 27 °C 
pACEBac1-HT-CNK1 Sf9 cells 3 days, 27 °C 
pACEBac1-HT-CNK1K414Q Sf9 cells 3 days, 27 °C 
pACEBac1-HT-CNK1dcc Sf9 cells 3 days, 27 °C 
pACEBac1-GST-IR-ICD Sf9 cells 3 days, 27 °C 
 
5.2.5 Protein purification 
After heterologous expression (chapter 5.2.4), the majority of proteins used in this study 
were prepared by affinity purification followed by polishing steps such as SEC. Since the 
purification procedure of myr-ARF1 as well as myr-ARF6 deviated significantly from the 
other proteins, their purification is described separately in chapter 5.2.6 and chapter 5.2.7. 
For the remaining proteins, the purification is presented grouped after the respective 
affinity tag. 
Purification of hexahistidine-tagged proteins 
Fusing a hexahistidine-tag to proteins is one of the most widely applied techniques to 
obtain proteins for biomedical research. The histidine-tag forms a complex with 
immobilised nickel ions which can be competed with the histidine analogue imidazole to 
elute the target protein (Hochuli et al. 1987, Hochuli et al. 1988). This form of 
chromatography is also referred to as immobilised metal ion affinity chromatography 
(IMAC). 
All purification steps were performed with cooled buffers at 4 °C or on ice. The cells 
obtained from 2 L LB medium expression (chapter 5.2.4) were resuspended in 20 mL lysis 
buffer + 1 x protease inhibitor mix. For proteins expressed in Sf9 cells, 30 mL lysis buffer 
+ 1 x protease inhibitor mix were used per 2 L of cell culture. The completely resuspended 
cells were disrupted by passing them through a French press for two cycles with a 
maximum pressure of 18000 PSI (1240 bar). The lysate was cleared by centrifugation at 
48000 xg for 30 min, added to 2.5 mL nickel nitrilotriacetic acid (Ni-NTA) beads previously 
equilibrated in lysis buffer and incubated for 1 h while shaking slightly. The suspension 
was then applied to Protino® columns equipped with a polymeric frit. The beads were 
washed with 15 mL lysis buffer and the target proteins were eluted with 12.5 mL lysis 
buffer + 230 mM imidazole. 
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In cases where the affinity tag was fused to the protein with a tobacco etch virus (TEV) 
protease-cleavable linker and should be removed, TEV protease, prepared by Volkmar 
Fieberg, was added in a 1:50 molar ratio (tab. 5-4). The protein was then transferred into 
dialysis tubing with a cut-off of 6-8 kDa and the protein was dialysed against 2 L dialysis 
buffer overnight while slowly stirring in order to remove the imidazole. To separate the tag 
and Ni-NTA-binding impurities from the digested target proteins, a re-binding affinity 
chromatography step was performed. Therefore, the sample was centrifuged at 3200 xg 
to remove aggregates and then mixed with 2.5 mL Ni-NTA beads, which were equilibrated 
in dialysis buffer, for 1 h. The samples were then applied to Protino® columns. The flow 
through fraction (sample + 5 mL wash with dialysis buffer), a 10 mL wash fraction with 
dialysis buffer + 20 mM imidazole and a 10 mL eluate fraction with dialysis buffer 
+ 250 mM imidazole were collected and the target protein was recovered either from the 
flow through or the wash fraction, while the impurities were found in the eluate fraction. 
The eluate fraction of the IMAC or the flow through/wash fraction of the reverse IMAC, 
respectively, were concentrated using Vivaspin turbo spin concentrators with appropriate 
molecular weight cut-off. 2-5 mL of the concentrated samples were then filtered through a 
0.22 µm filter and applied to either a HiLoadTM 16/600 Superdex 200 pg or a HiLoadTM 
16/600 Superdex 75 pg SEC column depending on the protein size. The column was 
previously equilibrated in storage buffer. Peak fractions were collected, concentrated with 
spin concentrators, flash frozen in liquid nitrogen and stored at -80 °C. 
Tab. 5-4: Purification of hexahistidine-tagged proteins. ARNO-Sec7 and NΔ17ARF1 were 
purified by Max Yin and Volkmar Fieberg, respectively. 
Protein Tag cleaved? Cleavage site SEC column Concentrator 
ARNO yes TEV S200 10 kDa 
ARNOΔpbr yes TEV S200 10 kDa 
ARNO-PH yes TEV S75 5 kDa 
ARNO-Sec7 yes TEV S75 5 kDa 
ARNO-cc-Sec7 yes TEV S200 10 kDa 
NΔ17ARF1 no Thrombin No SEC 10 kDa 
ARF6 no None S75 10 kDa 
NMT no TEV S200 10 kDa 
IR-ICD yes TEV S200 10 kDa 
IR-KC yes TEV S200 10 kDa 
CNK1 no TEV S200 10 kDa 
CNK1K414Q no TEV S200 10 kDa 
CNK1Δcc no TEV S200 10 kDa 
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Lysis buffer 
 50 mM HEPES 
 300 mM NaCl 
 3 mM MgCl2 
 20 mM imidazole  
 0.5 mM TCEP 
 pH 7.5 (pH 8.0 for ARF6) 
Dialysis buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 0.5 mM TCEP 
 pH 7.2 
Storage buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 pH 7.2 (pH 8.0 for ARF6) 
100 x protease inhibitor 
 1 mM AEBSF 
 5 µM E-64 
 5 µM Bestatin 
 5 µM Phosphoramidon 
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Purification of GST-tagged proteins 
Another commonly used affinity tag, which is significantly larger than the hexahistidine-
tag, is the GST tag (Smith and Johnson 1988). In this study, it was usually not cleaved, 
since it was subsequently exploited for pull-down assays (chapter 5.2.12). However, 
ARNOΔcc was purified in its GST-fusion form and enzymatically cleaved. 
All purification steps were performed with cooled buffers at 4 °C or on ice. The cells 
obtained by expression in 2 L LB medium (chapter 5.2.4) were resuspended in 20 mL 
lysis buffer + 1 x protease inhibitor mix. For GST-IR-ICD expressed in Sf9 cells, 30 mL 
lysis buffer + 1 x protease inhibitor mix were used per 2 L of cell culture. The completely 
resuspended cells were disrupted by passing them through a French press for two cycles 
with a maximum pressure of 18000 PSI (1240 bar). The lysate was subsequently cleared 
by centrifugation at 48000 xg for 30 min and then added to 6 mL Protino® glutathione 
agarose 4B beads, which were previously equilibrated in lysis buffer and incubated for 1 h 
while shaking slightly. The suspension was then applied to Protino® columns equipped 
with a polymeric frit. The beads were washed with 100 mL lysis buffer and the target 
proteins were eluted with 20 mL lysis buffer + 20 mM GSH, pH readjusted to 7.2. 
For ARNOΔcc, PreScission protease provided by Prof Matthias Geyer was added in a 
1:50 molar ratio to half of the sample (tab. 5-5). The protein was then transferred into 
dialysis tubing with a cut-off of 6-8 kDa and the protein was dialysed against 2 L dialysis 
buffer over night while slowly stirring in order to reduce the GSH concentration. To 
separate the tag and impurities from the digested ARNOΔcc, a re-binding affinity 
chromatography step was performed. Therefore, the sample was centrifuged at 3200 xg 
to remove aggregates and then mixed with 3 mL Protino® glutathione agarose 4B beads, 
which were equilibrated in dialysis buffer, for 1 h. The samples were then applied to 
Protino® columns. The flow through fraction (sample + 5 mL wash with dialysis buffer), a 
10 mL wash fraction with storage buffer and a 10 mL eluate fraction with storage buffer 
+ 20 mM GSH were collected and the protein was recovered from the flow through 
fraction, while the impurities and GST were found in the eluate fraction. 
The eluate fraction of the affinity purification or the flow through of the reverse affinity 
purification in case for ARNOΔcc, respectively, were concentrated using Vivaspin turbo 
spin concentrators with appropriate molecular weight cut-off. 2-5 mL of the concentrated 
samples were then filtered through a 0.22 µm filter and applied to a HiLoadTM 16/600 
Superdex 200 pg SEC column previously equilibrated in storage buffer. Peak fractions 
were collected, concentrated with spin concentrators, flash frozen in liquid nitrogen and 
stored at -80 °C. 
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Tab. 5-5: Purification of GST-tagged proteins. ARNOΔcc was purified as GST-fusion and 
without affinity tag. 
Protein Tag cleaved? Cleavage site SEC column Concentrator 
GST no PreScission S200 10 kDa 
GST-IR-ICD no PreScission S200 10 kDa 
GST-ARNO no PreScission S200 30 kDa 
GST-ARNOΔcc no + yes PreScission S200 10 kDa 
GST-ARNO-cc no PreScission S200 10 kDa 
 
Lysis buffer 
 50 mM HEPES 
 300 mM NaCl 
 3 mM MgCl2 
 0.5 mM TCEP 
 pH 7.5 
Dialysis buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 0.5 mM TCEP 
 pH 7.2 
Storage buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 pH 7.2 
100 x protease inhibitor 
 1 mM AEBSF 
 5 µM E-64 
 5 µM Bestatin 
 5 µM Phosphoramidon 
Purification of Halo-tagged proteins 
Since the HaloTag® binds covalently to its ligand, it cannot be used for multiple interaction 
cycles. Therefore, the Halo-tagged proteins were furthermore fused to an N-terminal 
hexahistidine-tag, which could be cleaved by TEV protease. The Halo-tagged proteins 
were hence purified as described for hexahistidine-tagged proteins. 
Tab. 5-6: Purification of hexahistidine-tagged proteins which also possess a HaloTag®. 
Protein His Tag cleaved? Cleavage site SEC column Concentrator 
Halo-ARNO yes TEV S200 30 kDa 
Halo yes TEV S75 10 kDa 
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Purification of MBP-tagged proteins 
The maltose-binding protein (MBP) can be used as an affinity tag since it binds to (cross-
linked) amylose and enhances gene expression as well as solubility (Bedouelle and 
Duplay 1988, Di Guana et al. 1988, Nallamsetty and Waugh 2006). 
Like the previously described purifications, all steps were performed with cooled buffers at 
4 °C or on ice. The cells obtained by expression in 2 L LB medium (chapter 5.2.4) were 
resuspended in 20 mL lysis buffer + 1 x protease inhibitor mix. The completely 
resuspended cells were disrupted by passing them through a French press for two cycles 
with a maximum pressure of 18000 PSI (1240 bar). The lysate was subsequently cleared 
by centrifugation at 48000 xg for 30 min, added to 7.5 mL amylose beads, which were 
previously equilibrated in lysis buffer and incubated for 1 h while shaking slightly. The 
suspension was then applied to Protino® columns equipped with a polymeric frit. The 
beads were washed with 25 mL lysis buffer and the target proteins were eluted with 25 mL 
lysis buffer + 20 mM maltose. 
All MBP fusion proteins also possessed a TEV protease cleavage site. CNK1-cc was 
purified as MBP-fusion and as the isolated domain. MBP-IR-CT was cleaved and the 
resulting MBP as well as the IR-CT fragment were used for subsequent experiments. 
In case the construct was cleaved, TEV protease, prepared by Volkmar Fieberg, was 
added in a 1:50 molar ratio (tab. 5-7) and the samples were incubated with rotation 
overnight without the need of dialysis. No re-binding steps were performed since the 
molecular weight difference between MBP on the one hand and CNK1-cc and IR-CT on 
the other hand were large enough to separate the proteins via SEC. 
The concentrated amylose purification eluate fraction or the digested sample (previously 
concentrated to reduce the volume for column application) was centrifuged at 3200 xg for 
10 min. A maximum of 5 mL of the concentrated samples was then filtered through a 
0.22 µm filter and applied to a HiLoadTM 16/600 Superdex 75 pg SEC column previously 
equilibrated in storage buffer. Peak fractions were collected, concentrated with spin 
concentrators, flash frozen in liquid nitrogen and stored at -80 °C. For the cleaved IR-CT 
sample however, an additional purification step was introduced to enhance purity. The 
SEC peak was applied to a 10 kDa spin concentrator but in contrast to a conventional 
concentration, the flow through was recovered, which was then devoid of any MBP 
contamination. The flow through was then further concentrated using a 2 kDa 
concentrator. 
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Tab. 5-7: Purification of MBP-tagged proteins. 
Protein Tag cleaved? Cleavage site SEC column Concentrator 
MBP-CNK1-cc no + yes TEV S75 10 kDa/no 
concentration for 
cleaved protein 
MBP-IR-CT yes TEV S75 2 kDa 
MBP yes (MBP was 
recovered from 
MBP-IR-CT 
cleavage) 
TEV S75 10 kDa 
 
Lysis buffer 
 50 mM HEPES 
 300 mM NaCl 
 3 mM MgCl2 
 0.5 mM TCEP 
 pH 7.5 
Storage buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 pH 7.2 
100 x protease inhibitor 
 1 mM AEBSF 
 5 µM E-64 
 5 µM Bestatin 
 5 µM Phosphoramidon 
5.2.6 Purification of myr-ARF1 
Myr-ARF1 was prepared following the general protocols of Franco et al. 1995 and Ha et 
al. 2005, where ARFs are co-expressed with an N-myristoyltransferase (NMT) in E. coli in 
presence of sodium myristate.  
E. coli BL21 (DE3) cells were transformed with the pMON5840-ARF1wt (non-tagged 
ARF1) and the pHV738 plasmid, which encodes the sequences of the human NMT1 
under control of the IPTG inducible tac promotor as well as the E. coli methionine 
aminopeptidase (MetAP) under control of its endogenous promotor (Van Valkenburgh and 
Kahn 2002). 
Starter and main culture contained 50 µg/mL kanamycin and 100 µg/mL ampicillin. 2 L LB 
was inoculated in 5 L baffled flasks with 50 mL of the overnight culture. The cells were 
grown at 37 °C with 110 rpm shaking until OD600 reached ~0.6. Then, 50 µM myristate 
bound to 6 µM fatty acid free BSA was added from a 100 x stock and the temperature was 
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reduced to 27 °C. After 10 min, NMT expression was induced with 0.5 mM IPTG. After 
additional 60 min, expression of ARF1 was induced with 30 µg/mL nalidixic acid, which 
was dissolved as a 30 mg/mL stock in 300 mM NaOH. The cells were grown for 4 h and 
then harvested at 4000 xg using the Beckman centrifuge. The supernatant was discarded 
and the cell pellet was stored at -80 °C until further processing. 
All subsequent purification steps were performed with cooled buffers at 4 °C or on ice. 
The cells were resuspended in 20 mL lysis buffer + 1 x protease inhibitor mix + 
1 mM GDP. The completely resuspended cells were disrupted by passing them through a 
French press for two cycles with a maximum pressure of 18000 PSI (1240 bar). The 
lysate was subsequently cleared by centrifugation at 48000 xg for 30 min. 
In order to enrich myristoylated ARF1, the cleared and filtered cell lysate was precipitated 
at 35 % ammonium sulphate over 45 min using a saturated ammonium sulphate solution 
while stirring in an ice bath. The solution was left stirring for another 60 min and the 
precipitate was pelleted for 20 min at 20000 xg. The supernatant was discarded and the 
precipitated myr-ARF1 was resolubilised in 3 mL rebuffering buffer. The lysate was 
desalted using the HiPrepTM 26/10 desalting column equilibrated in rebuffering buffer. 
After centrifugation at 3200 xg for 10 min, the desalted lysate was applied to a 5 mL 
DEAE FF anion exchange column at 0.5 mL/min, which was previously equilibrated in 
rebuffering buffer. Myr-ARF1 was eluted with a linear gradient to 100 % elution buffer in 
10 column volumes (i.e. 50 mL/100 min). The elution profile shows two major and two 
minor peaks and myr-ARF1 can be recovered from the first peak. 
This peak was pooled, filtered through a 0.22 µm filter and applied to a HiLoadTM 16/600 
Superdex 200 pg SEC column previously equilibrated in storage buffer. Peak fractions 
were collected, concentrated with 10 kDa spin concentrators, flash frozen in liquid 
nitrogen and stored at -80 °C. 
Lysis buffer 
 50 mM TRIS 
 1 mM MgCl2 
 1 mM DTT 
 pH 8.0 
Rebuffering buffer 
 10 mM TRIS 
 1 mM MgCl2 
 1 mM DTT 
 pH 8.0 
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Elution buffer 
 10 mM TRIS 
 1 M KCl 
 1 mM MgCl2 
 1 mM DTT 
 pH 8.0 
Storage buffer 
 20 mM HEPES 
 100 mM NaCl 
 1 mM MgCl2 
 pH 8.0 
100 x protease inhibitor 
 1 mM AEBSF 
 5 µM E-64 
 5 µM Bestatin 
 5 µM Phosphoramidon 
5.2.7 In vitro myristoylation of ARF6 
The in vivo myristoylation approach described for myr-ARF1 (chapter 5.2.6) proves even 
more difficult for ARF6 since GTP- and GDP-bound ARF6 localise to membranes (Macia 
et al. 2004). Therefore, myr-ARF6 was prepared in vitro as described recently (Padovani 
et al. 2013). The non-myristoylated ARF6 and NMT were expressed separately as 
hexahistidine-tagged fusion proteins (chapter 5.2.5 and chapter 3.5.1). 
100 µM ARF6 was mixed with 1 µM NMT in myristoylation buffer. Myristoyl-CoA was 
added to a final concentration of 160 µM from a 420 µM stock dissolved in 20 mM sodium 
acetate, 1 % Triton X-100, pH 5.6. The total reaction volume was 1 mL. The myristoylation 
reaction was allowed to take place at room temperature for 4.5 h. To separate myr-ARF6 
from non-myristoylated ARF6, myr-ARF6 was precipitated at 30 % ammonium sulphate, 
which was added over 30 min while stirring in an ice bath. After another 15 min 
incubation, the samples were centrifuged for 15 min at 20800 xg and the pellet was 
resolubilised in 200 µL HKM buffer. The sample was subsequently rebuffered by overnight 
dialysis against 400 mL HKM buffer and stored in liquid nitrogen. To confirm the 
myristoylation, the final sample was analysed via LC-MS (chapter 5.2.9). 
Myristoylation buffer 
 20 mM HEPES 
 100 mM NaCl 
 1 mM MgCl2 
 pH 8.0 
HKM buffer 
 50 mM HEPES 
 120 mM potassium acetate 
 1 mM MgCl2 
 2 mM β-mercaptoethanol 
 pH 7.4 
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5.2.8 Protein modification with fluorescein and SBED 
For MST measurements (chapter 5.2.15) as well as label transfer studies (chapter 5.2.13), 
the heterologously expressed and purified proteins needed to be covalently modified with 
fluorescein and Sulfosuccinimidyl-2-[6-(biotinamido)-2-(p-azidobenzamido) 
hexanoamido]ethyl-1,3´-dithiopropionate (Sulfo-SBED), respectively. To couple the 
molecules to the proteins, both compounds possess groups reactive towards primary 
amines such as the N-terminus and lysine side chains of the protein. 
N-Hydroxysuccinimide-fluorescein (NHS-fluorescein) was dissolved freshly at 10 mM in 
dimethylformamide (DMF). 50 µM ARNO and 750 µM NHS-fluorescein were mixed in 
labelling buffer and incubated on ice in the dark for 1.5 h. Unreacted dye was removed by 
NAP-5 chromatography yielding a protein with approximately 3 fluorescein molecules 
attached per protein in labelling buffer + 5 % glycerol. 
Sulfo-SBED consists of a biotin moiety, a sulfonated N-hydroxysuccinimide (Sulfo-NHS) 
active ester and a photoactivatable aryl azide (chapter 5.2.13). Sulfo-SBED was freshly 
dissolved at 50 mM in DMF. 100 µM ARNO and 25 µM IR-ICD were incubated with a 
three times molar excess of Sulfo-SBED on ice in the dark for 2 h in labelling buffer. The 
reaction was stopped by the addition of 100 mM TRIS, pH 7.5. To remove unreacted dye 
as well as TRIS buffer, the labelled proteins were rebuffered in labelling buffer 
+ 5 % glycerol using NAP-5 columns. 
Labelling buffer 
 50 mM HEPES 
 150 mM NaCl 
 1 mM MgCl2 
 0.05 % Triton X-100 
 pH 8.0 
5.2.9 LC-MS analysis 
To confirm the myristoylation of ARFs, the intact mass of the modified proteins was 
determined using an electron spray ionization ion trap mass spectrometer after reversed-
phase chromatography (LC-MS). Therefore, the protein of interest was diluted to 2.5 µM in 
0.1 % formic acid (buffer A) and a 20 µL sample (50 pmol) was injected onto a 
MultoHigh®-Bio-200-C18 5 µ column run with the Agilent 1100 HPLC. Chromatography 
was performed for 3 min in buffer A followed by a 20 min gradient to 100 % buffer B 
(acetonitrile) which was continued for another 3 min at a flow rate of 0.4 mL/min. The 
sample was measured with the BRUKER esquire HCT in positive mode. Charge 
deconvolution allowed for a maximum charge of 50.  
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5.2.10 Dynamic light scattering 
The dynamic light scattering (DLS) technology was employed to determine the size of the 
prepared liposomes. DLS allows the deduction of the hydrodynamic radius and thus 
estimation of the particle size by measuring the diffusion velocity due to Brownian motion. 
Therefore, monochromatic light is shone through a sample and the rate at which the 
intensity of scattered light fluctuates is measured (Stetefeld et al. 2016). For small and 
hence fast diffusing particles, the detector records different light intensities already after a 
short time interval. If the molecules are larger however, there is a good correlation for the 
intensity at a given time and the following situation which is analysed by a digital 
autocorrelator. 
The prepared liposomes (chapter 5.2.18) were diluted 1:100 in storage buffer and 
measured in the DLS Zetasizer nano Series S. The intensity representation was chosen to 
show the average of 3 measurements, each consisting of 15 10-sec runs of the same 
sample. 
Storage buffer 
 50 mM HEPES 
 120 mM potassium acetate 
 pH 7.2 
5.2.11 Autophosphorylation assay 
Activation of the insulin receptor is accompanied by autophosphorylation of three tyrosine 
residues within the activation loop (Hubbard 1997). Addition of 30 mM MgCl2 leads to 
receptor aggregation followed by autophosphorylation mimicking the cellular activation 
(Herrera and Rosen 1986). 
For the assay, 525 nM IR-ICD or 525 nM IR-ICD mixed with a tenfold ARNO excess was 
incubated with 30 mM MgCl2 and the phosphorylation reaction was started by addition of 
1 mM ATP. SDS-PAGE samples were taken in a time course and applied to 10 % SDS-
PAGE (chapter 5.2.2), transferred to a nitrocellulose membrane via western blot and 
detected with α-pY or α-pY1162/1163 antibodies (chapter 5.2.3). 
Autophosphorylation buffer 
 50 mM TRIS 
 150 mM NaCl 
 0.5 mM TCEP 
 pH 7.5 
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5.2.12 Pull-down assay 
Pull-down experiments, especially in combination with mass spectrometric analysis, are a 
powerful tool and enable screening for new or confirmation of putative protein-protein 
interactions (Brymora et al. 2004). A “bait” protein is immobilised on a solid support like 
functionalised polymeric beads and bound partners are analysed after incubation and 
washing steps (Einarson et al. 2007). Two different types of pull-down assays were 
performed using either GST- or Halo-fusion proteins to ascertain independence from the 
used tag. 
In the first system, GST-fusion proteins were pulled down using glutathione sepharose 
beads. Within cells, GST plays a central role in detoxification by catalysing the conjunction 
of reduced glutathione to xenobiotic substances (Mannervik et al. 2005, Combes and 
Stakelum 1961). GST hence binds to glutathione which can be exploited for protein 
purification and further biotechnological applications (Smith and Johnson 1988, 
Perperopoulou et al. 2017). 
As indicated in the results section, 1 µM or 5 µM GST and GST-fusion proteins and 1 µM, 
5 µM or 25 µM interaction partner (total volume 200 µL) were incubated in pull-down 
buffer with 10 µL glutathione sepharose 4 B beads for 30 min at RT or 3 h at 4 °C. After 
constant mixing in the overhead tumbler, the beads were washed three times with 500 µL 
pull-down buffer and pelleted at 500 xg. The proteins were eluted using 200 µL pull-down 
buffer supplemented with 50 mM reduced GSH to compete the protein-bead interaction. 
Eppendorf 1.5 mL protein LoBind tubes were used to reduce sticking to the plastic 
surface. Samples of the input before beads incubation, the supernatant after beads 
incubation and the eluate were mixed with sample buffer and analysed via SDS-PAGE 
and stained using Coomassie blue (see chapter 5.2.2). 
The HaloTag® is a 34 kDa mutated haloalkane dehalogenase, which covalently binds to a 
chloroalkane ligand (Zhang et al. 2006). In contrast to the reversible GST-GSH 
interaction, the His272 to Phe mutation within the catalytic triad renders the formed ester 
bond between the HaloTag® and its ligand unhydrolysable. 
5 µM Halo-ARNO or 5 µM Halo protein were mixed with equimolar amounts of interaction 
partner and 10 µL of HaloLinkTM resin in a total volume of 200 µL in pull-down buffer. The 
samples were incubated for 4 h at 4 °C while mixing in the overhead tumbler. After 
incubation, the beads were washed three times with 500 µL pull-down buffer and pelleted 
at 500 xg. The bound proteins were eluted using 50 µL pull-down buffer plus 10 µL 6 x 
SDS loading buffer (chapter 5.2.2). The Halo fusion protein itself cannot be eluted since it 
is covalently attached to the beads. Eppendorf 1.5 mL LoBind tubes were used to reduce 
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sticking to the plastic surface. Samples of the input before beads incubation and the 
supernatant after beads incubation were mixed with 6 x SDS loading buffer and, together 
with the eluate sample, analysed via SDS-PAGE/Coomassie stain (see chapter 5.2.2). 
Pull-down buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 0.15 % Triton X-100 
 pH 7.2 
5.2.13 SBED label transfer 
Transient protein-protein interactions can be stabilised by covalent chemical crosslinking 
which facilitates the characterisation of their interplay (Das and Fox 1979, Arora et al. 
2017). The trifunctional crosslinking reagent Sulfo-SBED was used to analyse the 
interaction between ARNO and the IR-ICD (Alley et al. 2000). The crosslinker consists of 
a biotin moiety, a sulfonated N-hydroxysuccinimide (Sulfo-NHS) active ester and a 
photoactivatable aryl azide (fig. 5-1).  
 
Fig. 5-1: Chemical structure of the trifunctional crosslinking reagent Sulfo-SBED. First, the 
compound is coupled via its NHS group to primary amines of the first interaction partner. Upon UV 
irradiation, the aryl azide is activated and reacts with the target protein. Reduction of the disulphide 
bridge separates the proteins and transfers the biotin moiety to the interaction partner. 
As described in chapter 5.2.8, the compound is coupled to primary amines of one of the 
interacting proteins (here ARNO and IR-ICD) via its NHS group to form a covalent amide 
bond. For the crosslinking experiment, 250 nM of the SBED-modified proteins were 
incubated with 1 µM of the interaction partners and irradiated at RT for 3 min with UV light 
in a transparent 96 well plate in label transfer buffer. The UV light activates the aryl azide 
group which in turn interacts with diverse functional groups in vicinity. The disulphide 
bridge was reduced by addition of 6 x SDS loading buffer containing 100 mM DTT as a 
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final concentration for 15 min, splitting the previously crosslinked partners. Samples pre 
and post irradiation were separated via SDS-PAGE (chapter 5.2.2), transferred to a 
nitrocellulose membrane by western blot and detected via fluorescently labelled 
streptavidin (chapter 5.2.3). 
Label transfer buffer 
 20 mM HEPES 
 150 mM NaCl 
 3 mM MgCl2 
 pH 7.4 
5.2.14 Analytical size-exclusion chromatography 
Molecular complex formation can be addressed by analytical size-exclusion 
chromatography (SEC). SEC separates molecules due to their hydrodynamic radius, 
which is in good accordance with the molecular weight for globular proteins (Hong et al. 
2012). Small molecules pass through all cavities of the porous beads and possess a 
correspondingly long retention time while larger molecules do not enter the matrix and 
elute earlier. 
All samples were diluted in SEC buffer which was also used for the SEC runs. 100 µL 
samples ranging from 7.5 µM to 50 µM (see results) were incubated for 5 min on ice, 
centrifuged at 20800 xg for 10 min and subjected to a Superdex 200 10/300 GL gel 
filtration column at a flow rate of 0.4 mL/min. The ÄKTA FPLC chromatography system 
was used. 500 µL peak fractions were collected and analysed via SDS-PAGE and 
Coomassie blue staining (chapter 5.2.2). 
In order to estimate the molecular weight of the analysed proteins and protein complexes, 
the BioRad gel filtration standard was run under the same conditions as the samples and 
the elution profile was recorded. The calibration was performed and evaluated according 
to Appendix 10 of the GE Size Exclusion Chromatography Principles and Methods 
handbook (GE 2014). In short, the Kav values for all elution maxima of the molecular 
weight standard within the separation range of the column were determined as: 
𝐾௔௩ =
𝑉௘ − 𝑉଴
𝑉௧ − 𝑉଴
 
with Ve = elution volume of the standard protein, V0 = column void volume (approximately 
6.7 mL), Vt = total bed volume (24 mL). The Kav values were then plotted against the 
molecular weight of the standard proteins on a logarithmic scale and a calibration curve 
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was generated by linear regression. The regression curve in turn serves to calculate the 
molecular weight of test proteins and complexes. 
SEC buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 pH 7.2 
5.2.15 Microscale thermophoresis 
One means of quantifying biomolecular interactions is microscale thermophoresis (MST). 
Two comprehensive review articles summarise the theoretical background as well as 
applications and served as the basis for this chapter (Jerabek-Willemsen et al. 2011, 
Seidel et al. 2013). Thermophoresis refers to the movement of particles in a temperature 
gradient, which is counterbalanced by mass diffusion. In the standard experimental setup, 
a fluorescently labelled molecule situated in a glass capillary is heated using an infrared 
laser at a precise location. Upon heating, the migration of molecules is monitored via a 
simultaneous fluorescence measurement. The movement is dependent on the size, 
charge and hydration shell of the molecule (Duhr and Braun 2006). Mathematically, the 
concentration change can be described as: 
𝑐ଵ
𝑐଴
= 𝑒(ିௌ೅௱்) 
with c0 = initial concentration, c1 = hot equilibrium concentration, ST = Soret coefficient and 
ΔT = temperature change. It is the Soret coefficient, the thermodiffusion constant divided 
by the diffusion coefficient, which encompasses the contribution of size, charge and 
hydration shell of the molecule as delineated in the following formula (Duhr and Braun 
2006): 
 
𝑆் =
𝐴
𝑘 𝑇 ቆ
−𝑠௛௬ௗ +
𝛽𝜎௘௙௙ଶ
4𝜀𝜀଴𝑇
× 𝜆஽ுቇ 
 
with A = particle surface, k = Boltzmann constant, T = temperature, shyd = hydration 
entropy, β = factor resulting from temperature derivatives, σeff = effective surface charge 
density, ε = dielectric constant, ε0 = vacuum permittivity and λDH = Debye length. 
size 
hydration 
shell 
charge2 
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To obtain binding data, the fluorescent molecule is mixed with increasing amounts of the 
interactor in up to 16 capillaries and the fluorescence is monitored before and during 
infrared laser irradiation (fig. 5-2). Since binding will at least influence one of the factors 
which determine the thermophoretic behaviour, the affinity can be inferred. Therefore, the 
ratio Fnorm of the normalised florescence of the hot equilibrium state F1 and the normalised 
initial fluorescence F0 is calculated and plotted against the logarithmic ligand 
concentration. The curve is then fitted by using a model derived from the law of mass 
action: 
𝐹௡௢௥௠ = (1 − 𝑥) × 𝐹௡௢௥௠(𝑢𝑛𝑏𝑜𝑢𝑛𝑑) + 𝑥 𝐹௡௢௥௠ (𝑏𝑜𝑢𝑛𝑑) 
with x = the fraction of labelled molecules bound to their targets. 
 
Fig. 5-2: Principle of microscale thermophoresis. The samples in up to 16 capillaries are heated 
by irradiation with an infrared laser and the fluorescence is measured through a mirror. The 
fluorescence is recorded, normalised and Fnorm = F1/F0 is plotted against the ligand concentration in 
a logarithmic scale. Adapted from Seidel et al. 2013. 
For the performed measurements, ARNO was labelled with fluorescein (chapter 5.2.8) 
and used at 100 nM final concentration. IR-ICD and IR-KC were titrated in 1:2 dilutions 
ranging from 5 nM to 100 µM. All proteins were prepared and diluted in MST buffer and 
the measurements were performed using standard treated capillaries from NanoTemper 
Technologies. Thermophoresis was measured using a Monolith NT.115 instrument at 
room temperature with 5 s/30 s/5 s laser off/on/off times, respectively. The instrument 
parameters were set to 40 % LED power and 10 % MST power. Data of two independent 
measurements were analysed using the signal from thermophoresis + t-jump (initial 
fluorescence change caused by temperature increase independent of particle flow). 
MST buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 0.05 % Triton X-100 
 pH 7.2  
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5.2.16 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) measurements enable the complete thermodynamic 
characterisation of (biomolecular) interactions including determination of the KD value, 
enthalpy and entropy. The underlying principle is a very accurate measurement of the 
required energy to adapt the temperature of a reference and a reaction chamber after 
repeated addition of a defined amount of a ligand to the molecule in the reaction chamber 
(Ladbury 2004). 
The heat development or consumption is subsequently integrated over time and plotted 
against the molar ratio of the reactants. Application of the appropriate non-linear least 
squares fit binding model enables the determination of the enthalpy, KD and reaction 
stoichiometry. These parameters are linked by the equation 
𝛥𝐺 = 𝛥𝐻 − 𝑇 × 𝛥𝑆 = − 𝑅 × 𝑇 × 𝑙𝑛𝐾஻ 
where ΔG = change in Gibb’s free energy, ΔH = change in enthalpy, T = temperature (in 
Kelvin), ΔS = change in entropy, R = gas constant and lnKB = natural logarithm of the 
binding constant = 1/KD (Ladbury 2004). 
Prior to the experiment, the purified proteins were dialysed overnight against 2 L of ITC 
buffer using Slide-A-Lyzer® MINI dialysis units, 10000 MWCO. The iTC200 
MicroCalorimeter cell contained 200 µL of the diluted interaction partner and the 
respective partner was injected via the 40 µL microsyringe at an approximately 10 times 
higher concentration (see results for exact concentrations). The 18 ligand injections were 
performed at 15 °C or 25 °C with a reference power of 5 µCal/sec and feedback mode 
gain high. The first 0.2 µL injection was omitted in the data analysis; the following 
injections were 2 µL each in volume with 120 sec intervals at a stirring speed 750 rpm with 
a twisted paddle syringe. The data was analysed with Microcal’s ITC software for ORIGIN 
and the control injections of protein into buffer were subtracted if necessary. A single 
binding site model was employed for all experiments. For the ARNO to CNK1Δcc 
experiment, the buffer contained 500 mM NaCl. 
ITC buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 pH 7.2 
  
5 Materials and Methods 
90 
5.2.17 Protein crystallisation 
Protein crystallography addresses the conversion of a highly pure soluble protein into a 
protein crystal where all molecules are positioned in an ordered manner. This ordered 
arrangement in so called unit cells is the prerequisite to determine the three-dimensional 
structure of the biomolecule via X-ray diffraction analysis. For a comprehensive 
introduction to protein crystallography and subsequent X-ray structure determination one 
may refer to Bernhard Rupp’s textbook Biomolecular Crystallography (Rupp 2009). 
The crystallisation complexes were obtained by mixing the respective proteins and 
applying them to the HiLoad 16/600 Superdex 200 pg or HiLoad 16/600 Superdex 75 pg 
(for ARNO-cc-Sec7/CNK1-cc) in SEC buffer at a flow rate of 1 mL/min and refreezing 
them in liquid nitrogen. 
The subsequent work of protein crystallisation and crystal testing at a synchrotron 
beamline was essentially performed by Dr Kanchan Anand at the Karlsruhe Institute of 
Technology. In short, the vapour diffusion sitting drop method was used. 100 nL of the 
concentrated protein complexes (10.3 mg/mL ARNO:CNK1, 7.4 mg/mL ARNO:CNK1-cc, 
6.7 mg/mL ARNO-cc-Sec7:CNK1-cc, 12.6 mg/mL ARNOΔpbr:CNK1-cc) were mixed 1:1 
with several different precipitants. The mix of protein and crystallisation screen solutions 
was kept at different temperatures ranging from 10 °C to 20 °C in an atmosphere 
containing the crystallisation buffer for several days to weeks. Since the precipitant 
concentration is higher in the reservoir solution than in the drop, water vapour diffuses out 
of the drop, so both the protein as well as the precipitant concentration increase, which 
can allow for crystal formation. Since the crystallisation conditions for the complexes were 
unknown, several commercial screens (such as Wizard 1+2, Wizard 3+4, JCSG+, 
Morpheus and Proplex, all by Molecular Dimensions) and home-made screens were used. 
Initial conditions were optimised using the hanging drop method. 
SEC buffer 
 20 mM HEPES 
 100 mM NaCl 
 3 mM MgCl2 
 pH 7.2 
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5.2.18 Liposome preparation 
Liposomes are spherical membrane systems which consist of at least one lipid bilayer. 
They can be prepared in a multitude of ways including sonication and extrusion methods 
leading to liposomes of different sizes and numbers of bilayers (Akbarzadeh et al. 2013). 
For the present study, liposomes were prepared following the general manufacturer’s 
advice as well as the described procedures for liposome preparation in the study of ARFs 
(Avanti Polar Lipids 2017, Robbe and Antonny 2003, Stalder et al. 2011). 
Adapted from Stalder et al. 2011, 20 % L-α-phosphatidylethanolamine (PE), 30 % L-α-
phosphatidylserine (PS), 48 % (or 50 %) L-α-phosphatidylcholine (PC) and 2 % (or no) 
L-α-phosphatidylinositol-4,5-bisphosphate (PIP2) (chapter 5.1.5) were mixed. The 
composition of liposomes containing DGS-NTA(Ni) is listed in tab. 5-8 where 
concentrations of PE and PS were slightly lowered accordingly. 
Tab. 5-8: Composition of DGS-NTA(Ni) containing liposomes. 
% DGS-NTA (Ni) Composition 
5 20 % PE, 30 % PS, 2 % PIP2, 43 % PC 
10 15 % PE, 25 % PS, 2 % PIP2, 48 % PC 
15 15 % PE, 25 % PS, 2 % PIP2, 43 % PC 
25 15 % PE, 25 % PS, 2 % PIP2, 33 % PC 
 
The lipids were prepared in a volume of 2 mL at 2 mM total lipid concentration in a 10 mL 
pointed hand vice. PE, PS and PC were dissolved in chloroform, PIP2 in a 20:9:1 mix of 
chloroform, methanol and ddH2O. To keep the polar PIP2 in solution, the final methanol 
concentration was adjusted to around 35 % (v/v) while the remaining solvent was 
chloroform. 
The lipids were equilibrated to 34 °C in a rotary evaporator for 5 min, rotating at 60 rpm 
without vacuum. Most of the solvent was then evaporated within one minute without 
boiling and full vacuum was applied for 1-2 h to evaporate the remaining solvent at RT 
without rotation. After drying, the lipids were hydrated for 25 min in 1 mL liposome buffer 
at a total lipid concentration of 4 mM leading to the formation of large multilamellar 
vesicles. The liposomes were transferred to a microcentrifuge tube and subjected to five 
freeze-thaw cycles using dry ice and a 37 °C heat block, which reduces the liposome size 
(Traïkia et al. 2000). As a last step, the liposomes were extruded through a 100 nm 
polycarbonate membrane using the Avanti mini extruder and two 1 mL gastight syringes. 
The liposomes were analysed via DLS (chapter 5.2.10), stored at RT and used within 
four days after production. 
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Liposome buffer 
 50 mM HEPES 
 120 mM potassium acetate 
 pH 7.2 
5.2.19 Guanine nucleotide exchange assay for soluble ARFs 
In order to test the enzymatic activity of different ARNO constructs, guanine nucleotide 
exchange assays on the soluble NΔ17ARF1 GTPase were performed. 
Apart from radioactive assays, either the intrinsic tryptophan fluorescence of ARFs or 
binding/release of a fluorescently labelled nucleotide analogue can be utilised (Kahn and 
Gilman 1986, Antonny et al. 1997, Remmers 1998, Stalder et al. 2011). For this assay, 
binding of the fluorescent nucleotide analogue Mant-GTP was monitored adapted from 
Stalder et al. 2011. When Mant-GTP is bound to the GTPase, excited tryptophan residues 
transfer energy to the Mant moiety via FRET. The radiationless energy transfer results in 
an increased emission fluorescence signal at around 450 nm when the tryptophans are 
exited at approximately 280 nm. 
The bound nucleotide of 1 µM NΔ17ARF1 was displaced by incubation with 2 mM EDTA 
and 5 µM GDP for 15 min at 37 °C in exchange buffer. GDP was allowed to bind by the 
addition of 3 mM MgCl2 and incubation for 5 min at 37 °C. For the actual exchange 
reaction, 400 nM NΔ17ARF1-GDP was mixed with 5 µM Mant-GTP and the reaction was 
initiated by addition of 20 nM or 200 nM ARNO in exchange buffer + 1 mM MgCl2. The 
exchange reaction was monitored in a Corning black 96 well non-binding surface half area 
plate with the Tecan infinite M1000 reader by Mant-FRET at 297/455 nm at 37 °C. 
Exchange buffer 
 50 mM HEPES 
 120 mM potassium acetate 
 5 µM CaCl2 
 100 µM EGTA 
 1 mM DTT 
 pH 7.2  
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5.2.20 Guanine nucleotide exchange assay for myr-ARFs 
A Mant-FRET assay similar to the one described for soluble ARFs (chapter 5.2.19) was 
also used to assess GEF activity on liposome-bound, myr-ARFs. In contrast to the assay 
for soluble ARFs however, the myr-ARFs were pre-loaded with Mant-GDP instead of GDP 
and hence a fluorescence decrease upon exchange of Mant-GDP for GTP was monitored. 
The bound nucleotide of 1 µM myr-ARF1 or myr-ARF6 was displaced by incubation with 
2 mM EDTA and 2.5 µM Mant-GDP for 15 min at 37 °C in exchange buffer. Mant-GDP 
was allowed to bind by the addition of 3 mM MgCl2 and incubation for 5 min at 37 °C. For 
the actual exchange reaction, 400 nM myr-ARF and liposomes (for composition see 
chapter 5.2.18, 200 µM total lipid concentration) were mixed with 100 µM GTP and the 
reaction was initiated by addition of 1 nM ARNO in exchange buffer + 1 mM MgCl2. For 
the initial assays, 0.25-10 nM ARNO were tested. To assess the effect of CNK1, 1-20 nM 
CNK1 were added to the reaction simultaneously with ARNO. The exchange reaction was 
monitored in a Corning black 96 well non-binding surface half area plate with the Tecan 
infinite M1000 reader by Mant-FRET at 297/455 nm at 37 °C. For myr-ARF1, the reaction 
was incubated at 37 °C for 20 min prior to the addition of ARNO to allow for complete 
temperature equilibration. Since the intrinsic exchange for myr-ARF6 is higher than for 
myr-ARF1, the reaction could not be pre-incubated but was started immediately. 
In case the exchange assay was performed using liposomes containing the DGS-NTA(Ni) 
lipid, a non-reducing exchange buffer omitting DTT was used to avoid reduction of the 
coordinated nickel. 
The nucleotide exchange kinetics were analysed assuming pseudo-first order rate 
constants which were obtained by fitting the fluorescence traces using a mono-
exponential fit with GraphPad PRISM (Stalder et al. 2011). 
Exchange buffer 
 50 mM HEPES 
 120 mM potassium acetate 
 5 µM CaCl2 
 100 µM EGTA 
 1 mM DTT 
 pH 7.2 
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5.2.21 Liposome flotation assay 
In order to assess protein binding to PIP2-containing liposomes or liposomes without PIP2 
(chapter 5.2.18), a previously described ultracentrifugation approach was applied (Bigay 
and Antonny 2005). Therefore, proteins and liposomes were mixed in a 30 % sucrose-
containing buffer, which was overlaid with a cushion of 25 % sucrose and a buffer layer. In 
case a protein binds to the liposomes, it migrates to the top fraction alongside the lipids. If 
the protein remains free in solution, it can be recovered from the bottom fraction (fig. 5-3). 
 
Fig. 5-3: Experimental setup of the liposome flotation assay. The protein-lipid mixtures were 
prepared in a buffer containing 30 % sucrose and added to the tube first with two layers of 25 % 
sucrose and 0 % sucrose on top. The samples were taken using a 50 µL gastight syringe according 
to the depicted scheme. Adapted from Bigay and Antonny 2005. 
30 nM ARNO, 30 nM CNK1, 30 nM CNK1K414Q or 60 nM CNK1 and liposomes (200 µM 
total lipid concentration) were prepared in liposome flotation buffer + 30 % sucrose, 
incubated for 10 min and overlaid with two layers of 25 % sucrose and 0 % sucrose, 
respectively. After centrifugation with the Beckman ultracentrifuge at 240000 xg for 1 h at 
20°C, the liposome-containing top fraction, the middle fraction and the bottom fraction with 
unbound protein were recovered with a gastight syringe. The samples were mixed with 
SDS loading buffer and analysed via SDS-PAGE (chapter 5.2.2) and western blot 
(chapter 5.2.3) as depicted in fig. 5-3. In case the flotation assay was performed using 
liposomes containing the DGS-NTA(Ni) lipid, a non-reducing exchange buffer without DTT 
was used to avoid reduction of the coordinated nickel. 
Liposome flotation buffer 
 50 mM HEPES 
 120 mM potassium acetate 
 1 mM MgCl2 
 1 mM DTT 
 pH 7.2 
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Appendix 
Protein sequences 
IR-ICD (aa 953-1355, IR-B numbering w/o signal sequence) 
MSHHHHHHEN LYFQGARKRQ PDGPLGPLYA SSNPEYLSAS DVFPCSVYVP DEWEVSREKI TLLRELGQGS 
FGMVYEGNAR DIIKGEAETR VAVKTVNESA SLRERIEFLN EASVMKGFTC HHVVRLLGVV SKGQPTLVVM 
ELMAHGDLKS YLRSLRPEAE NNPGRPPPTL QEMIQMAAEI ADGMAYLNAK KFVHRDLAAR NCMVAHDFTV 
KIGDFGMTRD IYETDYYRKG GKGLLPVRWM APESLKDGVF TTSSDMWSFG VVLWEITSLA EQPYQGLSNE 
QVLKFVMDGG YLDQPDNCPE RVTDLMRMCW QFNPKMRPTF LEIVNLLKDD LHPSFPEVSF FHSEENKAPE 
SEELEMEFED MENVPLDRSS HCQREEAGGR DGGSSLGFKR SYEEHIPYTH MNGGKKNGRI LTLPRSNPS 
 
IR-KC (aa 978-1283, IR-B numbering w/o signal sequence) 
MSHHHHHHEN LYFQGAVFPS SVYVPDEWEV SREKITLLRE LGQGSFGMVY EGNARDIIKG EAETRVAVKT 
VNESASLRER IEFLNEASVM KGFTCHHVVR LLGVVSKGQP TLVVMELMAH GDLKSYLRSL RPEAENNPGR 
PPPTLQEMIQ MAAEIADGMA YLNAKKFVHR DLAARNCMVA HDFTVKIGDF GMTRDIYETD YYRKGGKGLL 
PVRWMAPESL KDGVFTTSSD MWSFGVVLWE ITSLAEQPYQ GLSNEQVLKF VMDGGYLDQP DNCPERVTDL 
MRMCWQFNPK MRPTFLEIVN LLKDDLHPSF PEVSFFHSEE NK 
 
ARNO 
MASRGSHHHH HHGAGDRGPE FENLYFQSET EDGVYEPPDL TPEERMELEN IRRRKQELLV EIQRLREELS 
EAMSEVEGLE ANEGSKTLQR NRKMAMGRKK FNMDPKKGIQ FLVENELLQN TPEEIARFLY KGEGLNKTAI 
GDYLGEREEL NLAVLHAFVD LHEFTDLNLV QALRQFLWSF RLPGEAQKID RMMEAFAQRY CLCNPGVFQS 
TDTCYVLSFA VIMLNTSLHN PNVRDKPGLE RFVAMNRGIN EGGDLPEELL RNLYDSIRNE PFKIPEDDGN 
DLTHTFFNPD REGWLLKLGG GRVKTWKRRW FILTDNCLYY FEYTTDKEPR GIIPLENLSI REVDDPRKPN 
CFELYIPNNK GQLIKACKTE ADGRVVEGNH MVYRISAPTQ EEKDEWIKSI QAAVSVDPFY EMLAARKKRI 
SVKKKQEQP 
 
ARNOΔpbr (aa 2-378) 
MASRGSHHHH HHGAGDRGPE FENLYFQSET EDGVYEPPDL TPEERMELEN IRRRKQELLV EIQRLREELS 
EAMSEVEGLE ANEGSKTLQR NRKMAMGRKK FNMDPKKGIQ FLVENELLQN TPEEIARFLY KGEGLNKTAI 
GDYLGEREEL NLAVLHAFVD LHEFTDLNLV QALRQFLWSF RLPGEAQKID RMMEAFAQRY CLCNPGVFQS 
TDTCYVLSFA VIMLNTSLHN PNVRDKPGLE RFVAMNRGIN EGGDLPEELL RNLYDSIRNE PFKIPEDDGN 
DLTHTFFNPD REGWLLKLGG GRVKTWKRRW FILTDNCLYY FEYTTDKEPR GIIPLENLSI REVDDPRKPN 
CFELYIPNNK GQLIKACKTE ADGRVVEGNH MVYRISAPTQ EEKDEWIKSI QAAVSVD 
 
ARNO-PH (aa 261-378) 
MGSHHHHHHE NLYFQGSGSD REGWLLKLGG GRVKTWKRRW FILTDNCLYY FEYTTDKEPR GIIPLENLSI 
REVDDPRKPN CFELYIPNNK GQLIKACKTE ADGRVVEGNH MVYRISAPTQ EEKDEWIKSI QAAVSVD 
 
ARNO-Sec7 (aa 61-246) 
MGSHHHHHHE NLYFQGSRNR KMAMGRKKFN MDPKKGIQFL VENELLQNTP EEIARFLYKG EGLNKTAIGD 
YLGEREELNL AVLHAFVDLH EFTDLNLVQA LRQFLWSFRL PGEAQKIDRM MEAFAQRYCL CNPGVFQSTD 
TCYVLSFAVI MLNTSLHNPN VRDKPGLERF VAMNRGINEG GDLPEELLRN LYDSIRNEPF KIP 
 
ARNO-cc-Sec7 (aa 2-246) 
MASRGSHHHH HHGAGDRGPE FENLYFQSET EDGVYEPPDL TPEERMELEN IRRRKQELLV EIQRLREELS 
EAMSEVEGLE ANEGSKTLQR NRKMAMGRKK FNMDPKKGIQ FLVENELLQN TPEEIARFLY KGEGLNKTAI 
GDYLGEREEL NLAVLHAFVD LHEFTDLNLV QALRQFLWSF RLPGEAQKID RMMEAFAQRY CLCNPGVFQS 
TDTCYVLSFA VIMLNTSLHN PNVRDKPGLE RFVAMNRGIN EGGDLPEELL RNLYDSIRNE PFKIP 
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CNK1 
MSHHHHHHEN LYFQGSMEPV ETWTPGKVAT WLRGLDDSLQ DYPFEDWQLP GKNLLQLCPQ SLEALAVRSL 
GHQELILGGV EQLQALSSRL QTENLQSLTE GLLGATHDFQ SIVQGCLGDC AKTPIDVLCA AVELLHEADA 
LLFWLSRYLF SHLNDFSACQ EIRDLLEELS QVLHEDGPAA EKEGTVLRIC SHVAGICHNI LVCCPKELLE 
QKAVLEQVQL DSPLGLEIHT TSNCQHFVSQ VDTQVPTDSR LQIQPGDEVV QINEQVVVGW PRKNMVRELL 
REPAGLSLVL KKIPIPETPP QTPPQVLDSP HQRSPSLSLA PLSPRAPSED VFAFDLSSNP SPGPSPAWTD 
SASLGPEPLP IPPEPPAILP AGVAGTPGLP ESPDKSPVGR KKSKGLATRL SRRRVSCREL GRPDCDGWLL 
LRKAPGGFMG PRWRRRWFVL KGHTLYWYRQ PQDEKAEGLI NVSNYSLESG HDQKKKYVFQ LTHDVYKPFI 
FAADTLTDLS MWVRHLITCI SKYQSPGRAP PPREEDCYSE TEAEDPDDEA GSHSASPSPA QAGSPLHGDT 
SPAATPTQRS PRTSFGSLTD SSEEALEGMV RGLRQGGVSL LGQPQPLTQE QWRSSFMRCN RDPQLNERVH 
RVRALQSTLK AKLQELQVLE EVLGDPELTG EKFRQWKEQN RELYSEGLGA WGVAQAEGSS HILTSDSTEQ 
SPNSLPSDPE EHSHLCPLTS ESSLRPPDL 
 
CNK1K414Q 
MSHHHHHHEN LYFQGSMEPV ETWTPGKVAT WLRGLDDSLQ DYPFEDWQLP GKNLLQLCPQ SLEALAVRSL 
GHQELILGGV EQLQALSSRL QTENLQSLTE GLLGATHDFQ SIVQGCLGDC AKTPIDVLCA AVELLHEADA 
LLFWLSRYLF SHLNDFSACQ EIRDLLEELS QVLHEDGPAA EKEGTVLRIC SHVAGICHNI LVCCPKELLE 
QKAVLEQVQL DSPLGLEIHT TSNCQHFVSQ VDTQVPTDSR LQIQPGDEVV QINEQVVVGW PRKNMVRELL 
REPAGLSLVL KKIPIPETPP QTPPQVLDSP HQRSPSLSLA PLSPRAPSED VFAFDLSSNP SPGPSPAWTD 
SASLGPEPLP IPPEPPAILP AGVAGTPGLP ESPDKSPVGR KKSKGLATRL SRRRVSCREL GRPDCDGWLL 
LRQAPGGFMG PRWRRRWFVL KGHTLYWYRQ PQDEKAEGLI NVSNYSLESG HDQKKKYVFQ LTHDVYKPFI 
FAADTLTDLS MWVRHLITCI SKYQSPGRAP PPREEDCYSE TEAEDPDDEA GSHSASPSPA QAGSPLHGDT 
SPAATPTQRS PRTSFGSLTD SSEEALEGMV RGLRQGGVSL LGQPQPLTQE QWRSSFMRCN RDPQLNERVH 
RVRALQSTLK AKLQELQVLE EVLGDPELTG EKFRQWKEQN RELYSEGLGA WGVAQAEGSS HILTSDSTEQ 
SPNSLPSDPE EHSHLCPLTS ESSLRPPDL 
 
CNK1Δcc (aa 615-646 deleted) 
MSHHHHHHEN LYFQGSMEPV ETWTPGKVAT WLRGLDDSLQ DYPFEDWQLP GKNLLQLCPQ SLEALAVRSL 
GHQELILGGV EQLQALSSRL QTENLQSLTE GLLGATHDFQ SIVQGCLGDC AKTPIDVLCA AVELLHEADA 
LLFWLSRYLF SHLNDFSACQ EIRDLLEELS QVLHEDGPAA EKEGTVLRIC SHVAGICHNI LVCCPKELLE 
QKAVLEQVQL DSPLGLEIHT TSNCQHFVSQ VDTQVPTDSR LQIQPGDEVV QINEQVVVGW PRKNMVRELL 
REPAGLSLVL KKIPIPETPP QTPPQVLDSP HQRSPSLSLA PLSPRAPSED VFAFDLSSNP SPGPSPAWTD 
SASLGPEPLP IPPEPPAILP AGVAGTPGLP ESPDKSPVGR KKSKGLATRL SRRRVSCREL GRPDCDGWLL 
LRKAPGGFMG PRWRRRWFVL KGHTLYWYRQ PQDEKAEGLI NVSNYSLESG HDQKKKYVFQ LTHDVYKPFI 
FAADTLTDLS MWVRHLITCI SKYQSPGRAP PPREEDCYSE TEAEDPDDEA GSHSASPSPA QAGSPLHGDT 
SPAATPTQRS PRTSFGSLTD SSEEALEGMV RGLRQGGVSL LGQPQPLTQE QWRSSFMRCN RDPPELTGEK 
FRQWKEQNRE LYSEGLGAWG VAQAEGSSHI LTSDSTEQSP NSLPSDPEEH SHLCPLTSES SLRPPDL 
 
NΔ17ARF1 (aa 18-181) 
MGSSHHHHHH SSGLVPRGSH MCMRILMVGL DAAGKTTILY KLKLGEIVTT IPTIGFNVET VEYKNISFTV 
WDVGGQDKIR PLWRHYFQNT QGLIFVVDSN DRERVNEARE ELMRMLAEDE LRDAVLLVFA NKQDLPNAMN 
AAEITDKLGL HSLRHRNWYI QATCATSGDG LYEGLDWLSN QLRNQK 
 
ARF6 (in vitro myristoylated) 
MGKVLSKIFG NKEMRILMLG LDAAGKTTIL YKLKLGQSVT TIPTVGFNVE TVTYKNVKFN VWDVGGQDKI 
RPLWRHYYTG TQGLIFVVDC ADRDRIDEAR QELHRIINDR EMRDAIILIF ANKQDLPDAM KPHEIQEKLG 
LTRIRDRNWY VQPSCATSGD GLYEGLTWLT SNYKHHHHHH 
 
N-myristoyltransferase (NMT) 
MGSHHHHHHE NLYFQGSMNS LPAERIQEIQ KAIELFSVGQ GPAKTMEEAS KRSYQFWDTQ PVPKLGEVVN 
THGPVEPDKD NIRQEPYTLP QGFTWDALDL GDRGVLKELY TLLNENYVED DDNMFRFDYS PEFLLWALRP 
PGWLPQWHCG VRVVSSRKLV GFISAIPANI HIYDTEKKMV EINFLCVHKK LRSKRVAPVL IREITRRVHL 
EGIFQAVYTA GVVLPKPVGT CRYWHRSLNP RKLIEVKFSH LSRNMTMQRT MKLYRLPETP KTAGLRPMET 
KDIPVVHQLL TRYLKQFHLT PVMSQEEVEH WFYPQENIID TFVVENANGE VTDFLSFYTL PSTIMNHPTH 
KSLKAAYSFY NVHTQTPLLD LMSDALVLAK MKGFDVFNAL DLMENKTFLE KLKFGIGDGN LQYYLYNWKC 
PSMGAEKVGL VLQ 
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ARF1 (in vivo myristoylated) 
MGNIFANLFK GLFGKKEMRI LMVGLDAAGK TTILYKLKLG EIVTTIPTIG FNVETVEYKN ISFTVWDVGG 
QDKIRPLWRH YFQNTQGLIF VVDSNDRERV NEAREELMRM LAEDELRDAV LLVFANKQDL PNAMNAAEIT 
DKLGLHSLRH RNWYIQATCA TSGDGLYEGL DWLSNQLRNQ K 
 
GST 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA 
IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK 
TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF 
GGGDHPPKSD LEVLFQGPLG S 
 
GST-IR-ICD (aa 953-1355, IR-B numbering w/o signal sequence) 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA 
IIRYIADKHN MLGGSPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLSHK 
TYLNGDHVTH PDFMLYDALD VVLYMDPMSL DAFPKLVSFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF 
GGGDHPPKSG GGSGGGSGGG LEVLFQGPGS RKRQPDGPLG PLYASSNPEY LSASDVFPCS VYVPDEWEVS 
REKITLLREL GQGSFGMVYE GNARDIIKGE AETRVAVKTV NESASLRERI EFLNEASVMK GFTCHHVVRL 
LGVVSKGQPT LVVMELMAHG DLKSYLRSLR PEAENNPGRP PPTLQEMIQM AAEIADGMAY LNAKKFVHRD 
LAARNCMVAH DFTVKIGDFG MTRDIYETDY YRKGGKGLLP VRWMAPESLK DGVFTTSSDM WSFGVVLWEI 
TSLAEQPYQG LSNEQVLKFV MDGGYLDQPD NCPERVTDLM RMCWQFNPKM RPTFLEIVNL LKDDLHPSFP 
EVSFFHSEEN KAPESEELEM EFEDMENVPL DRSSHCQREE AGGRDGGSSL GFKRSYEEHI PYTHMNGGKK 
NGRILTLPRS NPS 
 
GST-ARNO 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA 
IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK 
TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF 
GGGDHPPKSD LEVLFQGPLG SMEDGVYEPP DLTPEERMEL ENIRRRKQEL LVEIQRLREE LSEAMSEVEG 
LEANEGSKTL QRNRKMAMGR KKFNMDPKKG IQFLVENELL QNTPEEIARF LYKGEGLNKT AIGDYLGERE 
ELNLAVLHAF VDLHEFTDLN LVQALRQFLW SFRLPGEAQK IDRMMEAFAQ RYCLCNPGVF QSTDTCYVLS 
FAVIMLNTSL HNPNVRDKPG LERFVAMNRG INEGGDLPEE LLRNLYDSIR NEPFKIPEDD GNDLTHTFFN 
PDREGWLLKL GGGRVKTWKR RWFILTDNCL YYFEYTTDKE PRGIIPLENL SIREVDDPRK PNCFELYIPN 
NKGQLIKACK TEADGRVVEG NHMVYRISAP TQEEKDEWIK SIQAAVSVDP FYEMLAARKK RISVKKKQEQ 
P 
 
GST-ARNOΔcc (aa 61-400) 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA 
IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK 
TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF 
GGGDHPPKSD LEVLFQGPLG SRNRKMAMGR KKFNMDPKKG IQFLVENELL QNTPEEIARF LYKGEGLNKT 
AIGDYLGERE ELNLAVLHAF VDLHEFTDLN LVQALRQFLW SFRLPGEAQK IDRMMEAFAQ RYCLCNPGVF 
QSTDTCYVLS FAVIMLNTSL HNPNVRDKPG LERFVAMNRG INEGGDLPEE LLRNLYDSIR NEPFKIPEDD 
GNDLTHTFFN PDREGWLLKL GGGRVKTWKR RWFILTDNCL YYFEYTTDKE PRGIIPLENL SIREVDDPRK 
PNCFELYIPN NKGQLIKACK TEADGRVVEG NHMVYRISAP TQEEKDEWIK SIQAAVSVDP FYEMLAARKK 
RISVKKKQEQ P 
 
GST-ARNO-cc (aa 1-60) 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA 
IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK 
TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF 
GGGDHPPKSD LEVLFQGPLG SMEDGVYEPP DLTPEERMEL ENIRRRKQEL LVEIQRLREE LSEAMSEVEG 
LEANEGSKTL Q 
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Halo 
MGSHHHHHHE NLYFQSELMA EIGTGFPFDP HYVEVLGERM HYVDVGPRDG TPVLFLHGNP TSSYVWRNII 
PHVAPTHRCI APDLIGMGKS DKPDLGYFFD DHVRFMDAFI EALGLEEVVL VIHDWGSALG FHWAKRNPER 
VKGIAFMEFI RPIPTWDEWP EFARETFQAF RTTDVGRKLI IDQNVFIEGT LPMGVVRPLT EVEMDHYREP 
FLNPVDREPL WRFPNELPIA GEPANIVALV EEYMDWLHQS PVPKLLFWGT PGVLIPPAEA ARLAKSLPNC 
KAVDIGPGLN LLQEDNPDLI GSEIARWLST LEISGEPTTL VPRGSG 
 
Halo-ARNO 
MGSHHHHHHE NLYFQSELMA EIGTGFPFDP HYVEVLGERM HYVDVGPRDG TPVLFLHGNP TSSYVWRNII 
PHVAPTHRCI APDLIGMGKS DKPDLGYFFD DHVRFMDAFI EALGLEEVVL VIHDWGSALG FHWAKRNPER 
VKGIAFMEFI RPIPTWDEWP EFARETFQAF RTTDVGRKLI IDQNVFIEGT LPMGVVRPLT EVEMDHYREP 
FLNPVDREPL WRFPNELPIA GEPANIVALV EEYMDWLHQS PVPKLLFWGT PGVLIPPAEA ARLAKSLPNC 
KAVDIGPGLN LLQEDNPDLI GSEIARWLST LEISGEPTTL VPRGSMEDGV YEPPDLTPEE RMELENIRRR 
KQELLVEIQR LREELSEAMS EVEGLEANEG SKTLQRNRKM AMGRKKFNMD PKKGIQFLVE NELLQNTPEE 
IARFLYKGEG LNKTAIGDYL GEREELNLAV LHAFVDLHEF TDLNLVQALR QFLWSFRLPG EAQKIDRMME 
AFAQRYCLCN PGVFQSTDTC YVLSFAVIML NTSLHNPNVR DKPGLERFVA MNRGINEGGD LPEELLRNLY 
DSIRNEPFKI PEDDGNDLTH TFFNPDREGW LLKLGGGRVK TWKRRWFILT DNCLYYFEYT TDKEPRGIIP 
LENLSIREVD DPRKPNCFEL YIPNNKGQLI KACKTEADGR VVEGNHMVYR ISAPTQEEKD EWIKSIQAAV 
SVDPFYEMLA ARKKRISVKK KQEQP 
 
MBP-IR-CT (aa 1278-1355, IR-B numbering w/o signal sequence) 
MAMKIEEGKL VIWINGDKGY NGLAEVGKKF EKDTGIKVTV EHPDKLEEKF PQVAATGDGP DIIFWAHDRF 
GGYAQSGLLA EITPDKAFQD KLYPFTWDAV RYNGKLIAYP IAVEALSLIY NKDLLPNPPK TWEEIPALDK 
ELKAKGKSAL MFNLQEPYFT WPLIAADGGY AFKYENGKYD IKDVGVDNAG AKAGLTFLVD LIKNKHMNAD 
TDYSIAEAAF NKGETAMTIN GPWAWSNIDT SKVNYGVTVL PTFKGQPSKP FVGVLSAGIN AASPNKELAK 
EFLENYLLTD EGLEAVNKDK PLGAVALKSY EEELAKDPRI AATMENAQKG EIMPNIPQMS AFWYAVRTAV 
INAASGRQTV DEALKDAQTS SGENLYFQGS HSEENKAPES EELEMEFEDM ENVPLDRSSH CQREEAGGRD 
GGSSLGFKRS YEEHIPYTHM NGGKKNGRIL TLPRSNPS 
 
MBP-CNK1-cc (aa 601-660) 
MAMKIEEGKL VIWINGDKGY NGLAEVGKKF EKDTGIKVTV EHPDKLEEKF PQVAATGDGP DIIFWAHDRF 
GGYAQSGLLA EITPDKAFQD KLYPFTWDAV RYNGKLIAYP IAVEALSLIY NKDLLPNPPK TWEEIPALDK 
ELKAKGKSAL MFNLQEPYFT WPLIAADGGY AFKYENGKYD IKDVGVDNAG AKAGLTFLVD LIKNKHMNAD 
TDYSIAEAAF NKGETAMTIN GPWAWSNIDT SKVNYGVTVL PTFKGQPSKP FVGVLSAGIN AASPNKELAK 
EFLENYLLTD EGLEAVNKDK PLGAVALKSY EEELAKDPRI AATMENAQKG EIMPNIPQMS AFWYAVRTAV 
INAASGRQTV DEALKDAQTS SGENLYFQGS EQWRSSFMRC NRDPQLNERV HRVRALQSTL KAKLQELQVL 
EEVLGDPELT GEKFRQWKEQ 
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Overview of all purified proteins 
In order to show the purity of all proteins used in this study, approximately 1 µg of the 
proteins were applied to SDS-PAGE and stained with Coomassie blue (supporting 
fig. A-1). 
 
Supp. fig. A-1: Overview of all purified proteins. Approximately 1µg of the proteins were applied 
to SDS-PAGE and stained with Coomassie blue. A | 12.5 % SDS-PAGE, B | 10 % SDS-PAGE, 
C | 15 % SDS-PAGE. 
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Influence of CNK1K414Q on ARNO/myr-ARF1 exchange 
 
Supp. fig. A-2: CNK1K414Q does not enhance ARNO exchange on myr-ARF1. 400 nM 
myr-ARF1 was pre-loaded with 1 µM Mant-GDP. The exchange reaction in presence of liposomes 
(2 % PIP2, 200 µM total lipid concentration) and 100 µM GTP was initiated by the addition of 1 nM 
ARNO or mixtures of 1 nM ARNO and the indicated CNK1K414Q concentrations. The reaction was 
performed at 37 °C and monitored by the decreasing Mant-FRET signal. The black lines show the 
mono-exponential fits of the data assuming pseudo-first order kinetics. 
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DLS analysis of liposomes containing DGS-NTA(Ni) 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. fig. A-3: DLS analysis of liposomes containing DGS-NTA(Ni). Description on next page. 
A 2 % PIP2, 5 % DGS-NTA(Ni), Day 0 
B 2 % PIP2, 5 % DGS-NTA(Ni), Day 9 
D 2 % PIP2, 10 % DGS-NTA(Ni), Day 7 
C 2 % PIP2, 10 % DGS-NTA(Ni), Day 1 
Size [nm] 
Size [nm] 
Size [nm] 
Size [nm] 
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Supp. fig. A-3: DLS analysis of liposomes containing DGS-NTA(Ni). The prepared liposomes were 
diluted 1:100 and measured in the DLS Zetasizer nano Series S. The averages of 3 measurements, 
each consisting of 15 runs of the same sample are shown in the intensity representation. 
E 2 % PIP2, 15 % DGS-NTA(Ni), Day 1 
F 2 % PIP2, 15 % DGS-NTA(Ni), Day 7 
H 2 % PIP2, 25 % DGS-NTA(Ni), Day 9 
G 2 % PIP2, 25 % DGS-NTA(Ni), Day 1 
Size [nm] 
Size [nm] 
Size [nm] 
Size [nm] 
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Original Coomassie stained SDS gels and western blots 
All Coomassie stained SDS gels as well as western blots, which are depicted in a cropped 
version in the results part, are shown completely here. Gels and western blots, which are 
depicted fully in the results section, are not shown again. The same applies to gels and 
western blots, where only empty lanes at the left or right gel/blot edges were cut. 
 
Supp. fig. A-4: IR-ICD and ARNO are catalytically active, unmodified original of figure 3-1. 
A | Lanes 1-6 correspond to the lanes shown in the results part, α-pY. B | Lanes 1-6 correspond to 
the lanes shown in the results part, α-pY1162/1163. C | Lanes 1-6 correspond to the lanes shown 
in the results part, Coomassie stain.  
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Supp. fig. A-5: IR-ICD autophosphorylation remains constant upon ARNO addition, 
unmodified original of figure 3-2. A | Lanes 1-9 correspond to the lanes shown in the results 
part, α-pY. B | Lanes 1-9 correspond to the lanes shown in the results part, Coomassie stain. 
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Supp. fig. A-6: Label transfer suggests interaction between ARNO and IR-ICD, unmodified 
original of figure 3-3. A | Lanes 1-6 and 13-14 correspond to the lanes shown in the results part, 
streptavidin blot. B | Lanes 1-6 and 13-14 correspond to the lanes shown in the results part, 
Coomassie stain. Since fig. 3-3 B contains uncropped pictures, no additional figure is shown here. 
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Supp. fig. A-7: Analytical SEC confirms the interaction of ARNO and CNK1, unmodified 
original of figure 3-12. A | Lanes 1-8 correspond to the lanes shown in the results part, 
7.5 µM ARNO + 7.5 µM CNK1, Coomassie blue stain. B | Lanes 1-8 correspond to the lanes 
shown in the results part, 7.5 µM ARNO + 15 µM CNK1, Coomassie blue stain. C | Lanes 1-9 
correspond to the lanes shown in the results part, 7.5 µM ARNOΔcc + 7.5 µM CNK1, Coomassie 
blue stain. 
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Supp. fig. A-8: Analytical SEC confirms that the CNK1 cc domain is sufficient for ARNO 
interaction, unmodified original of figure 3-13. A | Lanes 3-12 correspond to the lanes shown in 
the results part, MBP-CNK1-cc/ARNO interaction. Lane 1 shows an ARNO sample, lane 2 an 
MBP-CNK1-cc sample. B | Lanes 3-12 correspond to the lanes shown in the results part, 
MBP/ARNO interaction. Lane 1 shows an ARNO sample, lane 2 an MBP sample. 
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Supp. fig. A-9: Crystallisation of diverse ARNO-CNK1 complexes, unmodified original of 
figure 3-15. A | Lane 2 corresponds to the lane shown in the results part, ARNO:CNK1. B | Lane 
11 corresponds to the lane shown in the results part, ARNO:CNK1-cc. C | Lane 11 corresponds to 
the lane shown in the results part, ARNOΔpbr:CNK1-cc. D | Lane 12 corresponds to the lane 
shown in the results part, ARNO-cc-Sec7:CNK1-cc. 
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Supp. fig. A-10: Purification of myr-ARF1, unmodified original of figure 3-16. A | Lanes 1-4 
correspond to the cell debris, lysate, resolubilised precipitate and rebuffered lysate lanes shown in 
the results part. The rest of the gel depicts fractions of the anion exchange chromatography. 
B | Lane 1 corresponds to the IEX first peak lane shown in the results part. The rest of the gel 
depicts more fractions of the anion exchange chromatography. C | Lane 14 corresponds to the final 
after SEC lane shown in the results part. The rest of the gel depicts more SEC fractions. 
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Supp. fig. A-11: Purification and in vitro myristoylation of ARF6, unmodified original of 
figure 3-17 part 1. A | Lanes 6-10 correspond to the cell debris, lysate, flow through, wash and 
eluate lanes for ARF6 shown in the results part. B | Lane 11 corresponds to the final after SEC 
lane for ARF6 shown in the results part. The rest of the gel depicts more fractions of the SEC. 
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Supp. fig. A-12: Purification and in vitro myristoylation of ARF6, unmodified original of 
figure 3-17 part 2. A | Lanes 4-8 correspond to the cell debris, lysate, flow through, wash and 
eluate lanes for NMT shown in the results part. Lanes 1 and 2 show a sample of lysed bacteria 
before and after expression induction, respectively. B | Lane 13 corresponds to the final after SEC 
lane for NMT shown in the results part. The rest of the gel depicts more fractions of the SEC as 
well as the IMAC eluate fraction for comparison. 
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Supp. fig. A-13: CNK1 does not recruit ARNO to the liposome fraction, unmodified original 
of figure 3-22. A | Lanes 1-12 correspond to the lanes shown in the results part, α-ARNO. 
B | Lanes 1-12 correspond to the lanes shown in the results part, α-CNK1. 
 
Supp. fig. A-14: CNK1K414Q does not bind to liposomes, unmodified original of figure 3-23. 
Lanes 1-6 correspond to the lanes shown in the results part, α-CNK1. Lanes 7-12 show a replicate 
of the experiment. 
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Supp. fig. A-15: Binding of His-tagged CNK1 to liposomes with increasing concentration of 
DGS-NTA(Ni), unmodified original of figure 3-24. A | Lanes 1-12 correspond to the lanes shown 
in the results part, 0-25 % DGS-NTA(Ni). B | Lanes 1-3 correspond to the lanes shown in the 
results part, 5 % DGS-NTA(Ni). 
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